WO2014071832A1 - Alk kinase inhibitors - Google Patents

Alk kinase inhibitors Download PDF

Info

Publication number
WO2014071832A1
WO2014071832A1 PCT/CN2013/086571 CN2013086571W WO2014071832A1 WO 2014071832 A1 WO2014071832 A1 WO 2014071832A1 CN 2013086571 W CN2013086571 W CN 2013086571W WO 2014071832 A1 WO2014071832 A1 WO 2014071832A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino
dihydrobenzofuran
isopropylsulfonyl
phenyl
dimethyl
Prior art date
Application number
PCT/CN2013/086571
Other languages
French (fr)
Inventor
Weibo Wang
Meiyu Geng
Jian Ding
Xingdong ZHAO
Jing AI
Qiang Tian
Xia PENG
Weipeng Zhang
Hongbin Liu
Haohan TAN
Ling Chen
Original Assignee
Shanghai Fochon Pharmaceutical Co Ltd
Shanghai Institute Of Materia Medica Chinese Academy Of Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Fochon Pharmaceutical Co Ltd, Shanghai Institute Of Materia Medica Chinese Academy Of Sciences filed Critical Shanghai Fochon Pharmaceutical Co Ltd
Priority to JP2015540039A priority Critical patent/JP6359020B6/en
Priority to DK13853072.0T priority patent/DK2917210T3/en
Priority to CN201380058088.6A priority patent/CN104854101B/en
Priority to RU2015121374A priority patent/RU2675850C2/en
Priority to KR1020157014984A priority patent/KR102156398B1/en
Priority to EP13853072.0A priority patent/EP2917210B1/en
Priority to AU2013344049A priority patent/AU2013344049B2/en
Priority to BR112015010221-2A priority patent/BR112015010221B1/en
Priority to CA2890006A priority patent/CA2890006C/en
Priority to ES13853072T priority patent/ES2728008T3/en
Publication of WO2014071832A1 publication Critical patent/WO2014071832A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • Anaplastic lymphoma kinase (ALK), a member of the insulin receptor superfamily of receptor tyrosine kinases, has been implicated in oncogenesis in hematopoietic and non-hematopoietic tumors.
  • ALK insulin receptor superfamily of receptor tyrosine kinases
  • the aberrant expression of full-length ALK receptor proteins has been reported in neuroblastomas and glioblastomas; and ALK fusion proteins have occurred in anaplastic large cell lymphoma.
  • the study of ALK fusion proteins has also raised the possibility of new therapeutic treatments for patients with ALK-positive malignancies. (Pulford et al., Cell. Mol. Life. Sci. 61 :2939-2953 (2004)).
  • ALK inhibitors are provided herein.
  • each R 1 is independently selected from:
  • alkyl, cycloalkyl, and heterocyclyl are each unsubstituted or substituted with at least one substituent, such as one, two, three, or four substituents, independently selected from R 6a
  • aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, such as one, two, three, or four substituents, independently selected from R 6b
  • each R 2 is indepedently selected from:
  • alkyl, alkenyl, alkynyl, cycloalkyl, and heterocyclyl are each unsubstituted or substituted with at least one substituent, such as one, two, three, or four substituents, independently selected from R 6a , and each aryl and heteroaryl is unsubstituted or substituted with at least one substituent, such as one, two, three, or four substituents, independently selected from R 6b ;
  • each R 3 is independently selected from:
  • alkyl is unsubstituted or substituted with at least one substituent, such as one, two, three, or four substituents, independently selected from R 6a ;
  • each R 4 is independently selected from:
  • Ci-io alkyl, C2-io alkenyl, C2-io alkynyl, and C3_io cycloalkyl are each
  • R 3 and R 4 together with the carbon atoms to which they are attached form a 5-6 membered ring containing 0, 1 , 2 or 3 heteroatoms independently selected from oxygen, sulfur and nitrogen, and optionally substituted with 1-2 R 6b groups;
  • each R 5 is indepedently selected from:
  • Ci-io alkyl, C 2 _io alkenyl, C 2 _io alkynyl, and C 3 _io cycloalkyl are each unsubstituted or substituted with at least one substituent, such as one, two, three, or four substituents, independently selected from R 6a ;
  • each R 6a is independently selected from:
  • each R 6b is independently selected from:
  • each R 7 and each R 8 are independently selected from:
  • alkyl, alkenyl, alkynyl, cycloalkyl, and heterocyclyl are each unsubstituted or substituted with at least one substituent, such as one, two, three, or four substituents, independently selected from R 6a
  • aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, such as one, two, three, or four substituents, independently selected from R 6b ;
  • R and R together with the atom(s) to which they are attached form a heterocyclic ring of 4 to 7 members containing 0, 1 , or 2 additional heteroatoms independently selected from oxygen, sulfur and NR 11 ,
  • each R 7 and R 8 may be unsubstituted or substituted on a carbon or nitrogen atom with at least one substituent, such as one, two, or three substituents, selected from R 12 ; each R 9 and each R 10 are independently selected from:
  • R 9 and R 10 together with the carbon atom(s) to which they are attached form a ring of 3 to 7 members containing 0, 1, or 2 heteroatoms independently selected from oxygen, sulfur and nitrogen;
  • each R 11 is independently selected from:
  • each m is independently selected from 0, 1 and 2;
  • each n is independently selected from 1 , 2, and 3;
  • each p is independently selected from 0, 1 , 2, and 3;
  • each q is independently selected from 0, 1 , 2, and 3;
  • each r is independently selected from 1 and 2;
  • each t is independently selected from 1 , 2, and 3.
  • the present disclosure provides pharmaceutical
  • compositions comprising at least one compound of formula (I) and/or at least one
  • the disclosure provides methods for modulating ALK, comprising administering to a system or a subject in need thereof, a therapeutically effective amount of at least one compound of formula (I) and/or at least one pharmaceutically acceptable salt thereof or pharmaceutical compositions thereof, thereby modulating said ALK.
  • the disclosure also provides methods to treat, ameliorate or prevent a condition which responds to inhibition of ALK comprising administering to a system or subject in need of such treatment an effective amount of at least one compound of formula (I) and/or at least one pharmaceutically acceptable salt thereof or pharmaceutical compositions thereof, and optionally in combination with a second therapeutic agent, thereby treating said condition.
  • the present disclosure provides the use of at least one compound of formula (I) and/or at least one pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a condition mediated by ALK.
  • the compounds of the disclosure may be used alone or in combination with a second therapeutic agent to treat a condition mediated by ALK, wherein said condition is an autoimmune disease, a transplantation disease, an infectious disease or a cell proliferative disorder.
  • the disclosure provides methods for treating a cell proliferative disorder, comprising administering to a system or subject in need of such treatment an effective amount of at least one compound of formula (I) and/or at least one pharmaceutically acceptable salt thereof or pharmaceutical compositions thereof, and optionally in combination with a second therapeutic agent, thereby treating said condition.
  • the present disclosure provides the use of at least one compound of formula (I) and/or at least one pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a cell-proliferative disorder.
  • the compounds of the disclosure may be used alone or in combination with a chemotherapeutic agent to treat a cell proliferative disorder, including but not limited to, lymphoma, osteosarcoma, melanoma, or a tumor of breast, renal, prostate, colorectal, thyroid, ovarian, pancreatic, neuronal, lung, uterine or gastrointestinal tumor.
  • At least one compound of formula (I) and/or at least one pharmaceutically acceptable salt thereof may be administered to a system comprising cells or tissues, or to a mammalian subject such as a human or animal subject.
  • Figure 1 Effect of a compound disclosed herein on relative tumor volume. [012] As used herein the following definitions are applicable.
  • alkyl refers to both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms. Unless otherwise specified, “alkyl” refers to Ci-Cio alkyl. For example, Ci-Cio, as in “Ci_io alkyl” is defined to include groups having 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbons in a linear or branched arrangement.
  • Ci-io alkyl includes but is not limited to methyl, ethyl, n-propyl, i-propyl, n-butyl, t-butyl, i- butyl, pentyl, hexyl, heptyl, octyl, nonyl, and decyl.
  • cycloalkyl means a saturated aliphatic cyclic hydrocarbon group having the specified number of carbon atoms. Unless otherwise specified, “cycloalkyl” refers to C3-10 cycloalkyl.
  • cycloalkyl includes but is not limited to cyclopropyl, methyl- cyclopropyl, 2,2-dimethyl-cyclobutyl, 2-ethyl-cyclopentyl, and cyclohexyl.
  • alkenyl refers to a non-aromatic hydrocarbon radical, straight, branched or cyclic, containing from 2 to 10 carbon atoms and at least one carbon to carbon double bond. In some embodiments, one carbon to carbon double bond is present, and up to four non-aromatic carbon-carbon double bonds may be present.
  • C 2-10 alkenyl means an alkenyl radical having from 2 to 10 carbon atoms.
  • Alkenyl groups include but are not limited to ethenyl, propenyl, butenyl, 2-methylbutenyl and cyclohexenyl. The straight, branched or cyclic portion of the alkenyl group may contain double bonds and may be substituted if a substituted alkenyl group is indicated.
  • alkynyl refers to a hydrocarbon radical straight, branched or cyclic, containing from 2 to 10 carbon atoms and at least one carbon to carbon triple bond. In some embodiments, up to three carbon-carbon triple bonds may be present.
  • C 2-10 alkynyl means an alkynyl radical having from 2 to 10 carbon atoms.
  • Alkynyl groups include but are not limited to ethynyl, propynyl, butynyl, and 3-methylbutynyl.
  • the straight, branched or cyclic portion of the alkynyl group may contain triple bonds and may be substituted if a substituted alkynyl group is indicated.
  • alkoxy refers to either a cyclic or non-cyclic alkyl group of indicated number of carbon atoms attached through an oxygen bridge such as, for example, methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, pentoxy, 2-pentyloxy, isopentoxy, neopentoxy, hexoxy, 2-hexoxy, 3-hexoxy, 3-methylpentoxy, cyclopropanyloxy, and cyclobutyloxy,. "Alkoxy” therefore encompasses the definitions of alkyl and cycloalkyl above.
  • aryl encompasses: 5- and 6-membered carbocyclic aromatic rings, for example, benzene; bicyclic ring systems wherein at least one ring is carbocyclic and aromatic, for example, naphthalene, indane, and 1 , 2,3, 4-tetrahydroquino line; and tricyclic ring systems wherein at least one ring is carbocyclic and aromatic, for example, fluorene.
  • the aryl substituent is bicyclic or tricyclic and at least one ring is non-aromatic, it is understood that attachment is via the aromatic ring.
  • aryl includes 5- and 6-membered carbocyclic aromatic rings fused to a 5- to 7-membered heterocyclic ring containing one or more heteroatoms selected from N, O, and S, provided that the point of attachment is at the carbocyclic aromatic ring.
  • Bivalent radicals formed from substituted benzene derivatives and having the free valences at ring atoms are named as substituted phenylene radicals.
  • Bivalent radicals derived from univalent polycyclic hydrocarbon radicals whose names end in "-yl" by removal of one hydrogen atom from the carbon atom with the free valence are named by adding "-idene" to the name of the
  • naphthylidene a corresponding univalent radical, e.g., a naphthyl group with two points of attachment is termed naphthylidene.
  • Aryl does not encompass or overlap in any way with heteroaryl, separately defined below. Hence, if one or more carbocyclic aromatic rings are fused with a heterocyclic aromatic ring, the resulting ring system is heteroaryl, not aryl, as defined herein.
  • halogen refers to fluorine, chlorine, bromine and iodine.
  • heteroaryl refers to
  • 8- to 12-membered bicyclic rings containing one or more, for example, from 1 to 4, or, in some embodiments, from 1 to 3, heteroatoms selected from , O, and S, with the remaining ring atoms being carbon and wherein at least one heteroatom is present in an aromatic ring; and
  • 11- to 14-membered tricyclic rings containing one or more, for example, from 1 to 4, or in some embodiments, from 1 to 3, heteroatoms selected from , O, and S, with the remaining ring atoms being carbon and wherein at least one heteroatom is present in an aromatic ring.
  • the total number of S and O atoms in the heteroaryl group exceeds 1, those heteroatoms are not adjacent to one another. In some embodiments, the total number of S and O atoms in the heteroaryl group is not more than 2. In some embodiments, the total number of S and O atoms in the heteroaryl group is not more than 1.
  • heteroaryl groups include, but are not limited to, (as numbered from the linkage position assigned priority 1), 2-pyridyl, 3-pyridyl, 4-pyridyl, 2,3-pyrazinyl, 3,4- pyrazinyl, 2,4-pyrimidinyl, 3,5-pyrimidinyl, 1-pyrazolyl, 2,3-pyrazolyl, 2,4-imidazolinyl, isoxazolyl, oxazolyl, thiazolyl, thiadiazolyl, tetrazolyl, thienyl, benzothienyl, furyl, benzofuryl, benzoimidazolinyl, indolinyl, pyridizinyl, triazolyl, quinolinyl, pyrazolyl, and 5,6,7,8- tetrahydroisoquinoline.
  • heteroaryl groups include but are not limited to pyrrolyl, isothiazolyl, triazinyl, pyrazinyl, pyridazinyl, indolyl, benzotriazolyl, quinoxalinyl, and isoquinolinyl.
  • heteroaryl is also understood to include the N-oxide derivative of any nitrogen-containing heteroaryl.
  • Bivalent radicals derived from univalent heteroaryl radicals whose names end in "-yl” by removal of one hydrogen atom from the atom with the free valence are named by adding "-idene" to the name of the corresponding univalent radical, e.g., a pyridyl group with two points of attachment is a pyridylidene.
  • Heteroaryl does not encompass or overlap with aryl as defined above.
  • heteroaryl substituent is bicyclic or tricyclic and at least one ring is non-aromatic or contains no heteroatoms, it is understood that attachment is via the aromatic ring or via the heteroatom containing ring, respectively.
  • heterocycle (and variations thereof such as “heterocyclic”, or
  • heterocyclyl broadly refers to a single aliphatic ring, usually with 3 to 7 ring atoms, containing at least 2 carbon atoms in addition to 1-3 heteroatoms independently selected from oxygen, sulfur, and nitrogen, as well as combinations comprising at least one of the foregoing heteroatoms.
  • Heterocycle also refers to 5- to 7-membered heterocyclic ring containing one or more heteroatoms selected from N, O, and S fused with 5- and 6-membered carbocyclic aromatic ring, provided that the point of attachment is at the heterocyclic ring.
  • the rings may be saturated or have one or more double bonds (i.e. partially unsaturated).
  • the heterocycle can be substituted by oxo.
  • the point of the attachment may be carbon or heteroatom in the heterocyclic ring, provided that attachment results in the creation of a stable structure.
  • the heterocyclic ring has substituents, it is understood that the substituents may be attached to any atom in the ring, whether a heteroatom or a carbon atom, provided that a stable chemical structure results.
  • Heterocycle does not overlap with heteroaryl.
  • Suitable heterocycles include, for example (as numbered from the linkage position assigned priority 1), 1 -pyrrolidinyl, 2-pyrrolidinyl, 2,4-imidazolidinyl, 2,3-pyrazolidinyl, 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, 1 -piperazinyl, 2-piperazinyl, and 2,5- piperazinyl.
  • Morpholinyl groups are also contemplated, including 2-morpholinyl and 3- morpholinyl (numbered wherein the oxygen is assigned priority 1).
  • Substituted heterocycle also includes ring systems substituted with one or more oxo moieties, such as piperidinyl N-oxide, morpholinyl-N-oxide, 1-oxo-l-thiomorpholinyl and 1,1-dioxo-l-thiomorpholinyl.
  • oxo moieties such as piperidinyl N-oxide, morpholinyl-N-oxide, 1-oxo-l-thiomorpholinyl and 1,1-dioxo-l-thiomorpholinyl.
  • arylalkyl refers to an alkyl moiety substituted by an aryl group.
  • Example arylalkyl groups include benzyl, phenethyl, and naphthylmethyl groups. In some embodiments, arylalkyl groups have from 7 to 20 or 7 to 11 carbon atoms.
  • aryl-Ci- 4 alkyl the term “C1- 4 " refers to the alkyl portion of the moiety and does not describe the number of atoms in the aryl portion of the moiety.
  • aryl-Ci-10 alkyl the term “Ci_io” refers to the alkyl portion of the moiety and does not describe the number of atoms in the aryl portion of the moiety.
  • heterocyclylalkyl refers to alkyl substituted by heterocyclyl.
  • C M O refers to the alkyl portion of the moiety and does not describe the number of atoms in the heterocyclyl portion of the moiety.
  • cycloalkylalkyl refers to alkyl substituted by cycloalkyl.
  • C3-10 cycloalkylalkyl refers to the cycloalkyl portion of the moiety and does not describe the number of atoms in the alkyl portion of the moiety.
  • C3- 7 cycloalkylalkyl refers to the cycloalkyl portion of the moiety and does not describe the number of atoms in the alkyl portion of the moiety.
  • C3-8 cycloalkylalkyl refers to the cycloalkyl portion of the moiety and does not describe the number of atoms in the alkyl portion of the moiety.
  • C 1-10 refers to the alkyl portion of the moiety and does not describe the number of atoms in the cycloalkyl portion of the moiety.
  • heteroarylalkyl refers to alkyl substituted by heteroaryl.
  • C1-4 refers to the alkyl portion of the moiety and does not describe the number of atoms in the heteroaryl portion of the moiety.
  • heteroaryl -C 1-10 alkyl refers to the alkyl portion of the moiety and does not describe the number of atoms in the heteroaryl portion of the moiety.
  • substitution of alkyl, cycloalkyl, heterocyclyl, aryl, and/or heteroaryl refers to substitution of each of those groups individually as well as to substitutions of combinations of those groups. That is, if R 1 is arylalkyl, the aryl portion may be unsubstituted or substituted with at least one substituent, such as one, two, three, or four substituents, independently selected from R 6b and the alkyl portion may also be unsubstituted or substituted with at least one substituent, such as one, two, three, or four substituens, independently selected from R 6a .
  • salts derived from inorganic bases may be selected, for example, from aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic, manganous, potassium, sodium, and zinc salts. Further, for example, the pharmaceutically acceptable salts derived from inorganic bases may be selected from ammonium, calcium, magnesium, potassium, and sodium salts. Salts in the solid form may exist in one or more crystal structures, and may also be in the form of hydrates.
  • Salts derived from pharmaceutically acceptable organic non-toxic bases may be selected, for example, from salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, choline,
  • ⁇ , ⁇ '-dibenzylethylene-diamine diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethyl-morpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, and tripropylamine, tromethamine.
  • salts may be prepared using at least one pharmaceutically acceptable non-toxic acid, selected from inorganic and organic acids.
  • acid may be selected, for example, from acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, and p-toluenesulfonic acids.
  • such acid may be selected, for example, from citric, hydrobromic, hydrochloric, maleic, phosphoric, sulfuric, fumaric, and tartaric acids.
  • co-administration or “combined administration” or the like as used herein are meant to encompass administration of the selected therapeutic agents to a single patient, and are intended to include treatment regimens in which the agents are not necessarily administered by the same route of administration or at the same time.
  • pharmaceutical combination refers to a product obtained from mixing or combining active ingredients, and includes both fixed and non-fixed combinations of the active ingredients.
  • fixed combination means that the active ingredients, e.g. a compound of Formula (I) and a co-agent, are both administered to a patient simultaneously in the form of a single entity or dosage.
  • non-fixed combination means that the active ingredients, e.g. a compound of Formula (I) and a co-agent, are both administered to a patient as separate entities either simultaneously, concurrently or sequentially with no specific time limits, wherein such administration provides therapeutically effective levels of the active ingredients in the body of the patient.
  • cocktail therapy e.g. the administration of three or more active ingredients.
  • therapeutically effective amount means the amount of the subject compound that will elicit a biological or medical response in a cell, tissue, organ, system, animal or human that is being sought by the researcher, veterinarian, medical doctor or other clinician.
  • administration means providing a compound of the disclosure and prodrugs thereof to a subject in need of treatment.
  • composition as used herein is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
  • composition in relation to a pharmaceutical composition is intended to encompass a product comprising the active ingredient (s), and the inert ingredient (s) that make up the carrier, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients.
  • pharmaceutically acceptable it is meant compatible with the other ingredients of the formulation and not unacceptably deleterious to the recipient thereof.
  • protecting group refers to a substituent that can be commonly employed to block or protect certain functionality while reacting other functional groups on the compound.
  • an "amino-protecting group” is a substituent attached to an amino group that blocks or protects the amino functionality in the compound. Suitable amino-protecting groups include but are not limited to acetyl, trifluoroacetyl, t-butoxycarbonyl (BOC), benzyloxycarbonyl (CBZ) and 9-fluorenylmethylenoxycarbonyl (Fmoc).
  • a "hydroxy- protecting group” refers to a substituent of a hydroxy group that blocks or protects the hydroxy functionality. Suitable protecting groups include but are not limited to acetyl and silyl.
  • a “carboxy-protecting group” refers to a substituent of the carboxy group that blocks or protects the carboxy functionality. Common carboxy-protecting groups include
  • each R 1 is independently selected from:
  • alkyl, cycloalkyl, and heterocyclyl are each unsubstituted or substituted with at least one substituent, such as one, two, three, or four substituents, independently selected from R a , and wherein aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, such as one, two, three, or four substituents, independently selected from R 6b ;
  • each R is indepedently selected from:
  • alkyl, alkenyl, alkynyl, cycloalkyl, and heterocyclyl are each unsubstituted or substituted with at least one substituent, such as one, two, three, or four substituents, independently selected from R 6a , and each aryl and heteroaryl is unsubstituted or substituted with at least one substituent, such as one, two, three, or four substituents, independently selected from R 6b ;
  • each R is independently selected from:
  • Ci_io alkyl wherein alkyl is unsubstituted or substituted with at least one substituent, such as one, two, three, or four substituents, independently selected from R 6a ;
  • each R4 is independently selected from:
  • C 1-10 alkyl, C2-io alkenyl, C2-io alkynyl, and C3_io cycloalkyl are each
  • R 3 and R 4 together with the carbon atoms to which they are attached form a 5-6 membered ring containing 0, 1 , 2 or 3 heteroatoms independently selected from oxygen, sulfur and nitrogen, and optionally substituted with 1-2 R 6b groups;
  • each R 5 is indepedently selected from:
  • Ci_io alkyl, C 2 _io alkenyl, C 2 _io alkynyl, and C 3 _io cycloalkyl are each unsubstituted or substituted with at least one substituent, such as one, two, three, or four substituents, independently selected from R 6a ;
  • each R 6a is independently selected from:
  • each R 6b is independently selected from:
  • each R 7 and each R 8 are independently selected from:
  • alkyl, alkenyl, alkynyl, cycloalkyl, and heterocyclyl are each unsubstituted or substituted with at least one substituent, such as one, two, three, or four substituents, independently selected from R 6a
  • aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, such as one, two, three, or four substituents, independently selected from R 6b ; or R 7 and R 8 together with the atom(s) to which they are attached form a heterocyclic ring of 4 to 7 members containing 0, 1, or 2 additional heteroatoms independently selected from oxygen, sulfur and NR 11 ,
  • each R 7 and R 8 may be unsubstituted or substituted on a carbon or nitrogen atom with at least one substituent, such as one, two, or three substituents, selected from R 12 ;
  • each R 9 and each R 10 are independently selected from:
  • R 9 and R 10 together with the carbon to which they are attached form a ring of 3 to 7 members containing 0, 1, or 2 heteroatoms independently selected from oxygen, sulfur and nitrogen; each R 11 is independently selected from:
  • heteroaryl heteroaryl-Ci-4 alkyl
  • each R 12 is independently selected from: halogen,
  • each m is independently selected from 0, 1 and 2;
  • each n is independently selected from 1 , 2, and 3;
  • each p is independently selected from 0, 1 , 2, and 3;
  • each q is independently selected from 0, 1 , 2, and 3;
  • each r is independently selected from 1 and 2;
  • each t is independently selected from 1 , 2, and 3.
  • each R 1 is independently selected from hydrogen and Ci_io alkyl, wherein alkyl is unsubstituted or substituted with at least one substituent, such as one, two, three, or four substituents, independently selected from hydroxyl and Ci_io alkoxy.
  • R 1 is hydrogen
  • each R 1 is independently selected from C MO alkyl, wherein alkyl is unsubstituted or substituted with at least one substituent, such as one, two, three, or four substituents, independently selected from hydroxyl and C MO alkoxy.
  • R 1 is methyl, hydroxymethyl, or methoxymethyl.
  • each R 2 is independently selected from C MO alkyl, heterocyclylcarbonyl, and heterocyclyl, wherein alkyl and heterocyclyl are independently unsubstituted or substituted with at least one substituent, such as one, two, three, or four substituents, independently selected from R 6a , R 6a is as described above.
  • each R 2 is independently selected from C 1-10 alkyl and piperidinyl which are unsubstituted or substituted with at least one substituent, such as one, two, three, or four substituents, independently selected from R 6a , R 6a is as described above.
  • each R 2 is independently selected from methyl and 4- piperidinyl which are unsubstituted or substituted with at least one substituent, such as one, two, three, or four substituents, independently selected from R 6a , R 6a is as described above.
  • each R 2 is independently selected from methyl and 4- piperidinyl, wherein 4-piperidinyl is unsubstituted or substituted with at least one substituent, such as one, two, three, or four substituents, independently selected from R 6a , wherein R 6a is independently selected from C M0 alkyl, -C(0)R 7 , -S(0) r R 7 , -(CR 9 R 10 ) t CO 2 R 8 ,
  • R 3 is hydrogen
  • each R 4 is independently selected from hydrogen, Ci_io alkyl, and halogen.
  • each R 4 is independently selected from halogen. [057] In some embodiments, R 4 is chlorine.
  • R 3 and R 4 together with the carbon atoms to which they are attached form a 5-membered ring containing 2 nitrogen atoms, wherein the 5-membered ring is optionally substituted with lor 2 Ci_io alkyl.
  • R 3 and R 4 together with the carbon atoms to which they are attached form pyrazolo.
  • R 5 is -S(0) r R 7 , R 7 and r are as described above.
  • R 5 is -S(0) 2 R 7 ,wherein R 7 is selected from Ci_io alkyl.
  • R 5 is -S(0) 2 R 7 ,wherein R 7 is isopropyl.
  • n is 1.
  • p is 2.
  • m is 1.
  • q is 1.
  • At least one compound selected from:
  • compounds of formula (I) may inhibit the tyrosine kinase activity of ALK and the fusion protein of NPM-ALK.
  • This protein tyrosine kinase results from a gene fusion of nucleophosmin (NPM) and ALK, rendering the protein tyrosine kinase activity of ALK ligand independent.
  • NPM nucleophosmin
  • NPM-ALK plays a key role in signal transmission in a number of hematopoetic and other human cells leading to hematological and neoplastic diseases, for example in anaplastic large-cell lymphoma (ALCL) and non-Hodgkin's lymphomas (NHL), specifically in ALK+NHL or Alkomas, in inflammatory myofibroblastic tumors (IMT) and neuroblastomas.
  • ACL anaplastic large-cell lymphoma
  • NHL non-Hodgkin's lymphomas
  • IMT myofibroblastic tumors
  • neuroblastomas Duyster et al. 2001 Oncogene 20, 5623-5637.
  • TPM3-ALK a fusion of nonmuscle tropomyosin with ALK
  • ALK tyrosine kinase activity may be demonstrated using known methods, for example using the recombinant kinase domain of the ALK in analogy to the VEGF- R kinase assay described in J. Wood et al. Cancer Res. 60, 2178-2189 (2000).
  • Reactions are terminated by adding 50 ⁇ of 125 mM EDTA, and the reaction mixture is transferred onto a MAIP Multiscreen plate (Millipore, Bedford, Mass., USA), previously wet with methanol, and rehydrated for 5 min with H 2 0. Following washing (0.5% H 3 PO 4 ), plates are counted in a liquid scintillation counter. IC 50 values are calculated by linear regression analysis of the percentage inhibition.
  • Compounds of formula (I) may potently inhibit the growth of human NPM-ALK overexpressing murine BaF3 cells (DSMZ Manual Sammiung von Mikroorganismen und Zellkulturen GmbH, Germany).
  • the expression of NPM-ALK may be achieved by transfecting the BaF3 cell line with an expression vector pClneoTM (Pro mega Corp., Madison Wis., USA) coding for NPM-ALK and subsequent selection of G418 resistant cells.
  • Non-transfected BaF3 cells depend on IL-3 for cell survival.
  • NPM-ALK expressing BaF3 cells can proliferate in the absence of IL-3 because they obtain proliferative signal through NPM-ALK kinase. Putative inhibitors of the NPM-ALK kinase therefore abolish the growth signal and may result in antiproliferative activity.
  • the inhibitory activity of the compounds of the invention may be determined as follows.
  • BaF3-NPM-ALK cells (15,000/microtitre plate well) are transferred to 96- well microtitre plates.
  • Test compounds dissolved in dimethyl sulfoxide (DMSO) are added in a series of concentrations (dilution series) in such a manner that the final concentration of DMSO is not greater than 1% (v/v).
  • DMSO dimethyl sulfoxide
  • the plates are incubated for two days during which the control cultures without test compound are able to undergo two cell-division cycles.
  • the growth of the BaF3-NPM-ALK cells is measured by means of YOPROTM staining [T Idziorek et al. J. Immunol.
  • IC 50 value in those experiments is given as that concentration of the test compound in question that results in a cell count that is 50% lower than that obtained using the control without inhibitor.
  • the compounds of the disclosure in free form or in pharmaceutically acceptable salt form may exhibit valuable pharmacological properties, for example, as indicated by the in vitro tests described in this application.
  • compounds of the disclosure have IC 50 values from less than 1 nM to 10 ⁇ .
  • compounds of the disclosure have IC 50 values from less than 1 nM to 500 nM.
  • compounds of the disclosure have IC 50 values from ⁇ InM to 200 nM.
  • the antiproliferative action of the inventive compounds may also be determined in the human KARPAS-299 lymphoma cell line (DSMZ Manual Sammiung von
  • compounds disclosed herein may exhibit inhibitory activity with an IC 50 in the range from approximately less than lnm to 1 ⁇ .
  • the action of the inventive compounds on autophosphorylation of the ALK may be determined in the human KARPAS-299 lymphoma cell line by means of an immunoblot as described in WG Dirks et al. Int. J. Cancer 100, 49-56 (2002).
  • a pharmaceutical composition e.g. for use in any of the indications herein set forth above, comprising at least one compound disclosed herein as active ingredient together with one or more pharmaceutically acceptable diluents or carriers; (4) a method for treatment of any particular indication set forth above in a subject in need thereof which comprises administering an effective amount of at least one compound disclosed herein or at least one pharmaceutical composition comprising thereof;
  • composition comprising a therapeutically effective amount of at least one compound disclosed herein and at least one additional drug substance, wherein said additional drug substance is useful in any of the particular indications set forth above;
  • the disease to be treated is selected from anaplastic large cell lymphoma, non-Hodgkin's lymphomas, inflammatory myofibroblastic tumors, neuroblastomas and neoplastic diseases;
  • (11) a method for the treatment of a disease which responds to inhibition of the anaplastic lymphoma kinase, such as a disease selected from anaplastic large-cell lymphoma, non
  • Hodgkin's lymphomas, inflammatory myofibroblastic tumors, neuroblastomas and neoplastic diseases comprising administering an effective amount of at least one compound disclosed herein and/or a pharmaceutically acceptable salt thereof.
  • the compounds of the disclosure may be used alone or in combination with a chemotherapeutic agent to treat a cell proliferative disorder, including but not limited to, lymphoma, osteosarcoma, melanoma, or a tumor of breast, renal, prostate, colorectal, thyroid, ovarian, pancreatic, neuronal, lung, uterine or gastrointestinal tumor.
  • compounds of the disclosure will be administered in therapeutically effective amounts via any of the usual and acceptable modes known in the art, either singly or in combination with one or more therapeutic agents.
  • a therapeutically effective amount may vary widely depending on the severity of the disease, the age and relative health of the subject, the potency of the compound used and other factors known to those of ordinary skill in the art.
  • the required dosage will also vary depending on the mode of administration, the particular condition to be treated and the effect desired.
  • compositions by any conventional route for example, enterally, e.g., orally, e.g., in the form of tablets or capsules; parenterally, e.g., in the form of injectable solutions or suspensions; or topically, e.g., in the form of lotions, gels, ointments or creams, or in a nasal or suppository form.
  • compositions comprising a compound of the present disclosure in free form or in a pharmaceutically acceptable salt form in association with at least one
  • compositions comprising a compound of the disclosure in association with at least one pharmaceutical acceptable carrier or diluent may be manufactured in conventional manner by mixing with a pharmaceutically acceptable carrier or diluent.
  • Unit dosage forms for oral administration contain, for example, from about 0.1 mg to about 500 mg of active substance.
  • the pharmaceutical compositions are solutions of the active ingredient, including suspensions or dispersions, such as isotonic aqueous solutions.
  • suspensions or dispersions such as isotonic aqueous solutions.
  • dispersions or suspensions can be made up before use.
  • the pharmaceutical compositions may be sterilized and/or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers. Suitable preservatives include but are not limited to antioxidants such as ascorbic acid, or microbicides, such as sorbic acid or benzoic acid.
  • the solutions or suspensions may further comprise viscosity-increasing agents, including but not limited to, sodium
  • carboxymethylcellulose carboxymethylcellulose, carboxymethylcellulose, dextran, polyvinylpyrrolidone, gelatins, or solubilizers, e.g. Tween 80 (polyoxyethylene(20)sorbitan mono-oleate).
  • Suspensions in oil may comprise as the oil component the vegetable, synthetic, or semi-synthetic oils customary for injection purposes.
  • oils customary for injection purposes.
  • Examples include liquid fatty acid esters that contain as the acid component a long-chained fatty acid having from 8 to 22 carbon atoms, or in some embodiments, from 12 to 22 carbon atoms.
  • Suitable liquid fatty acid esters include but are not limited to lauric acid, tridecylic acid, myristic acid, pentadecylic acid, palmitic acid, margaric acid, stearic acid, arachidic acid, behenic acid or corresponding unsaturated acids, for example oleic acid, elaidic acid, erucic acid, brassidic acid and linoleic acid, and if desired, may contain antioxidants, for example vitamin E, 3-carotene or 3,5-di-tert-butyl-hydroxytoluene.
  • the alcohol component of these fatty acid esters may have six carbon atoms and may be monovalent or polyvalent, for example a mono-, di- or trivalent, alcohol. Suitable alcohol components include but are not limited to methanol, ethanol, propanol, butanol or pentanol or isomers thereof; glycol and glycerol.
  • Suitable fatty acid esters include but are not limited ethyl-oleate, isopropyl myristate, isopropyl palmitate, LABRAFIL® M 2375, (polyoxyethylene glycerol),
  • LABRAFIL® M 1944 CS (unsaturated polyglycolized glycerides prepared by alcoho lysis of apricot kernel oil and comprising glycerides and polyethylene glycol ester), LABRASOLTM (saturated polyglycolized glycerides prepared by alcoho lysis of TCM and comprising glycerides and polyethylene glycol ester; all available from GaKefosse, France), and/or MIGLYOL® 812 (triglyceride of saturated fatty acids of chain length C8 to C12 from Huls AG, Germany), and vegetable oils such as cottonseed oil, almond oil, olive oil, castor oil, sesame oil, soybean oil, or groundnut oil.
  • LABRASOLTM saturated polyglycolized glycerides prepared by alcoho lysis of TCM and comprising glycerides and polyethylene glycol ester; all available from GaKefosse, France
  • MIGLYOL® 812 triglyceride of saturated
  • compositions for oral administration may be obtained, for example, by combining the active ingredient with one or more solid carriers, and if desired, granulating a resulting mixture, and processing the mixture or granules by the inclusion of additional excipients, to form tablets or tablet cores.
  • Suitable carriers include but are not limited to fillers, such as sugars, for example lactose, saccharose, mannitol or sorbitol, cellulose preparations, and/or calcium phosphates, for example tricalcium phosphate or calcium hydrogen phosphate, and also binders, such as starches, for example corn, wheat, rice or potato starch, methylcellulose, hydroxypropyl methylcellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone, and/or, if desired, disintegrators, such as the above-mentioned starches, carboxymethyl starch, crosslinked polyvinylpyrrolidone, alginic acid or a salt thereof, such as sodium alginate.
  • Additional excipients include flow conditioners and lubricants, for example silicic acid, talc, stearic acid or salts thereof, such as magnesium or calcium stearate, and/or polyethylene glycol, or derivatives thereof.
  • Tablet cores may be provided with suitable, optionally enteric, coatings through the use of, inter alia, concentrated sugar solutions which may comprise gum arable, talc, polyvinylpyrrolidone, polyethylene glycol and/or titanium dioxide, or coating solutions in suitable organic solvents or solvent mixtures, or, for the preparation of enteric coatings, solutions of suitable cellulose preparations, such as acetylcellulose phthalate or
  • hydroxypropylmethylcellulose phthalate hydroxypropylmethylcellulose phthalate.
  • Dyes or pigments may be added to the tablets or tablet coatings, for example for identification purposes or to indicate different doses of active ingredient.
  • compositions for oral administration may also include hard capsules comprising gelatin or soft-sealed capsules comprising gelatin and a plasticizer, such as glycerol or sorbitol.
  • the hard capsules may contain the active ingredient in the form of granules, for example in admixture with fillers, such as corn starch, binders, and/or glidants, such as talc or magnesium stearate, and optionally stabilizers.
  • the active ingredient may be dissolved or suspended in suitable liquid excipients, such as fatty oils, paraffin oil or liquid polyethylene glycols or fatty acid esters of ethylene or propylene glycol, to which stabilizers and detergents, for example of the polyoxyethylene sorbitan fatty acid ester type, may also be added.
  • suitable liquid excipients such as fatty oils, paraffin oil or liquid polyethylene glycols or fatty acid esters of ethylene or propylene glycol, to which stabilizers and detergents, for example of the polyoxyethylene sorbitan fatty acid ester type, may also be added.
  • compositions suitable for rectal administration are, for example, suppositories comprising a combination of the active ingredient and a suppository base.
  • Suitable suppository bases are, for example, natural or synthetic triglycerides, paraffin hydrocarbons, polyethylene glycols or higher alkanols.
  • compositions suitable for parenteral administration may comprise aqueous solutions of an active ingredient in water-soluble form, for example of a water-soluble salt, or aqueous injection suspensions that contain viscosity-increasing substances, for example sodium carboxymethylcellulose, sorbitol and/or dextran, and, if desired, stabilizers.
  • the active ingredient optionally together with excipients, can also be in the form of a lyophilizate and can be made into a solution before parenteral administration by the addition of suitable solvents. Solutions such as are used, for example, for parenteral administration can also be employed as infusion solutions.
  • the manufacture of injectable preparations is usually carried out under sterile conditions, as is the filling, for example, into ampoules or vials, and the sealing of the containers.
  • the compounds of the disclosure may be administered as the sole active ingredient, or together with other drugs useful against neoplastic diseases or useful in
  • the compounds of the disclosure may be used in accordance with the disclosure in combination with pharmaceutical compositions effective in various diseases as described above, e.g. with cyclophosphamide, 5-fluorouracil, fludarabine, gemcitabine, cisplatinum, carboplatin, vincristine, vinblastine, etoposide, irinotecan, paclitaxel, docetaxel, rituxan, doxorubicine, gefitinib, or imatinib; or also with cyclosporins, rapamycins, ascomycins or their immunosuppressive analogs, e.g.
  • cyclosporin A cyclosporin G, FK-506, sirolimus or everolimus
  • corticosteroids e.g. prednisone, cyclophosphamide, azathioprene, methotrexate, gold salts, sulfasalazine, antimalarials, brequinar, leflunomide, mizoribine, mycophenolic acid, mycophenolate, mofetil, 15-deoxyspergualine, immuno-suppressive monoclonal antibodies, e.g. monoclonal antibodies to leukocyte receptors, e.g.
  • the disclosure also provides for a pharmaceutical combinations, e.g. a kit, comprising a) a first agent which is a compound of the disclosure as disclosed herein, in free form or in pharmaceutically acceptable salt form, and b) at least one co-agent.
  • a pharmaceutical combination e.g. a kit, comprising a) a first agent which is a compound of the disclosure as disclosed herein, in free form or in pharmaceutically acceptable salt form, and b) at least one co-agent.
  • the kit can comprise instructions for its administration.
  • the at least one compound of formula (I) can also be prepared as a
  • a pharmaceutically acceptable base addition salt of the at least one compound of formula (I) can be prepared by, for example, reacting the free acid form of the at least one compound with a pharmaceutically acceptable inorganic or organic base.
  • inorganic and organic acids and bases suitable for the preparation of the pharmaceutically acceptable salts of compounds of formula (I) are set forth in the definitions section of this Application.
  • salt forms of the compounds of formula (I) can be prepared using salts of the starting materials or intermediates.
  • the free acid or free base forms of the compounds of formula (I) can be prepared from the corresponding base addition salt or acid addition salt form.
  • a compound of formula (I) in an acid addition salt form can be converted to the corresponding free base thereof by treating with a suitable base (e.g., ammonium hydroxide solution, sodium hydroxide, and the like).
  • a suitable base e.g., ammonium hydroxide solution, sodium hydroxide, and the like.
  • a compound of formula (I) in a base addition salt form can be converted to the
  • a suitable acid e.g., hydrochloric acid, etc.
  • N-oxides of the at least one compound of formula (I) and/or at least one pharmaceutically acceptable salt thereof can be prepared by methods known to those of ordinary skill in the art.
  • N-oxides can be prepared by treating an unoxidized form of the compound of formula (I) with an oxidizing agent (e.g., trifluoroperacetic acid, permaleic acid, perbenzoic acid, peracetic acid, meta-chloroperoxybenzoic acid, or the like) in a suitable inert organic solvent (e.g., a halogenated hydrocarbon such as dichloromethane) at approximately 0 to 80 °C.
  • an oxidizing agent e.g., trifluoroperacetic acid, permaleic acid, perbenzoic acid, peracetic acid, meta-chloroperoxybenzoic acid, or the like
  • a suitable inert organic solvent e.g., a halogenated hydrocarbon such as dichloromethane
  • Compounds of formula (I) in an unoxidized form can be prepared from N-oxides of compounds of formula (I) by, for example, treating with a reducing agent (e.g., sulfur, sulfur dioxide, triphenyl phosphine, lithium borohydride, sodium borohydride, phosphorus trichloride, tribromide, and the like) in an suitable inert organic solvent (e.g., acetonitrile, ethanol, aqueous dioxane, and the like) at 0 to 80 °C.
  • a reducing agent e.g., sulfur, sulfur dioxide, triphenyl phosphine, lithium borohydride, sodium borohydride, phosphorus trichloride, tribromide, and the like
  • an inert organic solvent e.g., acetonitrile, ethanol, aqueous dioxane, and the like
  • Hydrates of the at least one compound of formula I and/or at least one pharmaceutically acceptable salt thereof may be conveniently prepared by recrystallization from an aqueous/organic solvent mixture, using organic solvents such as dioxin, tetrahydrofuran and/or methanol.
  • stereoisomers by reacting a racemic mixture of the compounds with an optically active resolving agent to form a pair of diastereoisomeric compounds, separating the diastereomers, and recovering the optically pure enantiomer. While resolution of enantiomers can be carried out using covalent diasteromeric derivatives of compounds, dissociable complexes are preferred (e.g., crystalline diastereoisomeric salts). Diastereomers have distinct physical properties (e.g., melting points, boiling points, solubilities, reactivity, etc.) and can be readily separated by taking advantage of these dissimilarities. The diastereomers can be separated by chromatography or, for example, by separation/resolution techniques based upon differences in solubility.
  • optically pure enantiomer is then recovered, along with the resolving agent, by any practical means that would not result in racemization.
  • a more detailed description of the techniques applicable to the resolution of stereoisomers of compounds from their racemic mixture can be found in Jean Jacques Andre Collet, Samuel H. Wilen, Enantiomers, Racemates and Resolutions, John Wiley & Sons, Inc. (1981).
  • H NMR spectra were recorded on a Varian Mercury Plus 400. Chemical shifts are expressed in parts per million (ppm). Coupling constants are in units of hertz (Hz). Splitting patterns describe apparent multiplicities and are designated as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), and br (broad).
  • the at least one compound of formula (I) and/or at least one pharmaceutically acceptable salt thereof may be synthesized according to a variety of reaction schemes. Some illustrative schemes are provided below and in the examples. Other reaction schemes could be readily devised by those skilled in the art in view of the present disclosure.
  • the title compound 5a was prepared according to the method for preparation of compound 3b of Example 3 by replacing (5)-2-methyloxirane with (ii)-2-methyloxirane.
  • Examples 15-58 were derivatized from Compound 9 or Compound 11 via N-alkylation, acylation, or sulfonylation as shown the following scheme using conditions known in the art.
  • the carbon marked with "*” has chirality as set forth in the chemical structures in Table 1.
  • SU-DHL- 1 cells were seeded in 96-well tissue culture plates. On the next day, cells were exposed to various concentrations of compounds and further cultured for 72 h. Cell proliferation was then determined using Cell Counting Kit-8 [(CCK-8), Dojindo] assay. Briefly, add 10 of the CCK-8 solution to each well of the plate. Incubate the plate for 1 -4 hours in the incubator. Measure the absorbance at 450 nm using a multi-well spectrophotometer
  • the inhibition rate (%) was calculated using the following equation: [1 -(A450 Compound/ A450 Control)] x l 00%.
  • IC 50 values were calculated according to inhibition curve by four-parameter fit.
  • LDK378 was prepared as example 7 of WO2008073687. in vivo antitumor activity
  • mice Male nude mice (6-week old) were housed in a specific pathogen-free room with a 12 h light/dark schedule at 20-25 °C and were fed an autoclaved chow diet and water ad libitum.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Disclosed herein are ALK kinase inhibitors, pharmaceutical compositions thereof, and pharmaceutical uses thereof. More particularly disclosed herein are compounds of Formula (I), wherein each substituent of Formula (I) is defined as in the description.

Description

ALK KINASE INHIBITORS
[001] Disclosed herein are protein kinase inhibitors, more particularly novel pyrimidine derivatives and pharmaceutical compositions thereof, and their use as pharmaceuticals.
[002] Anaplastic lymphoma kinase (ALK), a member of the insulin receptor superfamily of receptor tyrosine kinases, has been implicated in oncogenesis in hematopoietic and non-hematopoietic tumors. The aberrant expression of full-length ALK receptor proteins has been reported in neuroblastomas and glioblastomas; and ALK fusion proteins have occurred in anaplastic large cell lymphoma. The study of ALK fusion proteins has also raised the possibility of new therapeutic treatments for patients with ALK-positive malignancies. (Pulford et al., Cell. Mol. Life. Sci. 61 :2939-2953 (2004)).
[003] Because of the emerging disease-related roles of ALK, there is a continuing need for compounds which may be useful for treating and preventing a disease which responds to inhibition of ALK and have at least one advantageous property selected from potency, stability, selectivity, toxicity, pharmacodynamics properties and pharmacokinetics properties as an alternative. In this regard, a novel class of ALK inhibitors is provided herein..
[004] Disclosed herein are certain novel pyrimidine derivatives and pharmaceutical compositions thereof, and their use as pharmaceuticals.
[005] In one aspect, disclosed herein is at least one compound of formula (I):
Figure imgf000004_0001
and/or at least one pharmaceutically acceptable salt thereof,
wherein:
each R1 is independently selected from:
hydrogen,
halogen,
hydroxyl,
Ci_io alkyl,
C3_io cycloalkyl,
C3-10 cycloalkyl-alkyl,
heterocyclyl,
heterocyclylalkyl
aryl,
arylalkyl,
heteroaryl, and
heteroarylalkyl,
wherein alkyl, cycloalkyl, and heterocyclyl are each unsubstituted or substituted with at least one substituent, such as one, two, three, or four substituents, independently selected from R6a, and wherein aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, such as one, two, three, or four substituents, independently selected from R6b; each R2 is indepedently selected from:
hydrogen, halogen,
hydroxyl,
Ci_io alkyl,
C2-10 alkenyl,
C2-10 alkynyl,
C3- 10 cycloalkyl,
C3-10 cycloalkylalkyl,
heterocyclyl,
heterocyclylalkyl
heterocyclylcarbonyl,
aryl,
heteroaryl,
arylalkyl, and
heteroarylalkyl,
wherein alkyl, alkenyl, alkynyl, cycloalkyl, and heterocyclyl are each unsubstituted or substituted with at least one substituent, such as one, two, three, or four substituents, independently selected from R6a, and each aryl and heteroaryl is unsubstituted or substituted with at least one substituent, such as one, two, three, or four substituents, independently selected from R6b;
each R3 is independently selected from:
hydrogen,
halogen,
-CN,
-NR7R8, and
Ci_io alkyl;
wherein alkyl is unsubstituted or substituted with at least one substituent, such as one, two, three, or four substituents, independently selected from R6a;
each R4 is independently selected from:
hydrogen,
halogen, -CN,
Ci_io alkyl,
C2-10 alkenyl,
C2-io alkynyl, and
C3_io cycloalkyl;
wherein Ci-io alkyl, C2-io alkenyl, C2-io alkynyl, and C3_io cycloalkyl are each
unsubstituted or substituted with at least one substituent, such as one, two, three, or four substituents, independently selected from R6a;
or R3 and R4 together with the carbon atoms to which they are attached form a 5-6 membered ring containing 0, 1 , 2 or 3 heteroatoms independently selected from oxygen, sulfur and nitrogen, and optionally substituted with 1-2 R6b groups;
each R5 is indepedently selected from:
hydrogen,
Ci_io alkyl,
C2-10 alkenyl,
C2-10 alkynyl,
C3_io cycloalkyl,
-OR8,
-NR7S(0)rR8,
-N02,
halogen,
-S(0)rR7,
-SR8,
-S(0)2OR7,
-OS(0)2R8,
-S(0)rNR7R8,
-NR7R8,
-O(CR9R10)tNR7R8,
-C(0)R7,
-C02R8, -CO2(CR9R10)tCONR7R8,
-OC(0)R7,
-CN,
-C(0)NR7R8,
-NR7C(0)R8,
-OC(0)NR7R8,
-NR7C(0)OR8,
-NR7C(0)NR7R8,
-CR7( -OR8),
-CHF2,
-CF3,
-OCHF2, and
-OCF3;
wherein Ci-io alkyl, C2_io alkenyl, C2_io alkynyl, and C3_io cycloalkyl are each unsubstituted or substituted with at least one substituent, such as one, two, three, or four substituents, independently selected from R6a;
each R6ais independently selected from:
Ci_io alkyl,
C2_i0 alkenyl,
C2_i0 alkynyl,
C3_io cycloalkyl,
-OR8,
-NR7S(0)rR8,
-NO2,
halogen,
-S(0)rR7,
-SR8,
-S(0)2OR7,
-OS(0)2R8,
-S(0)rNR7R8, -NR7R8,
Figure imgf000008_0001
-(CR9R10)tNR7R8,
-(CR9R10)tSR8,
-(CR9R10)tS(O)rR8,
-(CR9R10)tCO2R8,
-(CR9R10)tCONR7R8,
-(CR9R10)tNR7CO2R8,
-(CR9R10)tOCONR7R8,
-(CR9R10)tNR7CONR7R8,
-(CR9R10)tNR7SO2NR7R8,
-O(CR9R10)tNR7R8,
-C(0)R7,
-C(O)(CR9R10)tOR8,
-C(O)(CR9R10)tNR7R8,
-C(O)(CR9R10)tSR8,
-C(O)(CR9R10)tS(O)rR8,
-C02R8,
-CO2(CR9R10)tCONR7R8,
-OC(0)R7,
-CN,
-C(0)NR7R8,
-NR7C(0)R8,
-OC(0)NR7R8,
-NR7C(0)OR8,
-NR7C(0)NR7R8,
-CR7( -OR8),
-CHF2,
-CF3,
-OCHF2, and each R6b is independently selected from:
R6a,
aryl,
aryl-Ci-4 alkyl,
heteroaryl, and
heteroaryl-Ci-4 alkyl;
each R7 and each R8 are independently selected from:
hydrogen,
Ci_io alkyl,
C2-10 alkenyl,
C2-10 alkynyl,
cycloalkyl,
cycloalkyl-Ci-io alkyl;
heterocyclyl,
heterocyclyl-Ci-io alkyl,
aryl,
heteroaryl,
aryl-Ci_io alkyl, and
heteroaryl-Ci-io alkyl;
wherein alkyl, alkenyl, alkynyl, cycloalkyl, and heterocyclyl are each unsubstituted or substituted with at least one substituent, such as one, two, three, or four substituents, independently selected from R6a, and aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, such as one, two, three, or four substituents, independently selected from R6b; or
7 8 ·
R and R together with the atom(s) to which they are attached form a heterocyclic ring of 4 to 7 members containing 0, 1 , or 2 additional heteroatoms independently selected from oxygen, sulfur and NR11,
each R7 and R8 may be unsubstituted or substituted on a carbon or nitrogen atom with at least one substituent, such as one, two, or three substituents, selected from R12; each R9 and each R10 are independently selected from:
hydrogen,
Ci_io alkyl,
C2-10 alkenyl,
C2-10 alkynyl,
cycloalkyl,
cycloalkyl-Ci-io alkyl,
heterocyclyl,
heterocyclyl-Ci-io alkyl,
aryl,
heteroaryl,
aryl-Ci-io alkyl, and
heteroaryl-Ci-io alkyl; or
R9 and R10 together with the carbon atom(s) to which they are attached form a ring of 3 to 7 members containing 0, 1, or 2 heteroatoms independently selected from oxygen, sulfur and nitrogen;
each R11 is independently selected from:
hydrogen,
Ci_io alkyl,
C3- io cycloalkyl,
C3_io cycloalkyl-Ci-4 alkyl,
heterocyclyl,
heterocyclyl-Ci-4 alkyl,
aryl,
aryl-Ci-4 alkyl,
heteroaryl,
heteroaryl-Ci-4 alkyl,
-S(0)rR7,
-C(0)R7,
-C02R7, -CO2(CR9R10)tCONR7R8, and -C(0)NR7R8;
2 is independently selected from: halogen,
C1-10 alkyl,
C3_io cycloalkyl,
C3-10 cycloalkylalkyl, heterocyclyl,
heterocyclylalkyl,
aryl,
aryl-Ci-4 alkyl,
heteroaryl,
heteroaryl-Ci-4 alkyl,
-OR7,
-NR7S(0)rR8,
-S(0)rR7,
-SR7,
-S(0)2OR7,
-OS(0)2R7,
-S(0)rNR7R8,
-NR7R8,
-O(CR9R10)tNR7R8,
-C(0)R7,
-C02R8,
-CO2(CR9R10)tCONR7R8,
-OC(0)R7,
-CN,
-C(0)NR7R8,
-NR7C(0)R8,
-OC(0)NR7R8, -NR7C(0)OR8,
-NR7C(0)NR7R8,
-CHF2,
-CF3,
-OCHF2, and
-OCF3;
each m is independently selected from 0, 1 and 2;
each n is independently selected from 1 , 2, and 3;
each p is independently selected from 0, 1 , 2, and 3;
each q is independently selected from 0, 1 , 2, and 3;
each r is independently selected from 1 and 2;
each t is independently selected from 1 , 2, and 3.
[006] In yet another aspect, the present disclosure provides pharmaceutical
compositions comprising at least one compound of formula (I) and/or at least one
pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.
[007] In yet another aspect, the disclosure provides methods for modulating ALK, comprising administering to a system or a subject in need thereof, a therapeutically effective amount of at least one compound of formula (I) and/or at least one pharmaceutically acceptable salt thereof or pharmaceutical compositions thereof, thereby modulating said ALK. The disclosure also provides methods to treat, ameliorate or prevent a condition which responds to inhibition of ALK comprising administering to a system or subject in need of such treatment an effective amount of at least one compound of formula (I) and/or at least one pharmaceutically acceptable salt thereof or pharmaceutical compositions thereof, and optionally in combination with a second therapeutic agent, thereby treating said condition. Alternatively, the present disclosure provides the use of at least one compound of formula (I) and/or at least one pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a condition mediated by ALK. In particular embodiments, the compounds of the disclosure may be used alone or in combination with a second therapeutic agent to treat a condition mediated by ALK, wherein said condition is an autoimmune disease, a transplantation disease, an infectious disease or a cell proliferative disorder.
[008] Furthermore, the disclosure provides methods for treating a cell proliferative disorder, comprising administering to a system or subject in need of such treatment an effective amount of at least one compound of formula (I) and/or at least one pharmaceutically acceptable salt thereof or pharmaceutical compositions thereof, and optionally in combination with a second therapeutic agent, thereby treating said condition.
[009] Alternatively, the present disclosure provides the use of at least one compound of formula (I) and/or at least one pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a cell-proliferative disorder. In particular examples, the compounds of the disclosure may be used alone or in combination with a chemotherapeutic agent to treat a cell proliferative disorder, including but not limited to, lymphoma, osteosarcoma, melanoma, or a tumor of breast, renal, prostate, colorectal, thyroid, ovarian, pancreatic, neuronal, lung, uterine or gastrointestinal tumor.
[010] In the above methods for using the compounds of the disclosure, at least one compound of formula (I) and/or at least one pharmaceutically acceptable salt thereof may be administered to a system comprising cells or tissues, or to a mammalian subject such as a human or animal subject.
BRIEF DESCRIPTION OF THE DRAWING
[01 1] Figure 1. Effect of a compound disclosed herein on relative tumor volume. [012] As used herein the following definitions are applicable.
[013] The term "alkyl" refers to both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms. Unless otherwise specified, "alkyl" refers to Ci-Cio alkyl. For example, Ci-Cio, as in "Ci_io alkyl" is defined to include groups having 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 10 carbons in a linear or branched arrangement. For example, "Ci-io alkyl" includes but is not limited to methyl, ethyl, n-propyl, i-propyl, n-butyl, t-butyl, i- butyl, pentyl, hexyl, heptyl, octyl, nonyl, and decyl. [014] The term "cycloalkyl" means a saturated aliphatic cyclic hydrocarbon group having the specified number of carbon atoms. Unless otherwise specified, "cycloalkyl" refers to C3-10 cycloalkyl. For example, "cycloalkyl" includes but is not limited to cyclopropyl, methyl- cyclopropyl, 2,2-dimethyl-cyclobutyl, 2-ethyl-cyclopentyl, and cyclohexyl.
[015] The term "alkenyl" refers to a non-aromatic hydrocarbon radical, straight, branched or cyclic, containing from 2 to 10 carbon atoms and at least one carbon to carbon double bond. In some embodiments, one carbon to carbon double bond is present, and up to four non-aromatic carbon-carbon double bonds may be present. Thus, "C2-10 alkenyl" means an alkenyl radical having from 2 to 10 carbon atoms. Alkenyl groups include but are not limited to ethenyl, propenyl, butenyl, 2-methylbutenyl and cyclohexenyl. The straight, branched or cyclic portion of the alkenyl group may contain double bonds and may be substituted if a substituted alkenyl group is indicated.
[016] The term "alkynyl" refers to a hydrocarbon radical straight, branched or cyclic, containing from 2 to 10 carbon atoms and at least one carbon to carbon triple bond. In some embodiments, up to three carbon-carbon triple bonds may be present. Thus, "C2-10 alkynyl" means an alkynyl radical having from 2 to 10 carbon atoms. Alkynyl groups include but are not limited to ethynyl, propynyl, butynyl, and 3-methylbutynyl. The straight, branched or cyclic portion of the alkynyl group may contain triple bonds and may be substituted if a substituted alkynyl group is indicated.
[017] The term "alkoxy" refers to either a cyclic or non-cyclic alkyl group of indicated number of carbon atoms attached through an oxygen bridge such as, for example, methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, pentoxy, 2-pentyloxy, isopentoxy, neopentoxy, hexoxy, 2-hexoxy, 3-hexoxy, 3-methylpentoxy, cyclopropanyloxy, and cyclobutyloxy,. "Alkoxy" therefore encompasses the definitions of alkyl and cycloalkyl above.
[018] The term "aryl" encompasses: 5- and 6-membered carbocyclic aromatic rings, for example, benzene; bicyclic ring systems wherein at least one ring is carbocyclic and aromatic, for example, naphthalene, indane, and 1 , 2,3, 4-tetrahydroquino line; and tricyclic ring systems wherein at least one ring is carbocyclic and aromatic, for example, fluorene. In cases where the aryl substituent is bicyclic or tricyclic and at least one ring is non-aromatic, it is understood that attachment is via the aromatic ring.
[019] For example, aryl includes 5- and 6-membered carbocyclic aromatic rings fused to a 5- to 7-membered heterocyclic ring containing one or more heteroatoms selected from N, O, and S, provided that the point of attachment is at the carbocyclic aromatic ring. Bivalent radicals formed from substituted benzene derivatives and having the free valences at ring atoms are named as substituted phenylene radicals. Bivalent radicals derived from univalent polycyclic hydrocarbon radicals whose names end in "-yl" by removal of one hydrogen atom from the carbon atom with the free valence are named by adding "-idene" to the name of the
corresponding univalent radical, e.g., a naphthyl group with two points of attachment is termed naphthylidene. Aryl, however, does not encompass or overlap in any way with heteroaryl, separately defined below. Hence, if one or more carbocyclic aromatic rings are fused with a heterocyclic aromatic ring, the resulting ring system is heteroaryl, not aryl, as defined herein.
[020] The term "halogen" (or "halo") refers to fluorine, chlorine, bromine and iodine.
[021 ] The term "heteroaryl" refers to
5- to 8-membered aromatic, monocyclic rings containing one or more, for example, from 1 to 4, or, in some embodiments, from 1 to 3, heteroatoms selected from N, O, and S, with the remaining ring atoms being carbon;
8- to 12-membered bicyclic rings containing one or more, for example, from 1 to 4, or, in some embodiments, from 1 to 3, heteroatoms selected from , O, and S, with the remaining ring atoms being carbon and wherein at least one heteroatom is present in an aromatic ring; and
11- to 14-membered tricyclic rings containing one or more, for example, from 1 to 4, or in some embodiments, from 1 to 3, heteroatoms selected from , O, and S, with the remaining ring atoms being carbon and wherein at least one heteroatom is present in an aromatic ring.
[022] When the total number of S and O atoms in the heteroaryl group exceeds 1, those heteroatoms are not adjacent to one another. In some embodiments, the total number of S and O atoms in the heteroaryl group is not more than 2. In some embodiments, the total number of S and O atoms in the heteroaryl group is not more than 1.
[023] Examples of heteroaryl groups include, but are not limited to, (as numbered from the linkage position assigned priority 1), 2-pyridyl, 3-pyridyl, 4-pyridyl, 2,3-pyrazinyl, 3,4- pyrazinyl, 2,4-pyrimidinyl, 3,5-pyrimidinyl, 1-pyrazolyl, 2,3-pyrazolyl, 2,4-imidazolinyl, isoxazolyl, oxazolyl, thiazolyl, thiadiazolyl, tetrazolyl, thienyl, benzothienyl, furyl, benzofuryl, benzoimidazolinyl, indolinyl, pyridizinyl, triazolyl, quinolinyl, pyrazolyl, and 5,6,7,8- tetrahydroisoquinoline.
[024] Further heteroaryl groups include but are not limited to pyrrolyl, isothiazolyl, triazinyl, pyrazinyl, pyridazinyl, indolyl, benzotriazolyl, quinoxalinyl, and isoquinolinyl. As with the definition of heterocycle below, "heteroaryl" is also understood to include the N-oxide derivative of any nitrogen-containing heteroaryl.
[025] Bivalent radicals derived from univalent heteroaryl radicals whose names end in "-yl" by removal of one hydrogen atom from the atom with the free valence are named by adding "-idene" to the name of the corresponding univalent radical, e.g., a pyridyl group with two points of attachment is a pyridylidene. Heteroaryl does not encompass or overlap with aryl as defined above.
[026] In cases where the heteroaryl substituent is bicyclic or tricyclic and at least one ring is non-aromatic or contains no heteroatoms, it is understood that attachment is via the aromatic ring or via the heteroatom containing ring, respectively.
[027] The term "heterocycle" (and variations thereof such as "heterocyclic", or
"heterocyclyl") broadly refers to a single aliphatic ring, usually with 3 to 7 ring atoms, containing at least 2 carbon atoms in addition to 1-3 heteroatoms independently selected from oxygen, sulfur, and nitrogen, as well as combinations comprising at least one of the foregoing heteroatoms. "Heterocycle" also refers to 5- to 7-membered heterocyclic ring containing one or more heteroatoms selected from N, O, and S fused with 5- and 6-membered carbocyclic aromatic ring, provided that the point of attachment is at the heterocyclic ring. The rings may be saturated or have one or more double bonds (i.e. partially unsaturated). The heterocycle can be substituted by oxo. The point of the attachment may be carbon or heteroatom in the heterocyclic ring, provided that attachment results in the creation of a stable structure. When the heterocyclic ring has substituents, it is understood that the substituents may be attached to any atom in the ring, whether a heteroatom or a carbon atom, provided that a stable chemical structure results.
Heterocycle does not overlap with heteroaryl.
[028] Suitable heterocycles include, for example (as numbered from the linkage position assigned priority 1), 1 -pyrrolidinyl, 2-pyrrolidinyl, 2,4-imidazolidinyl, 2,3-pyrazolidinyl, 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, 1 -piperazinyl, 2-piperazinyl, and 2,5- piperazinyl. Morpholinyl groups are also contemplated, including 2-morpholinyl and 3- morpholinyl (numbered wherein the oxygen is assigned priority 1). Substituted heterocycle also includes ring systems substituted with one or more oxo moieties, such as piperidinyl N-oxide, morpholinyl-N-oxide, 1-oxo-l-thiomorpholinyl and 1,1-dioxo-l-thiomorpholinyl.
[029] As used herein, "arylalkyl" refers to an alkyl moiety substituted by an aryl group. Example arylalkyl groups include benzyl, phenethyl, and naphthylmethyl groups. In some embodiments, arylalkyl groups have from 7 to 20 or 7 to 11 carbon atoms. When used in the phrase "aryl-Ci-4 alkyl", the term "C1-4" refers to the alkyl portion of the moiety and does not describe the number of atoms in the aryl portion of the moiety. Likewise, when used in the phrase "aryl-Ci-10 alkyl", the term "Ci_io" refers to the alkyl portion of the moiety and does not describe the number of atoms in the aryl portion of the moiety.
[030] As used herein, "heterocyclylalkyl" refers to alkyl substituted by heterocyclyl. When used in the phrase "heterocyclyl-Ci-io alkyl", the term "CMO" refers to the alkyl portion of the moiety and does not describe the number of atoms in the heterocyclyl portion of the moiety.
[031] As used herein, "cycloalkylalkyl" refers to alkyl substituted by cycloalkyl. When used in the phrase "C3-10 cycloalkylalkyl", the term "C3-10" refers to the cycloalkyl portion of the moiety and does not describe the number of atoms in the alkyl portion of the moiety. When used in the phrase "C3-7 cycloalkylalkyl", the term "C3-7" refers to the cycloalkyl portion of the moiety and does not describe the number of atoms in the alkyl portion of the moiety. When used in the phrase "C3-8 cycloalkylalkyl", the term "C3-8" refers to the cycloalkyl portion of the moiety and does not describe the number of atoms in the alkyl portion of the moiety. When used in the phrase "cycloalkyl -Q-10 alkyl", the term "C1-10" refers to the alkyl portion of the moiety and does not describe the number of atoms in the cycloalkyl portion of the moiety.
[032] As used herein, "heteroarylalkyl" refers to alkyl substituted by heteroaryl. When used in the phrase "heteroaryl -C1-4 alkyl", the term "C1-4" refers to the alkyl portion of the moiety and does not describe the number of atoms in the heteroaryl portion of the moiety.
Likewise, when used in the phrase "heteroaryl -C1-10 alkyl", the term "C1-10" refers to the alkyl portion of the moiety and does not describe the number of atoms in the heteroaryl portion of the moiety.
[033] For avoidance of doubt, reference, for example, to substitution of alkyl, cycloalkyl, heterocyclyl, aryl, and/or heteroaryl refers to substitution of each of those groups individually as well as to substitutions of combinations of those groups. That is, if R1 is arylalkyl, the aryl portion may be unsubstituted or substituted with at least one substituent, such as one, two, three, or four substituents, independently selected from R6b and the alkyl portion may also be unsubstituted or substituted with at least one substituent, such as one, two, three, or four substituens, independently selected from R6a.
[034] The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids including inorganic or organic bases and inorganic or organic acids. Salts derived from inorganic bases may be selected, for example, from aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic, manganous, potassium, sodium, and zinc salts. Further, for example, the pharmaceutically acceptable salts derived from inorganic bases may be selected from ammonium, calcium, magnesium, potassium, and sodium salts. Salts in the solid form may exist in one or more crystal structures, and may also be in the form of hydrates. Salts derived from pharmaceutically acceptable organic non-toxic bases may be selected, for example, from salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, choline,
Ν,Ν'-dibenzylethylene-diamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethyl-morpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, and tripropylamine, tromethamine.
[035] When the compound disclosed herein is basic, salts may be prepared using at least one pharmaceutically acceptable non-toxic acid, selected from inorganic and organic acids. Such acid may be selected, for example, from acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, and p-toluenesulfonic acids. In some embodiments, such acid may be selected, for example, from citric, hydrobromic, hydrochloric, maleic, phosphoric, sulfuric, fumaric, and tartaric acids.
[036] The terms "co-administration" or "combined administration" or the like as used herein are meant to encompass administration of the selected therapeutic agents to a single patient, and are intended to include treatment regimens in which the agents are not necessarily administered by the same route of administration or at the same time.
[037] The term "pharmaceutical combination" as used herein refers to a product obtained from mixing or combining active ingredients, and includes both fixed and non-fixed combinations of the active ingredients.
[038] The term "fixed combination" means that the active ingredients, e.g. a compound of Formula (I) and a co-agent, are both administered to a patient simultaneously in the form of a single entity or dosage.
[039] The term "non-fixed combination" means that the active ingredients, e.g. a compound of Formula (I) and a co-agent, are both administered to a patient as separate entities either simultaneously, concurrently or sequentially with no specific time limits, wherein such administration provides therapeutically effective levels of the active ingredients in the body of the patient. The latter also applies to cocktail therapy, e.g. the administration of three or more active ingredients. [040] The term "therapeutically effective amount" means the amount of the subject compound that will elicit a biological or medical response in a cell, tissue, organ, system, animal or human that is being sought by the researcher, veterinarian, medical doctor or other clinician.
[041] The term "administration" or "administering" of the subject compound means providing a compound of the disclosure and prodrugs thereof to a subject in need of treatment.
[042] The term "composition" as used herein is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts. Such term in relation to a pharmaceutical composition is intended to encompass a product comprising the active ingredient (s), and the inert ingredient (s) that make up the carrier, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients.
[043] By "pharmaceutically acceptable" it is meant compatible with the other ingredients of the formulation and not unacceptably deleterious to the recipient thereof.
[044] The term "protecting group" or "Pg" refers to a substituent that can be commonly employed to block or protect certain functionality while reacting other functional groups on the compound. For example, an "amino-protecting group" is a substituent attached to an amino group that blocks or protects the amino functionality in the compound. Suitable amino-protecting groups include but are not limited to acetyl, trifluoroacetyl, t-butoxycarbonyl (BOC), benzyloxycarbonyl (CBZ) and 9-fluorenylmethylenoxycarbonyl (Fmoc). Similarly, a "hydroxy- protecting group" refers to a substituent of a hydroxy group that blocks or protects the hydroxy functionality. Suitable protecting groups include but are not limited to acetyl and silyl. A "carboxy-protecting group" refers to a substituent of the carboxy group that blocks or protects the carboxy functionality. Common carboxy-protecting groups include
Figure imgf000020_0001
cyanoethyl, 2-(trimethylsilyl)ethyl, 2-(trimethylsilyl)ethoxymethyl, 2-(p-toluenesulfonyl)ethyl, 2-(p-nitrophenylsulfenyl)ethyl, 2-(diphenylphosphino)-ethyl, nitroethyl and the like. For a general description of protecting groups and their use, see T. W. Greene, Protective Groups in Organic Synthesis, John Wiley & Sons, New York, 1991.
[045] In one embodiment, disclosed herein is at least one compound of formula (I):
Figure imgf000021_0001
and/or at least one pharmaceutically acceptable salt thereof, wherein
each R1 is independently selected from:
hydrogen,
halogen,
hydroxyl,
Ci_io alkyl,
C3_io cycloalkyl,
C3-10 cycloalkyl-alkyl,
heterocyclyl,
heterocyclylalkyl
aryl,
arylalkyl,
heteroaryl, and
heteroarylalkyl,
wherein alkyl, cycloalkyl, and heterocyclyl are each unsubstituted or substituted with at least one substituent, such as one, two, three, or four substituents, independently selected from R a, and wherein aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, such as one, two, three, or four substituents, independently selected from R6b;
each R is indepedently selected from:
hydrogen,
halogen,
hydroxyl,
Ci_io alkyl,
C2-10 alkenyl,
C2-10 alkynyl,
C3_io cycloalkyl,
C3-10 cycloalkylalkyl,
heterocyclyl,
heterocyclylalkyl
heterocyclylcarbonyl,
aryl,
heteroaryl,
arylalkyl, and
heteroarylalkyl,
wherein alkyl, alkenyl, alkynyl, cycloalkyl, and heterocyclyl are each unsubstituted or substituted with at least one substituent, such as one, two, three, or four substituents, independently selected from R6a, and each aryl and heteroaryl is unsubstituted or substituted with at least one substituent, such as one, two, three, or four substituents, independently selected from R6b;
each R is independently selected from:
hydrogen,
halogen,
-CN,
-NR7R8, and
Ci_io alkyl; wherein alkyl is unsubstituted or substituted with at least one substituent, such as one, two, three, or four substituents, independently selected from R6a;
each R4 is independently selected from:
hydrogen,
halogen,
-CN,
Ci_io alkyl,
C2-10 alkenyl,
C2-io alkynyl, and
C3_io cycloalkyl;
wherein C1-10 alkyl, C2-io alkenyl, C2-io alkynyl, and C3_io cycloalkyl are each
unsubstituted or substituted with at least one substituent, such as one, two, three, or four substituents, independently selected from R6a;
or R3 and R4 together with the carbon atoms to which they are attached form a 5-6 membered ring containing 0, 1 , 2 or 3 heteroatoms independently selected from oxygen, sulfur and nitrogen, and optionally substituted with 1-2 R6b groups;
each R5 is indepedently selected from:
hydrogen,
Ci_io alkyl,
C2-10 alkenyl,
C2-10 alkynyl,
C3_io cycloalkyl,
-OR8,
-NR7S(0)rR8,
-NO2,
halogen,
-S(0)rR7,
-SR8,
-S(0)2OR7,
-OS(0)2R8, -S(0)rNR7R8,
-NR7R8,
Figure imgf000024_0001
-C(0)R7,
-C02R8,
-CO2(CR9R10)tCONR7R8,
-OC(0)R7,
-CN,
-C(0)NR7R8,
-NR7C(0)R8,
-OC(0)NR7R8,
-NR7C(0)OR8,
-NR7C(0)NR7R8,
-CR7( -OR8),
-CHF2,
-CF3,
-OCHF2, and
-OCF3;
wherein Ci_io alkyl, C2_io alkenyl, C2_io alkynyl, and C3_io cycloalkyl are each unsubstituted or substituted with at least one substituent, such as one, two, three, or four substituents, independently selected from R6a;
each R6ais independently selected from:
Ci_io alkyl,
C2_i0 alkenyl,
C2_i0 alkynyl,
C3_io cycloalkyl,
-OR8,
-NR7S(0)rR8,
-NO2,
halogen, -S(0)rR7,
-SR8,
-S(0)2OR7,
-OS(0)2R8,
-S(0)rNR7R8,
-NR7R8,
-(CR9R10)tOR8,
-(CR9R10)tNR7R8,
-(CR9R10)tSR8,
-(CR9R10)tS(O)rR8,
-(CR9R10)tCO2R8,
-(CR9R10)tCONR7R8,
-(CR9R10)tNR7CO2R8,
-(CR9R10)tOCONR7R8,
-(CR9R10)tNR7CONR7R8,
-(CR9R10)tNR7SO2NR7R8,
-O(CR9R10)tNR7R8,
-C(0)R7,
-C(O)(CR9R10)tOR8,
-C(O)(CR9R10)tNR7R8,
-C(O)(CR9R10)tSR8,
-C(O)(CR9R10)tS(O)rR8,
-C02R8,
-CO2(CR9R10)tCONR7R8,
-OC(0)R7,
-CN,
-C(0)NR7R8,
-NR7C(0)R8,
-OC(0)NR7R8,
-NR7C(0)OR8, -NR7C(0)NR7R8,
-CR7(N-OR8),
-CHF2,
-CF3,
-OCHF2, and each R6b is independently selected from:
R6a,
aryl,
aryl-Ci-4 alkyl,
heteroaryl, and
heteroarylCi-4 alkyl;
each R7 and each R8 are independently selected from:
hydrogen,
Ci_io alkyl,
C2- 10 alkenyl,
C2- 10 alkynyl,
cycloalkyl,
cycloalkyl-C]_io alkyl;
heterocyclyl,
heterocyclyl-Ci-10 alkyl,
aryl,
heteroaryl,
aiyl-Ci-io alkyl, and
heteroaryl-Ci-io alkyl;
wherein alkyl, alkenyl, alkynyl, cycloalkyl, and heterocyclyl are each unsubstituted or substituted with at least one substituent, such as one, two, three, or four substituents, independently selected from R6a, and aryl and heteroaryl are each unsubstituted or substituted with at least one substituent, such as one, two, three, or four substituents, independently selected from R6b; or R7 and R8 together with the atom(s) to which they are attached form a heterocyclic ring of 4 to 7 members containing 0, 1, or 2 additional heteroatoms independently selected from oxygen, sulfur and NR11,
each R 7 and R 8 may be unsubstituted or substituted on a carbon or nitrogen atom with at least one substituent, such as one, two, or three substituents, selected from R12;
each R9 and each R10 are independently selected from:
hydrogen,
Ci_io alkyl,
C2-10 alkenyl,
C2-10 alkynyl,
cycloalkyl,
cycloalkyl-Ci-io alkyl,
heterocyclyl,
heterocyclyl -C1-10 alkyl,
aryl,
heteroaryl,
aryl-Ci-io alkyl, and
heteroaryl-Ci-io alkyl; or
R9 and R10 together with the carbon to which they are attached form a ring of 3 to 7 members containing 0, 1, or 2 heteroatoms independently selected from oxygen, sulfur and nitrogen; each R11 is independently selected from:
hydrogen,
Ci_io alkyl,
C3_ io cycloalkyl,
C3_io cycloalkyl-Ci-4 alkyl,
heterocyclyl,
heterocyclyl-Ci-4 alkyl,
aryl,
aryl-Ci-4 alkyl,
heteroaryl, heteroaryl-Ci-4 alkyl,
-S(0)rR7,
-C(0)R7,
-C02R7,
-CO2(CR9R10)tCONR7R8, and -C(0)NR7R8;
each R12 is independently selected from: halogen,
Ci_io alkyl,
C3_io cycloalkyl,
C3-10 cycloalkylalkyl,
heterocyclyl,
heterocyclylalkyl,
aryl,
aryl-Ci-4 alkyl,
heteroaryl,
heteroaryl-Ci-4 alkyl,
-OR7,
-NR7S(0)rR8,
-S(0)rR7,
-SR7,
-S(0)2OR7,
-OS(0)2R7,
-S(0)rNR7R8,
-NR7R8,
-O(CR9R10)tNR7R8,
-C(0)R7,
-C02R8,
-CO2(CR9R10)tCONR7R8,
-OC(0)R7, -CN,
-C(0)NR7R8,
-NR7C(0)R8,
-OC(0)NR7R8,
-NR7C(0)OR8,
-NR7C(0)NR7R8,
-CHF2,
-CF3,
-OCHF2, and
-OCF3;
each m is independently selected from 0, 1 and 2;
each n is independently selected from 1 , 2, and 3;
each p is independently selected from 0, 1 , 2, and 3;
each q is independently selected from 0, 1 , 2, and 3;
each r is independently selected from 1 and 2;
each t is independently selected from 1 , 2, and 3.
[046] In some embodiments, each R1 is independently selected from hydrogen and Ci_io alkyl, wherein alkyl is unsubstituted or substituted with at least one substituent, such as one, two, three, or four substituents, independently selected from hydroxyl and Ci_io alkoxy.
[047] In some embodiments, R1 is hydrogen.
[048] In some embodiments, each R1 is independently selected from CMO alkyl, wherein alkyl is unsubstituted or substituted with at least one substituent, such as one, two, three, or four substituents, independently selected from hydroxyl and CMO alkoxy.
[049] In some embodiments, R1 is methyl, hydroxymethyl, or methoxymethyl.
[050] In some embodiments, each R2 is independently selected from CMO alkyl, heterocyclylcarbonyl, and heterocyclyl, wherein alkyl and heterocyclyl are independently unsubstituted or substituted with at least one substituent, such as one, two, three, or four substituents, independently selected from R6a, R6ais as described above. [051] In some embodiments, each R2 is independently selected from C1-10 alkyl and piperidinyl which are unsubstituted or substituted with at least one substituent, such as one, two, three, or four substituents, independently selected from R6a, R6ais as described above.
[052] In some embodiments, each R2 is independently selected from methyl and 4- piperidinyl which are unsubstituted or substituted with at least one substituent, such as one, two, three, or four substituents, independently selected from R6a, R6ais as described above.
[053] In some embodiments, each R2 is independently selected from methyl and 4- piperidinyl, wherein 4-piperidinyl is unsubstituted or substituted with at least one substituent, such as one, two, three, or four substituents, independently selected from R6a, wherein R6ais independently selected from CM0 alkyl, -C(0)R7, -S(0)rR7, -(CR9R10)tCO2R8,
-C(O)(CR9R10)tNR7R8, -(CR9R10)tOR8, -(CR9R10)tCONR7R8, -(CR9R10)tS(O)rR8, -(CR9R10)tOR8, R7 ,R8, R9 , R10 ,t and r are as described above.
[054] In some embodiments, R3 is hydrogen.
[055] In some embodiments, each R4 is independently selected from hydrogen, Ci_io alkyl, and halogen.
[056] In some embodiments, each R4 is independently selected from halogen. [057] In some embodiments, R4 is chlorine.
[058] In some embodiments, R3 and R4 together with the carbon atoms to which they are attached form a 5-membered ring containing 2 nitrogen atoms, wherein the 5-membered ring is optionally substituted with lor 2 Ci_io alkyl.
[059] In some embodiments, R3 and R4 together with the carbon atoms to which they are attached form pyrazolo.
[060] In some embodiments, R5 is -S(0)rR7, R7 and r are as described above.
[061] In some embodiments, R5 is -S(0)2R7,wherein R7 is selected from Ci_io alkyl.
[062] In some embodiments, R5 is -S(0)2R7,wherein R7 is isopropyl. [063] In some embodiments, n is 1.
[064] In some embodiments, p is 2.
[065] In some embodiments, m is 1. [066] In some embodiments, q is 1.
[067] Also provided is at least one compound, selected from:
N-4-(2-(isopropylsulfonyl)phenyl)-3-methyl-N-6-(5-methyl-4-(piperidin-4-yl)-2,3- dihydrobenzofuran-7-yl)-iH-pyrazolo[3,4-d]pyrimidine-4,6-diamine;
N-4-(2-(isopropylsulfonyl)phenyl)-3-methyl-N-6-(5-methyl-4-(l -methylpiperidin-4-yl)- 2,3-dihydrobenzofuran-7-yl)-iH-pyrazolo[3,4-d]pyrimidine-4,6-diamine;
(ii)-N-6-(2,5-dimethyl-4-(piperidin-4-yl)-2,3-dihydrobenzofuran-7-yl)-N-4-(2- (isopropylsulfonyl)phenyl)-3-methyl-iH-pyrazolo[3,4-d]pyrimidine-4,6-diamine;
(ii)-N-6-(2,5-dimethyl-4-(l-methylpiperidin-4-yl)-2,3-dihydrobenzofuran-7-yl)-N-4-(2- (isopropylsulfonyl)phenyl)-3-methyl- lH-pyrazolo[3,4-d]pyrimidine-4,6-diamine;
(5)-N-6-(2,5-dimethyl-4-(piperidin-4-yl)-2,3-dihydrobenzofuran-7-yl)-N-4-(2- (isopropylsulfonyl)phenyl)-3-methyl-iH-pyrazolo[3,4-d]pyrimidine-4,6-diamine;
(5)-N-6-(2,5-dimethyl-4-(l-methylpiperidin-4-yl)-2,3-dihydrobenzofuran-7-yl)-N-4-(2- (isopropylsulfonyl)phenyl)-3-methyl-iH-pyrazolo[3,4-d]pyrimidine-4,6-diamine;
(7-(4-(2-(isopropylsulfonyl)phenylamino)-3-methyl-iH-pyrazolo[3,4-d]pyrimidin-6- ylamino)-5-methyl-4-(piperidin-4-yl)-2,3-dihydrobenzofuran-2-yl)methanol;
N-4-(2-(isopropylsulfonyl)phenyl)-N-6-(2-(methoxymethyl)-5-methyl-4-(piperidin-4-yl)- 2,3-dihydrobenzofuran-7-yl)-3-methyl-iH-pyrazolo[3,4-d]pyrimidine-4,6-diamine;
(ii)-5-chloro-N-2-(2,5-dimethyl-4-(piperidin-4-yl)-2,3-dihydrobenzofuran-7-yl)-N-4-(2- (isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine;
(ii)-5-chloro-N-2-(2,5-dimethyl-4-(l-methylpiperidin-4-yl)-2,3-dihydrobenzofuran-7-yl)- N-4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine;
(5)-5-chloro-N-2-(2,5-dimethyl-4-(piperidin-4-yl)-2,3-dihydrobenzofuran-7-yl)-N-4-(2- (isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; (S)-5-chloro-N-2-(2,5-dimethyl-4-(l -m
N-4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine;
5-chloro-N-4-(2-(isopropylsulfonyl)phenyl)-N-2-(5-methyl-4-(piperidin-4-yl)-2,3- dihydrobenzofuran-7-yl)pyrimidine-2,4-diamine;
5-chloro-N-4-(2-(isopropylsulfonyl)phenyl)-N-2-(5-methyl-4-(l -methylpiperidin-4-yl)- 2,3-dihydrobenzofuran-7-yl)pyrimidine-2,4-diamine;
(5)-l -(4-(7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-2,5- dimethyl-2,3-dihydrobenzofuran-4-yl)piperidin- 1 -yl)ethanone;
(ii)-l -(4-(7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)- 2,5-dimethyl-2,3-dihydrobenzofuran-4-yl)piperidin-l-yl)ethanone;
(5)-5-chloro-N-2-(2,5-dimethyl-4-(l-(methylsulfonyl)piperidin-4-yl)-2,3- dihydrobenzofuran-7-yl)-N-4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine;
(ii)-5-chloro-N-2-(2,5-dimethyl-4-(l-(methylsulfonyl)piperidin-4-yl)-2,3- dihydrobenzofuran-7-yl)-N-4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine;
(5)-2-(4-(7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-2,5- dimethyl-2,3-dihydrobenzofuran-4-yl)piperidin- 1 -yl)acetic acid;
(ii)-2-(4-(7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)- 2,5-dimethyl-2,3-dihydrobenzofuran-4-yl)piperidin- 1 -yl)acetic acid;
(5)-2-amino- l-(4-((^)-7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2- yl)amino)-2,5-dimethyl-2,3-dihydrobenzofuran-4-yl)piperidin- 1 -yl)propan- 1 -one;
(5)-2-amino- l-(4-((ii)-7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2- yl)amino)-2,5-dimethyl-2,3-dihydrobenzofuran-4-yl)piperidin- 1 -yl)propan- 1 -one;
(ii)-l-(4-((ii)-7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2- yl)amino)-2,5-dimethyl-2,3-dihydrobenzofuran-4-yl)piperidin-l-yl)propan-2-ol;
(5)-l-(4-((ii)-7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)- 2,5-dimethyl-2,3-dihydrobenzofuran-4-yl)piperidin-l -yl)propan-2-ol;
(5)-2-(4-(7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-2,5- dimethyl-2,3-dihydrobenzofuran-4-yl)piperidin- 1 -yl)acetamide;
(ii)-2-(4-(7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)- 2,5-dimethyl-2,3-dihydrobenzofuran-4-yl)piperidin-l-yl)acetamide; (5)-2-(4-(7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-2,5- dimethyl-2,3-dihydrobenzofuran-4-yl)piperidin-l-yl)-N,N-dimethylacetamide;
(ii)-2-(4-(7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)- 2,5-dimethyl-2,3-dihydrobenzofuran-4-yl)piperidin-l-yl)-NN-dimethylacetamide;
(5)-5-chloro-N-2-(2,5-dimethyl-4-(l -(2-(methylsulfonyl)ethyl)piperidin-4-yl)-2,3- dihydrobenzofuran-7-yl)-N-4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine;
(ii)-5-chloro-N-2-(2,5-dimethyl-4-(l-(2-(methylsulfonyl)ethyl)piperidin-4-yl)-2,3- dihydrobenzofuran-7-yl)-N-4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine;
(5)-5-chloro-N-4-(2-(isopropylsulfonyl)phenyl)-N-2-(4-(l-(2-methoxyethyl)piperidin-4- yl)-2,5-dimethyl-2,3-dihydrobenzofuran-7-yl)pyrimidine-2,4-diamine;
(ii)-5-chloro-N-4-(2-(isopropylsulfonyl)phenyl)-N-2-(4-(l-(2-methoxyethyl)piperidin-4- yl)-2,5-dimethyl-2,3-dihydrobenzofuran-7-yl)pyrimidine-2,4-diamine;
(ii)-2-(4-(7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)- 2,5-dimethyl-2,3-dihydrobenzofuran-4-yl)piperidin-l -yl)ethanol;
(5)-2-(4-(7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-2,5- dimethyl-2,3-dihydrobenzofuran-4-yl)piperidin- 1 -yl)ethanol;
(ii)-l-(4-((5)-7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)- 2,5-dimethyl-2,3-dihydrobenzofuran-4-yl)piperidin-l -yl)propan-2-ol;
(5)-l-(4-((^)-7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)- 2,5-dimethyl-2,3-dihydrobenzofuran-4-yl)piperidin-l -yl)propan-2-ol;
(ii)-l -(4-(7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)- 2,5-dimethyl-2,3-dihydrobenzofuran-4-yl)piperidin-l-yl)-2-hydroxyethanone;
(5)-l-(4-((ii)-7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)- 2,5-dimethyl-2,3-dihydrobenzofuran-4-yl)piperidin- 1 -yl)-2-hydroxypropan- 1 -one;
(ii)-l-(4-((ii)-7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2- yl)amino)-2,5-dimethyl-2,3-dihydrobenzofuran-4-yl)piperidin- 1 -yl)-2-hydroxypropan- 1 -one;
(S)-methyl 4-(7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2- yl)amino)-2,5-dimethyl-2,3-dihydrobenzofuran-4-yl)piperidine-l-carboxylate;
(S)-ethyl 2-(4-(7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2- yl)amino)-2,5-dimethyl-2,3-dihydrobenzofuran-4-yl)piperidin-l-yl)acetate; (5)-2-amino-l -(4-(7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2- yl)amino)-2,5-dimethyl-2,3-dihydrobenzofuran-4-yl)piperidin-l-yl)ethanone;
(5)-4-(7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-2,5- dimethyl-2,3-dihydrobenzofuran-4-yl)piperidine- 1 -carboxamide;
(5)-l -(4-(7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-2,5- dimethyl-2,3-dihydrobenzofuran-4-yl)piperidin-l -yl)-2-(methylamino)ethanone;
(5)-l -(4-(7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-2,5- dimethyl-2,3-dihydrobenzofuran-4-yl)piperidin-l-yl)-2-(dimethylamino)ethanone;
(5)-(7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-2,5- dimethyl-2,3-dihydrobenzofuran-4-yl)(piperazin- 1 -yl)methanone;
(5)-(7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-2,5- dimethyl-2,3-dihydrobenzofuran-4-yl)(4-methylpiperazin-l -yl)methanone;
(5)-(7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-2,5- dimethyl-2,3-dihydrobenzofuran-4-yl)(morpholino)methanone;
(ii)-l -(4-(7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)- 2,5-dimethyl-2,3-dihydrobenzofuran-4-yl)piperidin- 1 -yl)propan- 1 -one;
(ii)-l -(4-(7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)- 2,5-dimethyl-2,3-dihydrobenzofuran-4-yl)piperidin- 1 -yl)-2-methylpropan- 1 -one;
(ii)-(4-(7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-2,5- dimethyl-2,3-dihydrobenzofuran-4-yl)piperidin-l -yl)(cyclopropyl)methanone;
(ii)-5-chloro-N-2-(4-(l-(ethylsulfonyl)piperidin-4-yl)-2,5-dimethyl-2,3- dihydrobenzofuran-7-yl)-N-4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine;
(ii)-5-chloro-N-4-(2-(isopropylsulfonyl)phenyl)-N-2-(4-(l-(isopropylsulfonyl)piperidin- 4-yl)-2,5-dimethyl-2,3-dihydrobenzofuran-7-yl)pyrimidine-2,4-diamine;
(ii)-5-chloro-N-2-(4-(l-(cyclopropylsulfonyl)piperidin-4-yl)-2,5-dimethyl-2,3- dihydrobenzofuran-7-yl)-N-4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine;
(ii)-l-(4-((5)-7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)- 2,5-dimethyl-2,3-dihydrobenzofuran-4-yl)piperidin- 1 -yl)-2-methoxypropan- 1 -one;
(ii)-l-(4-((ii)-7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2- yl)amino)-2,5-dimethyl-2,3-dihydrobenzofuran-4-yl)piperidin- 1 -yl)-2-methoxypropan- 1 -one; (5)-l-(4-((ii)-7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)- 2,5-dimethyl-2,3-dihydrobenzofuran-4-yl)piperidin- 1 -yl)-2-methoxypropan- 1 -one;
(5)-l-(4-((^)-7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)- 2,5-dimethyl-2,3-dihydrobenzofuran-4-yl)piperidin- 1 -yl)-2-methoxypropan- 1 -one, and pharmaceutically acceptable salts thereof.
[068] The compounds disclosed herein and their pharmaceutically acceptable salts exhibit valuable pharmacological properties when tested in vitro in cell-free kinase assays and in cellular assays, and are therefore useful as pharmaceuticals.
[069] In one aspect, compounds of formula (I) may inhibit the tyrosine kinase activity of ALK and the fusion protein of NPM-ALK. This protein tyrosine kinase results from a gene fusion of nucleophosmin (NPM) and ALK, rendering the protein tyrosine kinase activity of ALK ligand independent. NPM-ALK plays a key role in signal transmission in a number of hematopoetic and other human cells leading to hematological and neoplastic diseases, for example in anaplastic large-cell lymphoma (ALCL) and non-Hodgkin's lymphomas (NHL), specifically in ALK+NHL or Alkomas, in inflammatory myofibroblastic tumors (IMT) and neuroblastomas. (Duyster et al. 2001 Oncogene 20, 5623-5637). In addition to NPM-ALK, other gene fusions have been identified in human hematological and neoplastic diseases; for example, TPM3-ALK (a fusion of nonmuscle tropomyosin with ALK).
[070] The inhibition of ALK tyrosine kinase activity may be demonstrated using known methods, for example using the recombinant kinase domain of the ALK in analogy to the VEGF- R kinase assay described in J. Wood et al. Cancer Res. 60, 2178-2189 (2000). In general, in vitro enzyme assays using GST-ALK protein tyrosine kinase are performed in 96-well plates as a filter binding assay in 20 mM Tris HC1, pH = 7.5, 3 mM MgCl2, 10 mM MnCl2, 1 mM DTT, 0.1 μα/assay (=30 μΐ) [γ-33Ρ]-ΑΤΡ, 2 μΜ ATP, 3 μg/mL poly (Glu, Tyr 4: 1) Poly-EY (Sigma P- 0275), 1% DMSO, 25 ng ALK enzyme. Assays are incubated for 10 min at ambient temperature. Reactions are terminated by adding 50 μΐ of 125 mM EDTA, and the reaction mixture is transferred onto a MAIP Multiscreen plate (Millipore, Bedford, Mass., USA), previously wet with methanol, and rehydrated for 5 min with H20. Following washing (0.5% H3PO4), plates are counted in a liquid scintillation counter. IC50 values are calculated by linear regression analysis of the percentage inhibition.
[071] Compounds of formula (I) may potently inhibit the growth of human NPM-ALK overexpressing murine BaF3 cells (DSMZ Deutsche Sammiung von Mikroorganismen und Zellkulturen GmbH, Germany). The expression of NPM-ALK may be achieved by transfecting the BaF3 cell line with an expression vector pClneo™ (Pro mega Corp., Madison Wis., USA) coding for NPM-ALK and subsequent selection of G418 resistant cells. Non-transfected BaF3 cells depend on IL-3 for cell survival. In contrast, NPM-ALK expressing BaF3 cells (named BaF3-NPM-ALK hereinafter) can proliferate in the absence of IL-3 because they obtain proliferative signal through NPM-ALK kinase. Putative inhibitors of the NPM-ALK kinase therefore abolish the growth signal and may result in antiproliferative activity. The
antiproliferative activity of putative inhibitors of the NPM-ALK kinase can however be overcome by addition of IL-3, which provides growth signals through an NPM-ALK
independent mechanism. An analogous cell system using FLT3 kinase has also been described (see, E Weisberg et al. Cancer Cell; 1 , 433-443 (2002)).
[072] The inhibitory activity of the compounds of the invention may be determined as follows. In general, BaF3-NPM-ALK cells (15,000/microtitre plate well) are transferred to 96- well microtitre plates. Test compounds dissolved in dimethyl sulfoxide (DMSO) are added in a series of concentrations (dilution series) in such a manner that the final concentration of DMSO is not greater than 1% (v/v). After the addition, the plates are incubated for two days during which the control cultures without test compound are able to undergo two cell-division cycles. The growth of the BaF3-NPM-ALK cells is measured by means of YOPRO™ staining [T Idziorek et al. J. Immunol. Methods; 185: 249-258 (1995)]: 25 μΐ of lysis buffer comprising 20 mM sodium citrate, pH 4.0, 26.8 mM sodium chloride, 0.4% NP40, 20 mM EDTA and 20 mM is added to each well. Cell lysis is completed within 60 min at room temperature and total amount of YOPRO™ bound to DNA is determined by measurement using the Cytofluor II 96-well reader (PerSeptive Biosystems) with the following settings: Excitation (nm) 485/20 and
Emission (nm) 530/25. [073] IC50 values may be determined by a computer-aided system using the formula: IC50=[(ABS test -ABS start)/(ABS control -ABS start)] 100. (ABS=absorption)
[074] The IC50 value in those experiments is given as that concentration of the test compound in question that results in a cell count that is 50% lower than that obtained using the control without inhibitor. The compounds of the disclosure in free form or in pharmaceutically acceptable salt form, may exhibit valuable pharmacological properties, for example, as indicated by the in vitro tests described in this application. In general, compounds of the disclosure have IC50 values from less than 1 nM to 10 μΜ. In some examples, compounds of the disclosure have IC50 values from less than 1 nM to 500 nM. In other examples, compounds of the disclosure have IC50 values from < InM to 200 nM.
[075] The antiproliferative action of the inventive compounds may also be determined in the human KARPAS-299 lymphoma cell line (DSMZ Deutsche Sammiung von
Mikroorganismen und Zellkulturen GmbH, Braunschweig, Germany, described in WG Dirks et al. Int. J. Cancer 100, 49-56 (2002)) using the same methodology described above for the BaF3- NPM-ALK cell line. In some embodiments, compounds disclosed herein may exhibit inhibitory activity with an IC50 in the range from approximately less than lnm to 1 μΜ. The action of the inventive compounds on autophosphorylation of the ALK may be determined in the human KARPAS-299 lymphoma cell line by means of an immunoblot as described in WG Dirks et al. Int. J. Cancer 100, 49-56 (2002).
[076] In accordance with the foregoing, the present disclosure provides:
(1) a compound disclosed herein for use as a pharmaceutical;
(2) a compound disclosed herein for use as an ALK inhibitor, for example, for use in any of the particular indications set forth above;
(3) a pharmaceutical composition, e.g. for use in any of the indications herein set forth above, comprising at least one compound disclosed herein as active ingredient together with one or more pharmaceutically acceptable diluents or carriers; (4) a method for treatment of any particular indication set forth above in a subject in need thereof which comprises administering an effective amount of at least one compound disclosed herein or at least one pharmaceutical composition comprising thereof;
(5) the use of a compound disclosed herein for making a medicament for treatment or prevention of a disease or condition in which ALK activation plays a role or is implicated;
(6) the method as defined above under (4) comprising co-administration, e.g.
concomitantly or in sequence, of a therapeutically effective amount of a compound disclosed herein and one or more additional drug substances, said additional drug substance being useful in any of the particular indications set forth above;
(7) a composition comprising a therapeutically effective amount of at least one compound disclosed herein and at least one additional drug substance, wherein said additional drug substance is useful in any of the particular indications set forth above;
(8) use of a compound disclosed herein for making a medicament for treatment or prevention of a disease which responds to inhibition of the anaplastic lymphoma kinase;
(9) the use according to (8), wherein the disease to be treated is selected from anaplastic large cell lymphoma, non-Hodgkin's lymphomas, inflammatory myofibroblastic tumors, neuroblastomas and neoplastic diseases;
(10) the use according to (8) or (9), wherein the compound isa pharmaceutically acceptable salt of any one of the examples disclosed herein;
(11) a method for the treatment of a disease which responds to inhibition of the anaplastic lymphoma kinase, such as a disease selected from anaplastic large-cell lymphoma, non
Hodgkin's lymphomas, inflammatory myofibroblastic tumors, neuroblastomas and neoplastic diseases, comprising administering an effective amount of at least one compound disclosed herein and/or a pharmaceutically acceptable salt thereof. In some examples, the compounds of the disclosure may be used alone or in combination with a chemotherapeutic agent to treat a cell proliferative disorder, including but not limited to, lymphoma, osteosarcoma, melanoma, or a tumor of breast, renal, prostate, colorectal, thyroid, ovarian, pancreatic, neuronal, lung, uterine or gastrointestinal tumor.
Administration and Pharmaceutical Compositions
[077] In general, compounds of the disclosure will be administered in therapeutically effective amounts via any of the usual and acceptable modes known in the art, either singly or in combination with one or more therapeutic agents. A therapeutically effective amount may vary widely depending on the severity of the disease, the age and relative health of the subject, the potency of the compound used and other factors known to those of ordinary skill in the art. For example, for the treatment of neoplastic diseases and immune system disorders, the required dosage will also vary depending on the mode of administration, the particular condition to be treated and the effect desired.
[078] In general, satisfactory results are indicated to be obtained systemically at daily dosages of from about 0.001 to about 100 mg/kg per body weight, or particularly, from about 0.03 to 2.5 mg/kg per body weight. An indicated daily dosage in the larger mammal, e.g. humans, may be in the range from about 0.5 mg to about 2000 mg, or more particularly, from about 0.5 mg to about 100 mg, conveniently administered, for example, in divided doses up to four times a day or in retard form. Suitable unit dosage forms for oral administration comprise from ca. 1 to 50 mg active ingredient.
[079] Compounds of the disclosure may be administered as pharmaceutical
compositions by any conventional route; for example, enterally, e.g., orally, e.g., in the form of tablets or capsules; parenterally, e.g., in the form of injectable solutions or suspensions; or topically, e.g., in the form of lotions, gels, ointments or creams, or in a nasal or suppository form.
[080] Pharmaceutical compositions comprising a compound of the present disclosure in free form or in a pharmaceutically acceptable salt form in association with at least one
pharmaceutically acceptable carrier or diluent may be manufactured in a conventional manner by mixing, granulating, coating, dissolving or lyophilizing processes. For example, pharmaceutical compositions comprising a compound of the disclosure in association with at least one pharmaceutical acceptable carrier or diluent may be manufactured in conventional manner by mixing with a pharmaceutically acceptable carrier or diluent. Unit dosage forms for oral administration contain, for example, from about 0.1 mg to about 500 mg of active substance.
[081] In one embodiment, the pharmaceutical compositions are solutions of the active ingredient, including suspensions or dispersions, such as isotonic aqueous solutions. In the case of lyophilized compositions comprising the active ingredient alone or together with a carrier such as mannitol, dispersions or suspensions can be made up before use. The pharmaceutical compositions may be sterilized and/or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers. Suitable preservatives include but are not limited to antioxidants such as ascorbic acid, or microbicides, such as sorbic acid or benzoic acid. The solutions or suspensions may further comprise viscosity-increasing agents, including but not limited to, sodium
carboxymethylcellulose, carboxymethylcellulose, dextran, polyvinylpyrrolidone, gelatins, or solubilizers, e.g. Tween 80 (polyoxyethylene(20)sorbitan mono-oleate).
[082] Suspensions in oil may comprise as the oil component the vegetable, synthetic, or semi-synthetic oils customary for injection purposes. Examples include liquid fatty acid esters that contain as the acid component a long-chained fatty acid having from 8 to 22 carbon atoms, or in some embodiments, from 12 to 22 carbon atoms. Suitable liquid fatty acid esters include but are not limited to lauric acid, tridecylic acid, myristic acid, pentadecylic acid, palmitic acid, margaric acid, stearic acid, arachidic acid, behenic acid or corresponding unsaturated acids, for example oleic acid, elaidic acid, erucic acid, brassidic acid and linoleic acid, and if desired, may contain antioxidants, for example vitamin E, 3-carotene or 3,5-di-tert-butyl-hydroxytoluene. The alcohol component of these fatty acid esters may have six carbon atoms and may be monovalent or polyvalent, for example a mono-, di- or trivalent, alcohol. Suitable alcohol components include but are not limited to methanol, ethanol, propanol, butanol or pentanol or isomers thereof; glycol and glycerol.
[083] Other suitable fatty acid esters include but are not limited ethyl-oleate, isopropyl myristate, isopropyl palmitate, LABRAFIL® M 2375, (polyoxyethylene glycerol),
LABRAFIL® M 1944 CS (unsaturated polyglycolized glycerides prepared by alcoho lysis of apricot kernel oil and comprising glycerides and polyethylene glycol ester), LABRASOL™ (saturated polyglycolized glycerides prepared by alcoho lysis of TCM and comprising glycerides and polyethylene glycol ester; all available from GaKefosse, France), and/or MIGLYOL® 812 (triglyceride of saturated fatty acids of chain length C8 to C12 from Huls AG, Germany), and vegetable oils such as cottonseed oil, almond oil, olive oil, castor oil, sesame oil, soybean oil, or groundnut oil.
[084] Pharmaceutical compositions for oral administration may be obtained, for example, by combining the active ingredient with one or more solid carriers, and if desired, granulating a resulting mixture, and processing the mixture or granules by the inclusion of additional excipients, to form tablets or tablet cores.
[085] Suitable carriers include but are not limited to fillers, such as sugars, for example lactose, saccharose, mannitol or sorbitol, cellulose preparations, and/or calcium phosphates, for example tricalcium phosphate or calcium hydrogen phosphate, and also binders, such as starches, for example corn, wheat, rice or potato starch, methylcellulose, hydroxypropyl methylcellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone, and/or, if desired, disintegrators, such as the above-mentioned starches, carboxymethyl starch, crosslinked polyvinylpyrrolidone, alginic acid or a salt thereof, such as sodium alginate. Additional excipients include flow conditioners and lubricants, for example silicic acid, talc, stearic acid or salts thereof, such as magnesium or calcium stearate, and/or polyethylene glycol, or derivatives thereof.
[086] Tablet cores may be provided with suitable, optionally enteric, coatings through the use of, inter alia, concentrated sugar solutions which may comprise gum arable, talc, polyvinylpyrrolidone, polyethylene glycol and/or titanium dioxide, or coating solutions in suitable organic solvents or solvent mixtures, or, for the preparation of enteric coatings, solutions of suitable cellulose preparations, such as acetylcellulose phthalate or
hydroxypropylmethylcellulose phthalate. Dyes or pigments may be added to the tablets or tablet coatings, for example for identification purposes or to indicate different doses of active ingredient.
[087] Pharmaceutical compositions for oral administration may also include hard capsules comprising gelatin or soft-sealed capsules comprising gelatin and a plasticizer, such as glycerol or sorbitol. The hard capsules may contain the active ingredient in the form of granules, for example in admixture with fillers, such as corn starch, binders, and/or glidants, such as talc or magnesium stearate, and optionally stabilizers. In soft capsules, the active ingredient may be dissolved or suspended in suitable liquid excipients, such as fatty oils, paraffin oil or liquid polyethylene glycols or fatty acid esters of ethylene or propylene glycol, to which stabilizers and detergents, for example of the polyoxyethylene sorbitan fatty acid ester type, may also be added.
[088] Pharmaceutical compositions suitable for rectal administration are, for example, suppositories comprising a combination of the active ingredient and a suppository base. Suitable suppository bases are, for example, natural or synthetic triglycerides, paraffin hydrocarbons, polyethylene glycols or higher alkanols.
[089] Pharmaceutical compositions suitable for parenteral administration may comprise aqueous solutions of an active ingredient in water-soluble form, for example of a water-soluble salt, or aqueous injection suspensions that contain viscosity-increasing substances, for example sodium carboxymethylcellulose, sorbitol and/or dextran, and, if desired, stabilizers. The active ingredient, optionally together with excipients, can also be in the form of a lyophilizate and can be made into a solution before parenteral administration by the addition of suitable solvents. Solutions such as are used, for example, for parenteral administration can also be employed as infusion solutions. The manufacture of injectable preparations is usually carried out under sterile conditions, as is the filling, for example, into ampoules or vials, and the sealing of the containers.
[090] The compounds of the disclosure may be administered as the sole active ingredient, or together with other drugs useful against neoplastic diseases or useful in
immunomodulating regimens. For example, the compounds of the disclosure may be used in accordance with the disclosure in combination with pharmaceutical compositions effective in various diseases as described above, e.g. with cyclophosphamide, 5-fluorouracil, fludarabine, gemcitabine, cisplatinum, carboplatin, vincristine, vinblastine, etoposide, irinotecan, paclitaxel, docetaxel, rituxan, doxorubicine, gefitinib, or imatinib; or also with cyclosporins, rapamycins, ascomycins or their immunosuppressive analogs, e.g. cyclosporin A, cyclosporin G, FK-506, sirolimus or everolimus, corticosteroids, e.g. prednisone, cyclophosphamide, azathioprene, methotrexate, gold salts, sulfasalazine, antimalarials, brequinar, leflunomide, mizoribine, mycophenolic acid, mycophenolate, mofetil, 15-deoxyspergualine, immuno-suppressive monoclonal antibodies, e.g. monoclonal antibodies to leukocyte receptors, e.g. MHC, CD2, CD3, CD4, CD7, CD25, CD28, 1 CD40, CD45, CD58, CD80, CD86, CD152, CD137, CD154, ICOS, LFA-1, VLA-4 or their ligands, or other immunomodulatory compounds, e.g. CTLA41g.
[091] The disclosure also provides for a pharmaceutical combinations, e.g. a kit, comprising a) a first agent which is a compound of the disclosure as disclosed herein, in free form or in pharmaceutically acceptable salt form, and b) at least one co-agent. The kit can comprise instructions for its administration.
EXAMPLES
[092] Various methods may be developed for synthesizing the at least one compound of formula (I) and/or at least one pharmaceutically acceptable salt thereof. Representative methods for synthesizing the at least one compound of formula (I) and/or at least one pharmaceutically acceptable salt thereof are provided in the Examples. It is noted, however, that the at least one compound of formula (I) and/or at least one pharmaceutically acceptable salt thereof may also be synthesized by other synthetic routes that others may devise.
[093] It will be readily recognized that certain compounds of formula (I) have atoms with linkages to other atoms that confer a particular stereochemistry to the compound (e.g., chiral centers). It is recognized that synthesis of the at least one compound of formula (I) and/or at least one pharmaceutically acceptable salt thereof may result in the creation of mixtures of different stereoisomers (enantiomers, diastereomers). Unless a particular stereochemistry is specified, recitation of a compound is intended to encompass all of the different possible stereoisomers.
[094] The at least one compound of formula (I) can also be prepared as a
pharmaceutically acceptable acid addition salt by, for example, reacting the free base form of the at least one compound with a pharmaceutically acceptable inorganic or organic acid.
Alternatively, a pharmaceutically acceptable base addition salt of the at least one compound of formula (I) can be prepared by, for example, reacting the free acid form of the at least one compound with a pharmaceutically acceptable inorganic or organic base. Inorganic and organic acids and bases suitable for the preparation of the pharmaceutically acceptable salts of compounds of formula (I) are set forth in the definitions section of this Application.
Alternatively, the salt forms of the compounds of formula (I) can be prepared using salts of the starting materials or intermediates.
[095] The free acid or free base forms of the compounds of formula (I) can be prepared from the corresponding base addition salt or acid addition salt form. For example, a compound of formula (I) in an acid addition salt form can be converted to the corresponding free base thereof by treating with a suitable base (e.g., ammonium hydroxide solution, sodium hydroxide, and the like). A compound of formula (I) in a base addition salt form can be converted to the
corresponding free acid thereof by, for example, treating with a suitable acid (e.g., hydrochloric acid, etc).
[096] The N-oxides of the at least one compound of formula (I) and/or at least one pharmaceutically acceptable salt thereof can be prepared by methods known to those of ordinary skill in the art. For example, N-oxides can be prepared by treating an unoxidized form of the compound of formula (I) with an oxidizing agent (e.g., trifluoroperacetic acid, permaleic acid, perbenzoic acid, peracetic acid, meta-chloroperoxybenzoic acid, or the like) in a suitable inert organic solvent (e.g., a halogenated hydrocarbon such as dichloromethane) at approximately 0 to 80 °C. Alternatively, the N-oxides of the compounds of formula (I) can be prepared from the N- oxide of an appropriate starting material.
[097] Compounds of formula (I) in an unoxidized form can be prepared from N-oxides of compounds of formula (I) by, for example, treating with a reducing agent (e.g., sulfur, sulfur dioxide, triphenyl phosphine, lithium borohydride, sodium borohydride, phosphorus trichloride, tribromide, and the like) in an suitable inert organic solvent (e.g., acetonitrile, ethanol, aqueous dioxane, and the like) at 0 to 80 °C.
[098] Protected derivatives of the compounds of formula (I) can be made by methods known to those of ordinary skill in the art. A detailed description of the techniques applicable to the creation of protecting groups and their removal can be found in T.W. Greene, Protecting Groups in Organic Synthesis, 3rd edition, John Wiley & Sons, Inc. 1999. [099] The at least one compound of formula (I) and/or at least one pharmaceutically acceptable salt thereof may be conveniently prepared, or as solvates (e.g. hydrates). Hydrates of the at least one compound of formula I and/or at least one pharmaceutically acceptable salt thereof may be conveniently prepared by recrystallization from an aqueous/organic solvent mixture, using organic solvents such as dioxin, tetrahydrofuran and/or methanol.
[0100] The compounds of formula (I) can also be prepared as their individual
stereoisomers by reacting a racemic mixture of the compounds with an optically active resolving agent to form a pair of diastereoisomeric compounds, separating the diastereomers, and recovering the optically pure enantiomer. While resolution of enantiomers can be carried out using covalent diasteromeric derivatives of compounds, dissociable complexes are preferred (e.g., crystalline diastereoisomeric salts). Diastereomers have distinct physical properties (e.g., melting points, boiling points, solubilities, reactivity, etc.) and can be readily separated by taking advantage of these dissimilarities. The diastereomers can be separated by chromatography or, for example, by separation/resolution techniques based upon differences in solubility. The optically pure enantiomer is then recovered, along with the resolving agent, by any practical means that would not result in racemization. A more detailed description of the techniques applicable to the resolution of stereoisomers of compounds from their racemic mixture can be found in Jean Jacques Andre Collet, Samuel H. Wilen, Enantiomers, Racemates and Resolutions, John Wiley & Sons, Inc. (1981).
[0101] As used herein the symbols and conventions used in these processes, schemes and examples are consistent with those used in the contemporary scientific literature, for example, the Journal of the American Chemical Society or the Journal of Biological Chemistry. Standard single-letter or three-letter abbreviations are generally used to designate amino acid residues, which are assumed to be in the L-configuration unless otherwise noted. Unless otherwise noted, all starting materials were obtained from commercial suppliers and used without further purification. For example, the following abbreviations may be used in the examples and throughout the specification: g (grams); mg (milligrams); L (liters); mL (milliliters); uL
(microliters); psi (pounds per square inch); M (molar); mM (millimolar); i.v. (intravenous); Hz (Hertz); MHz (megahertz); mol (moles); mmol (millimoles); RT (room temperature); min (minutes); h (hours); mp (melting point); TLC (thin layer chromatography); Rt (retention time); RP (reverse phase); MeOH (methanol); i-PrOH (isopropanol); TEA (triethylamine); TFA (trifluoroacetic acid); TFAA (trifluoroacetic anhydride); THF (tetrahydrofuran); DMSO
(dimethyl sulfoxide); EtOAc (ethyl acetate); DME (1,2-dimethoxyethane); DCM
(dichloromethane); DCE (dichloroethane); DMF ( ,Ν-dimethylformamide); DMPU (Ν,Ν'- dimethylpropyleneurea); CDI (1,1-carbonyldiimidazole); IBCF (isobutyl chloro formate); HO Ac (acetic acid); HOSu ( -hydroxysuccinimide); HOBT (1-hydroxybenzotriazole); Et20 (diethyl ether); EDCI (l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride); BOC (tert- butyloxycarbonyl); FMOC (9-fluorenylmethoxycarbonyl); DCC (dicyclohexylcarbodiimide); CBZ (benzyloxycarbonyl); Ac (acetyl); atm (atmosphere); TMSE (2-(trimethylsilyl)ethyl); TMS (trimethylsilyl); TIPS (triisopropylsilyl); TBS (t-butyldimethylsilyl); DMAP (4- dimethylaminopyridine); Me (methyl); OMe (methoxy); Et (ethyl); tBu (tert-butyl); HPLC (high pressure liquid chomatography); BOP (bis(2-oxo-3-oxazolidinyl)phosphinic chloride); TBAF (tetra-n-butylammonium fluoride); m-CPBA (meta-chloroperbenzoic acid).
[0102] References to ether or Et20 are to diethyl ether; brine refers to a saturated aqueous solution of NaCl. Unless otherwise indicated, all temperatures are expressed in °C (degrees Centigrade). All reactions were conducted under an inert atmosphere at RT unless otherwise noted.
[0103] H NMR spectra were recorded on a Varian Mercury Plus 400. Chemical shifts are expressed in parts per million (ppm). Coupling constants are in units of hertz (Hz). Splitting patterns describe apparent multiplicities and are designated as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), and br (broad).
[0104] Low-resolution mass spectra (MS) and compound purity data were acquired on a Shimadzu LC/MS single quadrapole system equipped with electrospray ionization (ESI) source, UV detector (220 and 254 nm), and evaporative light scattering detector (ELSD). Thin- layer chromatography was performed on 0.25 mm E. Merck silica gel plates (60F-254), visualized with UV light, 5% ethanolic phosphomolybdic acid, ninhydrin, or p-anisaldehyde solution. Flash column chromatography was performed on silica gel (230-400 mesh, Merck). Synthetic Schemes
[0105] The at least one compound of formula (I) and/or at least one pharmaceutically acceptable salt thereof may be synthesized according to a variety of reaction schemes. Some illustrative schemes are provided below and in the examples. Other reaction schemes could be readily devised by those skilled in the art in view of the present disclosure.
[0106] In the reactions disclosed below, it may be necessary to protect reactive functional groups, for example hydroxy, amino, imino, thio or carboxy groups, where these are desired in the final product, to avoid their unwanted participation in the reactions. Conventional protecting groups may be used in accordance with standard practice, for example, see T.W. Greene and P. G. M. Wuts in "Protective Groups in Organic Chemistry" John Wiley and Sons, 1991.
[0107] Synthetic methods for preparing the compounds in the present disclosure are illustrated in the following Schemes and Examples. Starting materials are commercially available or may be made according to procedures known in the art or as illustrated herein.
Preparation of Intermediates
Intermediate A
[0108] 4-Hydroxy-3-methyl-6-mercaytoyyrazolo[ 3,4-dlyyrimidine (A-l )
Figure imgf000047_0001
A-1
[0109] This reagent was prepared according to the method described in literature: J. Med. Chem. 1990, 33: 2174-2178.
[01 10] 4-Hydroxy-3-methyl-6-methylmercavtoyyrazolof 3 ,4-d lyyrimidine (A-2)
Figure imgf000048_0001
A-1 A-2
[01 1 1] To a mixture of 4-hydroxy-6-mercapto-3-methylpyrazolo[3,4-d]pyrimidine (A-1) (2.86 g, 1 1.8 mmol) and NaOH (0.8 g, 20 mmol) in water (20 mL) at 5 °C was added CH3I (2.0 g, 14.2 mmol). After stirred at ambient temperature for 30 min, the solution was acidified with HO Ac to give the crude product of the title compound (A-2), which used in next step without further purification. MS-ESI (m/z): 197.0 (M + H)+.
[01 12] 4-chloro-3-methyl-6-methylmercaptopyrazolo[3,4-dlpyrimidine (A-3)
Figure imgf000048_0002
A-2 A-3
[01 13] To a mixture of POCl3 (26 mL) and of dimethylaniline (2 mL) was added crude 4- hydroxy-3-methyl-6-methylmercaptopyrazolo[3,4-d]pyrimidine (A-2) (1.46 g, 7.45 mmol). The solution was heated to reflux for 60 min until all solid dissolved. The excess of POCl3 was removed under reduced pressure. The residue was poured into ice water with vigorous stirring, it is stirred for 10 min, and the aqueous solution was extracted with ether. The ether layer was washed with cold water, dried with anhydrous Na2SC>4 and concentrated to give the title compound (A-3) (1.21 g, 5.63 mmol). MS-ESI (m z): 215.0 (M + H)+.
[01 14] 2-( isopropylthio )aniline (A-4)
Figure imgf000048_0003
A-4 [01 15] This reagent was prepared according to the method described in literature: J. Med. Chem. 2002, 45: 2229-2239.
[01 16] N-(2-(isopropylthio)phenyl)-3-methyl-6-(methylthio)-lH-pyrazolo[3,4- d]pyrimidin-4-amine (A-5)
Figure imgf000049_0001
[01 17] A mixture of 4-chloro-3-methyl-6-methylmercaptopyrazolo[3,4-d]pyrimidine (A- 3) (1.21 g, 5.63 mmol) and 2-(isopropylthio)aniline (A-4) (1.42 g, 8.50 mmol) in isopropanol (56 mL) was stirred at reflux for 3 h. After cooling down to ambient temperature, TEA (0.78 mL, 5.66 mmol) was added to the mixture, and the solution was again heated to reflux for 0.5 h. After cooling down to ambient temperature, the mixture was filtered to give the title compound (A-5) as white solid (1.30 g, 3.77mmol). MS-ESI (m/z): 346 (M + H)+.
[01 18] N-( 2-( isopropylsulfonyl)phenyl)-3-methyl-6-( methylsulfonyl)-! H-pyrazolof 3,4- dlyyrimidin-4-amine (Intermediate A )
Figure imgf000049_0002
Intermed iate A
[01 19] To a solution of N-(2-(isopropylsulfonyl)phenyl)-6-(methylthio)-lH- pyrazolo[3,4-d]pyri-midin-4-amine (A-5) (1.3 g, 3.77 mmol) in DCM (150 mL) was added m- CPBA (5.6 g, 22.6 mmol) at 0 C. Then the reaction mixture was warmed to ambient temperature and stirred for 4.5 h, washed with saturated NaHS03, brine, dried with Na2SC>4 and concentrated to give the title compound (Intermediate A) as a solid. MS-ESI (m/z): 410 (M + H)+.
Intermediate B
[0120] 2,5-dichloro-N-( 2-( isopropylsulfonyl)phenyl)pyrimidin-4-amine (B )
Figure imgf000050_0001
B-1
[0121] To a mixture of 2-(isopropylthio)aniline (23 g, 0.14 mol) in acetonitrile (250 mL) at RT was added DMAP (8.5 g, 70 mmol) and (Boc)20 (150 g, 688 mmol). After stirred at ambient temperature for 12 h, the solution was concentrated. The residue was purified by column chromatography on silica gel eluting with hexanes/EtOAc (10: 1) to give the title compound (B-
1).
Figure imgf000050_0002
B-1 B-2
[0122] To a mixture of (B-1) (54 g, 0.14 mol) in DCM (500 mL) at 0 °C was added m- CPBA (101 g, 0.44 mol). After stirred at ambient temperature for 12 h, the solution was washed with saturated NaHS03, brine, dried with Na2SC>4 and concentrated to give the compound (B-2) as a solid.
[0123] 2-( isopropylsulfonyl)aniline (B-3)
Figure imgf000051_0001
B-2 B-3
[0124] To a mixture of (B-2) (64 g, 0.32 mol) in DCM (500 mL) at 0 °C was added TFA (60 mL, 1 mol). After stirred at ambient temperature for 12 h, the solution was concentrated, diluted with EtOAc, washed with saturated. Na2C03, brine, dried with Na2SC>4 and concentrated to give the compound (B-3) as a solid. MS-ESI (m/z): 200 (M + 1)+.
[0125] 2, 5-dichloro-N-( 2-( isopropylsulfonyl )phenyl )pyrimidin-4-amine ( B )
Figure imgf000051_0002
B-3
[0126] To a mixture of 2-(isopropylsulfonyl)aniline (B-3) (32 g, 0.16 mol) in DMF (300 mL) at 0 °C was added NaH (13 g , 0.32 mol). After stirred at 0 °C for 0.5 h, 2,4,5- trichloropyrimidine (35 g, 0.13 mol) was dropwised to the mixture at 0 C. The solution was stirred for 12 h at RT, then poured into water, extracted with EtOAc, washed with water, brine, dried and concentrated. The residue was purified by column chromatography on silica gel eluting with hexanes/EtOAc (10: 1 to 5: 1) to give the title compound (B) as a yellow solid. MS-ESI (m/z): 346 (M + 1)+. Example 1
[0127] N-4-( 2-( isopropylsulfonyl)phenyl)-3-methyl-N-6-( 5-methyl-4-(piperidin-4-yl)-2,3- dihydrobenzofuran-7-yl)-lH-pyrazolof 3,4-dlpyrimidine-4,6-diamine ( 1 )
Figure imgf000052_0001
[0128] 2-bromo-l-(2-bromoethoxy)-4-methylbenzene (la)
Figure imgf000052_0002
1a
[0129] A mixture of 2-bromo-4-methylphenol (5.0 g, 26 mmol), 1 ,2-dibromoethane (7.0 g, 37 mmol) in water (20 mL) and aOH (1.1 g, 28 mmol) was stirred at 100 C for 24 h. The mixture was extracted with DCM (150 mL), washed with water, brine, dried and concentrated. The residue was purified by column chromatography on silica gel eluting with hexanes/EtOAc (20: 1) to give the title compound (la).
[0130] 5-methyl-2,3-dihydrobenzofuran (lb)
Figure imgf000052_0003
1a 1 b [0131] To a solution of 2-bromo-l-(2-bromoethoxy)-4-methylbenzene (la) (1.0 g, 3.4 mmol) in THF (20 mL) at -78 C under N2 was added n-BuLi (2.5 M, 11 mL, 27 mmol) and the resulting mixture was stirred at -78 C for 1 h. The mixture was quenched with saturated NH4CI (10 mL), extracted with EtOAc (150 mL), washed with brine, dried and concentrated to give the title compound (lb) as a colorless oil.
[0132] 5-methyl-7-nitro-2,3-dihydrobenzofuran (lc)
Figure imgf000053_0001
1 b 1c
[0133] A mixture of 5-methyl-2,3-dihydrobenzofuran (lb) (2.7 g, 20 mmol) in TFA (50 mL) was cooled to 0 C, NaN02 (2.5 g, 36 mmol) was added thereto. Then it was warmed up to ambient temperature and stirred for 12 h. The mixture was concentrated, poured into water (50 mL), extracted with EtOAc (150 mL), washed with brine, dried and concentrated. The residue was purified by column chromatography on silica gel eluting with hexanes/EtOAc (10: 1) to give the title compound (lc).
[0134] 5-methyl-2,3-dihydrobenzofuran-7-amine ( Id)
Figure imgf000053_0002
1c 1d
[0135] A mixture of 5-methyl-7-nitro-2,3-dihydrobenzofuran (lc) (0.30 g, 1.7 mmol) and Pd/C (150 mg, 50%) in THF (5 mL) was introduced H2. It was stirred at ambient temperature for 12 h. The mixture was filtered through celite and concentrated to give the title compound (Id) as a solid. MS-ESI (m/z): 150 (M + 1)+.
[0136] 4-bromo-5-methyl-2,3-dihydrobenzofuran-7-amine (le)
Figure imgf000054_0001
[0137] To a mixture of 5-methyl-2,3-dihydrobenzofuran-7-amine (Id) (1.0 g, 6.7 mmol) in DMF (21 mL) at 0 °C was added NBS (1.19 g, 6.7 mmol), it was stirred at 0 °C for 15 min. The mixture was extracted with EtOAc (150 mL), washed with saturated NaHS03 (50 mL), water, brine, dried and concentrated. The residue was purified by column chromatography on silica gel eluting with hexanes/EtOAc (20: 1) to give the title compound (le) as a yellow solid. MS-ESI (m/z): 228 (M + 1)+.
[0138] 5 -meth l-4-( p ridin-4- l)-2,3-dih drobenzofuran-7 -amine ( If)
Figure imgf000054_0002
1e 1f
[0139] A mixture of 4-bromo-5-methyl-2,3-dihydrobenzofuran-7-amine (le) (0.80 g, 3.5 mmol), pyridin-4-ylboronic acid (0.86 g, 7 mmol), Cs2C03 (2.84 g, 8.7 mmol), Pd(PPh3)4 (0.40 g, 0.346 mmol) and water (7 mL) in DMF (35 mL) was stirred at 135 C under N2 for 1 h. It was cooled to ambient temperature, poured into water (50 mL), extracted with EtOAc (150 mL), washed with water, brine, dried and concentrated. The residue was purified by column chromatography on silica gel eluting with hexanes/EtOAc (20: 1 to 5: 1 to 1 : 1) to give the title compound (If) as a yellow solid. MS-ESI (m/z): 227 (M + 1)+.
[0140] 5-meth l-4-(piperidin-4- l)-2,3-dih drobenzofuran-7-amine (Ig)
Figure imgf000055_0001
1 f i g
[0141] A mixture of 5-methyl-4-(pyridin-4-yl)-2,3-dihydrobenzofuran-7-amine (If) (0.40 g, 1.8 mmol) , Pt02 (120 mg, 35%) and TEA (0.24 mL, 3.6 mmol) in HOAc (30 mL) was introduced H2 and stirred at ambient temperature for 24 h (88 psi). The mixture was filtered, concentrated, diluted with EtOAc (50 mL). A solution of ammonium hydroxide was added until pH = 10, it was extracted with EtOAc (150 mL), washed with water, brine, dried and
concentrated to give the title compound (lg) as a yellow oil. MS-ESI (m/z): 233 (M + 1)+.
[0142] N-4-( 2-( isoyroyylsulfonyl)vhenyl)-3-methyl-N-6-( 5-methyl-4-( yiyeridin-4-yl)-2,3- dihydrobenzofuran-7-yl)-lH-pyrazolof 3,4-dlpyrimidine-4,6-diamine ( 1 )
Figure imgf000055_0002
[0143] A mixture of 5-methyl-4-(piperidin-4-yl)-2,3-dihydrobenzofuran-7-amine (lg) (25 mg, 0.017 mmol), N-(2-(isopropylsulfonyl)phenyl)-3-methyl-6-(methylsulfonyl)-lH- pyrazolo[3,4-d]pyrimidin-4-amine (intermediate A) (53 mg, 0.12 mmol) and p-TsOH (20 mg, 0.1 1 mmol) in -PrOH (0.5 mL) was stirred in a sealed tube at 160 C for 5 h. The mixture was diluted with EtOAc (20 mL). A solution of ammonium hydroxide was added until pH = 10, it was extracted with EtOAc (60 mL), washed with water, brine, dried and concentrated. The residue was purified by column chromatography on silica gel eluting with DCM/MeOH (10: 1) to give the title compound (1) as a yellow solid. MS-ESI (m/z): 562 (M + 1)+.
Example 2
[0144] N-4-(2-(isopropylsulfonyl)phenyl)-3-methyl-N-6-(5-methyl-4-(l-methylpiperidin- 4-yl)-2,3-dihydrobenzofuran-7-yl)-lH-yyrazolof 3,4-dlyyrimidine-4,6-diamine ( 2 )
Figure imgf000056_0001
1 2
[0145] A mixture of of N-4-(2-(isopropylsulfonyl)phenyl)-3-methyl-N-6-(5-methyl-4- (piperidin-4-yl)-2,3-dihydrobenzofuran-7-yl)-lH-pyrazolo[3,4-d]pyrimidine-4,6-diamine (1) (37 mg, 0.064 mmol), formaldehyde (5.5 L, 0.64 mmol), HOAc (cat.) and aBH3CN (10.3 mg, 0.16 mmol) was stirred at ambient temperature for 0.5 h. The mixture was diluted with NaHC03 (10 mL) and EtOAc (20 mL), extracted with EtOAc (60 mL), washed with water, brine, dried and concentrated. The residue was purified by column chromatography on silica gel eluting with DCM/MeOH (10: 1) to give the title compound (2) as a yellow solid. MS-ESI (m/z): 576 (M + Example 3
[0146] ( R)-N-6-( 2,5-dimethyl-4-(piperidin-4-yl)-2,3-dihydrobenzofuran-7-yl)-N-4-( 2- ( isopropylsulfonyl)phenyl)-3-methyl-lH-pyrazolof 3,4-dlpyrimidine-4,6-diamine (3)
Figure imgf000057_0001
3
[0147] l-(benzyloxy)-2-bromo-4-methylbenzene ( 3a)
Figure imgf000057_0002
[0148] To a mixture of 2-bromo-4-methylphenol (5.0 g, 27 mmol) and K2CO3 (7.4 g, 53 mmol) in DMF (20 mL) was added benzyl bromide (3.5 mL, 29 mmol) at ambient temperature. It was stirred at 70 C for 12 h. The mixture was poured into water (50 mL), extracted with EtOAc (150 mL), washed with water, brine, dried and concentrated. The residue was purified by column chromatography on silica gel eluting with hexaness/EtOAc (10: 1) to give the title comound (3a).
[0149] (S)-l-(2-(benzyloxy)-5-methylphenyl)propan-2-ol (3b)
Figure imgf000058_0001
3a
[0150] To a solution of 1 -(benzyloxy)-2-bromo-4-methylbenzene (3a) (1.0 g, 3.6 mmol) in THF (20 mL) at -78 C under N2 atmosphere was added n-BuLi (2.5 M, 1.6 mL, 3.9 mmol), the resulting mixture was stirred for 30 min and (,S')-2-methyloxirane (0.38 mL, 5.4 mmol) and BF3.Et20 (0.67 mL, 5.4 mmol) were added to the mixture. It was stirred at -78 C for 1.5 h and warmed up to ambient temperature, quenched with water (10 mL), extracted with EtOAc (30 mL), washed with brine, dried and concentrated. The residue was purified by column
chromatography on silica gel eluting with hexanes/EtOAc (10: 1) to give the title compound (3b).
[0151] ( S)-2-(2-hydroxypropyl)-4-methylphenol (3 c)
Figure imgf000058_0002
3b
[0152] The mixture of (5)-l -(2-(benzyloxy)-5-methylphenyl)-propan-2-ol (3b) (0.50 g, 1.9 mmol) and Pd/C (100 mg, 20%) in MeOH (10 mL) was introduced H2 at ambient
temperature. It was stirred at ambient temperature for 18 h. The mixture was filtered through Celite and concentrated to give the title compound (3c).
[0153] (R)-2,5-dimethyl-2,3-dihydrobenzofuran ( 3d)
Figure imgf000058_0003
3c 3d
[0154] To a mixture of (5)-2-(2-hydroxypropyl)-4-methylphenol (3c) (1.6 g, 8.4 mmol) and triphenylphosphine (2.7 g, 10 mmol) in THF (60 mL) was added DIAD at ambient temperature. It was concentrated in vacuo. The residue was purified by column chromatography on silica gel eluting with hexanes/EtOAc (10: 1) to give the title compound (3d). [0155] (R)-2,5-dimethyl-7-nitro-2,3-dihydrobenzofuran ( 3e)
Figure imgf000059_0001
3d 3e
[0156] A mixture of (i?)-2,5-dimethyl-2,3-dihydrobenzofuran (3d) (2.0 g, 13 mmol) in TFA (40 mL) was cooled to 0 C, NaN02 (1.7 g, 23 mmol) was added thereto. It was stirred at ambient temperature for 12 h. The mixture was concentrated, poured into water (50 mL), extracted with EtOAc (150 mL), washed with brine, dried and concentrated. The residue was purified by column chromatography on silica gel eluting with hexanes/EtOAc (20: 1) to give the title compound (3e).
[0157] (R)-2,5-dimethyl-2,3-dihydrobenzofuran-7-amine ( 3f)
Figure imgf000059_0002
3e 3f
[0158] The mixture of (ii)-2,5-dimethyl-7-nitro-2,3-dihydrobenzofuran (3e) (0.84 g, 4.3 mmol) and Pd/C (100 mg, 15%) in THF (10 mL) was introduced H2 at ambient temperature. It was stirred at ambient temperature for 12 h. The mixture was filtered through Celite and concentrated to give the title compound (3f) as a solid. MS-ESI (m/z): 164 (M + 1)+.
[0159] (R)-4-bromo-2,5-dimethyl-2,3-dihydrobenzofuran-7-amine ( 3g)
Figure imgf000059_0003
3f [0160] To a mixture of (i?)-2,5-dimethyl-2,3-dihydrobenzofuran-7-amine (3f) (1.3 g, 7.9 mmol) in DMF (16 mL) was added NBS (1.42 g, 7.9 mmol) at 0 °C. It was stirred for 15 min at 0 C. The mixture was extracted with EtOAc (150 mL), washed with NaHS03 (50 mL), water and brine, dried and concentrated. The residue was purified by column chromatography on silica gel eluting with hexanes/EtOAc (20: 1) to give the title compound (3g) as a solid. MS-ESI (m/z): 242 (M + 1)+.
[0161] (R)-2,5-dimethyl-4-(pyridin-4-yl)-2,3-dihydrobenzofuran-7 -amine ( 3h )
Figure imgf000060_0001
3g 3h
[0162] The mixture of (ii)-4-bromo-2,5-dimethyl-2,3-dihydrobenzofuran-7-amine (3g) (1.0 g, 4.3 mmol), pyridin-4-ylboronic acid (1.08 g, 8.77 mmol), Cs2C03 (3.56 g, 10.9 mmol), Pd(PPh3)4 (0.506 g, 0.438 mmol) and water (9 mL) in DMF (44 mL) was stirred at 135 °C under N2 for 1 h . It was cooled to ambient temperature, poured into water (50 mL), extracted with EtOAc (150 mL, washed with water, brine, dried and concentrated. The residue was purified by column chromatography on silica gel eluting with hexanes/EtOAc (20: 1 to 5: 1 to 1 : 1) to give the title compound (3h) as a solid. MS-ESI (m/z): 241 (M + 1)+.
[0163] (R)-2,5-dimethyl-4-(piperidin-4-yl)-2,3-dihydrobenzofuran-7-amine (3i)
Figure imgf000060_0002
3h 3i [0164] [The mixture of (ii)-2,5-dimethyl-4-(pyridin-4-yl)-2,3-dihydrobenzofuran-7- amine (3h) (0.60 g, 2.4 mmol), Pt02 (240 mg, 35 %) and TEA (0.38 mL, 4.9 mmol) in HO Ac (40 mL) was introduced H2 and stirred for 24 h at ambient temperature (88 psi). The mixture was filtered, concentrated, and diluted with EtOAc (50 mL). A solution of ammonium hydroxide was added until pH = 10, then extracted with EtOAc (150 mL), washed with water, brine, dried and concentrated to give the title compound (3i) as a yellow oil. MS-ESI (m/z): 247 (M + 1)+.
[0165] (R)-N-6-(2,5-dimethyl-4-(piperidin-4-yl)-2,3-dihydrobenzofuran-7-yl)-N-4-(2- ( isopropylsulfonyl)phenyl)-3-methyl-lH-pyrazolof 3,4-dlpyrimidine-4,6-diamine (3)
Figure imgf000061_0001
[0166] A mixture of (ii)-2,5-dimethyl-4-(piperidin-4-yl)-2,3-dihydrobenzofuran-7-amine (3i) (44 mg, 0.017 mmol), N-(2-(isopropylsulfonyl)phenyl)-3-methyl-6-(methylsulfonyl)-lH- pyrazolo[3,4-d]pyrimidin-4-amine (Intermediate A) (83 mg, 0.20 mmol) and p-TsOH (32 mg, 0.17 mmol) in -PrOH (0.5 mL) was stirred in a sealed tube at 160 C for 5 h. The mixture was diluted with EtOAc (20 mL), ammonium hydroxide was added until pH = 10, it was extracted with EtOAc (60 mL), washed with water, brine, dried and concentrated. The residue was purified by column chromatography on silica gel eluting with DCM/MeOH (10: 1) to give the title compound (3) as a yellow solid. MS-ESI (m z): 576 (M + 1)+. Example 4
[0167] (R)-N-6-(2,5-dimethyl-4-(l-methylpiperidin-4-yl)-2,3-dihydrobenzof ran-7-yl)-N- 4-( 2-( isopropylsulfonyl)phenyl)-3-methyl-lH-pyrazolof 3,4-dlpyrimidine-4,6-diamine (4)
Figure imgf000062_0001
[0168] A mixture (ii)-N-6-(2,5-dimethyl-4-(piperidin-4-yl)-2,3-dihydrobenzofuran-7-yl)- N-4-(2-(isopropylsulfonyl)phenyl)-3-methyl-lH-pyrazolo[3,4-d]pyrimidine-4,6-diamine (3) (37 mg, 0.064 mmol), formaldehyde (5.5 μί, 0.64 mmol), HOAc (cat.) and aBH3CN (10.3 mg, 0.16 mmol) was stirred at ambient temperature for 0.5 h. The mixture was diluted with NaHC03 (10 mL) and EtOAc (20 mL), extracted with EtOAc (60 mL), washed with water, brine, dried and concentrated. The residue was purified by column chromatography on silica gel eluting with DCM/MeOH (10: 1) to give the title compound (4) as a solid. MS-ESI (m/z): 590 (M + 1)+.
Example 5
[0169] (S)-N-6-(2,5-dimethyl-4-(piperidin-4-yl)-2,3-dihydrobenz.ofuran-7-yl)-N-4-(2- ( isopropylsulfonyl)phenyl)-3-methyl-lH-pyrazolof 3,4-dlpyrimidine-4,6-diamine ( 5)
Figure imgf000063_0001
[0170] (R)-l-( 2-(benzyloxy)-5-methylphenyl )propan-2-ol ( 5 a )
Figure imgf000063_0002
3a 5a
[0171] The title compound 5a was prepared according to the method for preparation of compound 3b of Example 3 by replacing (5)-2-methyloxirane with (ii)-2-methyloxirane.
[0172] (R)-2-(2-hydroxypropyl)-4-methylphenol (5b)
Figure imgf000063_0003
5a 5b
[0173] The title compound 5b was prepared according to the method for preparation of compound 3c of Example 3 by replacing 3b with 5a.
[0174] ( S)-2,5-dimethyl-2,3-dihydrobenzofuran ( 5c)
Figure imgf000064_0001
5b 5c
[0175] The title compound 5c was prepared according to the method for preparation of compound 3d of Example 3 by replacing 3c with 5b.
[0176] ( S)-2,5-dimethyl-7-nitro-2,3-dihydrobenzofuran ( 5d)
Figure imgf000064_0002
5c 5d
[0177] The title compound 5d was prepared according to the method for preparation of compound 3e of Example 3 by replacing 3d with 5c.
[0178] (S)-2,5-dimethyl-2,3-dihydrobenzofuran-7-amine (5e)
Figure imgf000064_0003
5d 5e
[0179] The title compound 5e was prepared according to the method for preparation of compound 3f of Example 3 by replacing 3e with 5d. MS-ESI (m/z): 164 (M + 1)+.
[0180] ( S)-4-bromo-2,5-dimethyl-2,3-dihydrobenzofuran-7-amine ( 5f)
Figure imgf000065_0001
[0181] The title compound 5f was prepared according to the method for preparation of compound 3g of Example 3 by replacing 3f with 5e. MS-ESI (m/z): 242 (M + 1)+.
[0182] ( S)-2,5-dimethyl-4-(pyridin-4-yl)-2,3-dihydrobenzofuran-7-amine ( 5g)
Figure imgf000065_0002
5f 5g
[0183] The title compound 5g was prepared according to the method for preparation of compound 3h of Example 3 by replacing 3g with 5f. MS-ESI (m/z): 241 (M + 1)+.
[0184] ( S)-2,5-dimethyl-4-(piperidin-4-yl)-2,3-dihydrobenzofuran-7-amine ( 5h )
Figure imgf000065_0003
5g 5h [0185] The title compound 5h was prepared according to the method for preparation of compound 3i of Example 3 by replacing 3h with 5g. MS-ESI (m/z): 247 (M + 1)+.
[0186] ( S)-N-6-( 2,5-dimethyl-4-(piperidin-4-yl)-2,3-dihydrobenzofuran-7-yl)-N-4-( 2- ( isopropylsulfonyl)phenyl)-3-methyl-lH-pyrazolof 3,4-dlpyrimidine-4,6-diamine ( 5)
Figure imgf000066_0001
5h 5
[0187] The title compound (5) was prepared according to the method for preparation of compound 3 of Example 3 by replacing 3i with 5h. MS-ESI (m/z): 576 (M + 1)+.
Example 6
[0188] (S)-N-6-(2,5-dimethyl-4-(l-methylpiperidin-4-yl)-2,3-dihydrobenzofuran-7-yl)-N- 4-(2-(isopropylsulfonyl)phenyl)-3-methyl-lH^yrazolof3 -dlpyrimidine-4,6-diamine (6)
Figure imgf000067_0001
[0189] Prepared according to the method of Example 4 by replacing (ii)-N-6-(2,5- dimethyl-4-(piperidin-4-yl)-2,3-dihydrobenzofuran-7-yl)-N-4-(2-(isopropylsulfonyl)phenyl)-3- methyl-lH-pyrazolo[3,4-d]pyrimidine-4,6-diamine (3) with (lS')-N-6-(2,5-dimethyl-4-(piperidin- 4-yl)-2,3-dihydrobenzofuran-7-yl)-N-4-(2-(isopropylsulfonyl)phenyl)-3-methyl-lH- pyrazolo[3,4-d]pyrimidine-4,6-diamine (5). The title compound (6) was obtained. MS-ESI (m/z): 590 (M + 1)+.
Example 7
[0190] (7-(4-(2-(isoyrovylsulfonyl)vhenylamino)-3-methyl-lH-yyrazolo[3A-dlvyrimidin-
6-ylamino)-5-methyl -(viyeridin-4-yl)-2,3-dihydrobenzofuran-2-yl)methanol (7)
Figure imgf000068_0001
Figure imgf000068_0002
[0192] A mixture of 4-methyl-2-nitrophenol (5.0 g, 0.033 mol), 3-bromoprop-l-ene (4.2 g, 0.034 mol) and K2CO3 (4.6 g, 0.033 mol) in acetone (20 mL) was stirred for 8 h at ambient temperature. The mixture was poured into water (50 mL), extracted with EtOAc (90 mL), washed with brine, dried and concentrated to give the title compound (7a).
[0193] 2-allyl-4-methyl-6-nitrophenol ( 7b )
Figure imgf000068_0003
[0194] The compound l-(allyloxy)-4-methyl-2-nitrobenzene (7a) (6.1 g, 0.032 mol) was stirred for 5 h at 200 C. The mixture was purified by column chromatography on silica gel eluting with hexanes/EtOAc (50: 1) to give the title compound (7b) as a yellow oil. [0195] (5-methyl-7-nitro-2,3-dihydrobenzofuran-2-yl)methanol (7c)
Figure imgf000069_0001
7b 7c
[0196] A mixture of 2-allyl-4-methyl-6-nitrophenol (7b) (0.50 g, 2.5 mmol) and m- CPBA (0.64 g, 2.5 mmol) in CHC13 (9 mL) was stirred for 6 h at 85 C. The mixture was poured into saturated NaHS03 (20 mL), extracted with DCM (40 mL), washed with brine, dried and concentrated. The residue was purified by column chromatography on silica gel eluting with hexanes/EtOAc (10: 1) to give the title compound (7c) as a solid. MS-ESI (m/z): 210 (M + 1)+.
[0197] (7-amino-5-methyl-2,3-dihydrobenzofuran-2-yl)methanol (7d)
Figure imgf000069_0002
7c 7d
[0198] A mixture of (5-methyl-7-nitro-2,3-dihydrobenzofuran-2-yl)methanol (7c) (2.3 g, 0.01 1 mol) and Pd/C (230 mg, 10%) in THF (30 mL) was introduced H2 and stirred at ambient temperature for 12 h. The mixture was filtered through celite and concentrated to give the title compound (7d) as a solid. MS-ESI (m/z): 180 (M + 1)+.
[0199] <7-amino-4-bromo-5-methyl-2,3-dihydrobenz.ofuran-2-yl)methanol (7e)
Figure imgf000069_0003
7d 7e
[0200] To a mixture of (7-amino-5-methyl-2,3-dihydrobenzofuran-2-yl)methanol (7d) (0.80 g, 4.5 mmol) in DMF (13 mL) at 0 °C was added NBS (0.08 g, 4.5 mmol), it was stirred at 0 C for 15 min. The mixture was extracted with EtOAc (150 mL), washed with NaHS03 (50 mL), water, brine, dried and concentrated to give the title compound (7e) as a yellow solid. MS- ESI (m/z): 258 (M + 1)+.
[0201] (7-amino-5-methyl-4-(pyridin-4-yl)-2,3-dihydrobenzofuran-2-yl)methanol (7f)
Figure imgf000070_0001
[0202] A mixture of (7-amino-4-bromo-5-methyl-2,3-dihydrobenzofuran-2-yl)methanol (7e) (1.7 g, 6.6 mmol), pyridin-4-ylboronic acid (1.6 g, 1.3 mmol), Cs2C03 (5.3 g, 16 mmol), Pd(PPh3)4 (0.76 g, 0.66 mmol) and water (13 mL) in DMF (60 mL) was stirred at 135 °C under N2 for 1 h. It was cooled to ambient temperature, poured into water (100 mL), extracted with EtOAc (150 mL), washed with water, brine, dried and concentrated. The residue was purified by column chromatography on silica gel eluting with hexanes/EtOAc (20: 1 to 5: 1 to 1 : 1) to give the title compound (7f) as a yellow solid. MS-ESI (m/z): 257 (M + 1)+.
[0203] (7 -amino-5 -methyl-4-(piperidin-4-yl )-2,3-dihydrobenzofuran-2-yl jmethanol ( 7s )
Figure imgf000070_0002
7f 79
[0204] A mixture of (7-amino-5-methyl-4-(pyridin-4-yl)-2,3-dihydrobenzofuran-2- yl)methanol (7f) (0.10 g, 0.39 mmol), PtO2 (50 mg, 50%) and TEA (0.061 mL, 0.78 mmol) in HO Ac (5 mL) was introduced H2 and stirred at ambient temperature for 24 h (88 psi). The mixture was filtered, concentrated, and diluted with EtOAc (50 mL). A solution of ammonium hydroxide was added until pH = 10, it was extracted with EtOAc (150 mL), washed with water, brine, dried and concentrated to give the title compound (7g) as a yellow oil. MS-ESI (m/z): 262 (M + 1)+.
[0205] (7-( ( 4-( ( 2-( isoyrovylsulfonyl)vhenyl)amino)-3-methyl-lH-yyrazolof 3,4- d]vyrimidin-6-yl)amino)-5-met yl-4-(viveridin-4-yl)-2,3-di ydm (7)
Figure imgf000071_0001
[0206] A mixture of (7-amino-5-methyl-4-(piperidin-4-yl)-2,3-dihydrobenzofuran-2- yl)methanol (7g) (40 mg, 0.15 mmol), N-(2-(isopropylsulfonyl)phenyl)-3-methyl-6- (methylsulfonyl)- lH-pyrazolo[3,4-d]pyrimidin-4-amine (Intermediate A) (75 mg, 0.18 mmol) and p-TsOH (29 mg, 0.15 mmol) in -PrOH (0.5 mL) was stirred in a sealed tube at 160 C for 5 h. The mixture was diluted with EtOAc (20 mL), ammonium hydroxide was added until pH =10, it was extracted with EtOAc (60 mL), washed with water, brine, dried and concentrated. The residue was purified by column chromatography on silica gel eluting with DCM/MeOH (10: 1) to give the title compound (7) as a yellow solid. MS-ESI (m z): 592 (M + 1)+.
Example 8
[0207] N-4-(2-(isopropylsulfonyl)phenyl)-N-6-(2-(methoxymethyl)-5-methyl-4-(piperidin- 4-yl)-2,3-dihydrobenzofuran-7-yl)-3-methyl-lH-pyrazolo[3,4-dlpyrimidine-4,6-diamine (8)
Figure imgf000072_0001
[0208] 2-( methoxymethyl)-5-methyl-7-nitro-2,3-dihydrobenzofuran ( 8a)
Figure imgf000072_0002
8a
[0209] A mixture of (5-methyl-7-nitro-2,3-dihydrobenzofuran-2-yl)methanol (0.70 g, 3.3 mmol) in THF was cooled to 0 C. NaH was added to the mixture at 0 C. It was stirred for 15 min at 0 C. Mel was added dropwise to the mixture at 0 C. It was stirred for 0.5 h at 0 C. The mixture was poured into water (20 mL), extracted with EtOAc (40 mL), washed with water, brine, dried and concentrated to give the title compound (8a) as a yellow oil. MS-ESI (m/z): 224 (M + 1)+.
[0210] 2-( methoxymethyl)-5 -methyl-2,3-dihydrobenzofuran-7 -amine ( 8b)
Figure imgf000072_0003
8a 8b [021 1] A mixture of 2-(methoxymethyl)-5-methyl-7-nitro-2,3-dihydrobenzofuran (8a) (0.85 g, 3.8 mmol) and Pd/C (90 mg, 10%) in THF (10 mL) was introduced H2 and stirred at ambient temperature for 12 h. The mixture was filtered through celite and concentrated to give the title compound (8b) as oil. MS-ESI (m/z): 194 (M + 1)+.
[0212] 4-bromo-2-( methoxymethyl)-5-methyl-2,3-dihydrobenzofuran-7-amine ( 8c)
Figure imgf000073_0001
[0213] To a mixture of 2-(methoxymethyl)-5-methyl-2,3-dihydrobenzofuran-7-amine (8b) (0.60 g, 3.1 mmol) in DMF (8 mL) at 0 °C was added NBS (0.55 g, 3.1 mmol). It was stirred at 0 C for 15 min. The mixture was extracted with EtOAc (40 mL), washed with NaHS03 (20 mL), water, brine, dried and concentrated to give the title compound (8c) as a yellow oil. MS-ESI (m/z): 272 (M + 1)+.
[0214] 2-( methoxymethyl)-5-methyl-4-( pyridin-4-yl)-2,3-dihydrobenzofuran-7-amine ( 8d)
Figure imgf000073_0002
[0215] A mixture of 4-bromo-2-(methoxymethyl)-5-methyl-2,3-dihydrobenzofuran-7- amine (8c) (0.85 g, 3.1 mmol), pyridin-4-ylboronic acid (0.76 g, 6.2 mmol), Cs2C03 (2.5 g, 7.8 mmol), Pd(PPh3)4 (0.18 g, 0.16 mmol) and water (6 mL) in DMF (20 mL) was stirred at 135 °C under N2 for 1 h. It was cooled to ambient temperature, poured into water (50 mL), extracted with EtOAc (60 mL), washed with water, brine, dried and concentrated. The residue was purified by column chromatography on silica gel eluting with hexanes/EtOAc (20: 1 to 5: 1 to 1 : 1) to give the title compound (8d) as a yellow oil. MS-ESI (m/z): 271 (M + 1)+.
[0216] 2-(methoxymethyl)-5-methylA-(piperidinA-yl)-2,3-dihydrobenzofuran-7-amine
Figure imgf000074_0001
[0217] A mixture of 2-(methoxymethyl)-5-methyl-4-(pyridin-4-yl)-2,3- dihydrobenzofuran-7-amine (8d) (0.57 g, 2.1 mmol), PtO2 (300 mg, 50%) and TEA (0.323 mL, 4.20 mmol) in HOAc (15 mL) was introduced H2 and stirred at ambient temperature for 24 h (88 psi). The mixture was filtered, concentrated, diluted with EtOAc (50 mL), a solution of ammonium hydroxide was added until pH = 10. It was extracted with EtOAc (150 mL), washed with water, brine, dried and concentrated to give the title compound (8e) as a yellow oil. MS-ESI (m/z): 277 (M + 1)+.
[0218] N-4-(2-(isopropylsulfonyl)phenyl)-N-6-(2-(methoxymethyl)-5-methyl-4-(piperidin-
4-yl)-2,3-dihydrobenzofuran-7-yl)-3-methyl-lH^yrazolo[3A-dlpyrimidine-4,6-diamine (8)
Figure imgf000075_0001
[0219] A mixture of (7-amino-5-methyl-4-(piperidin-4-yl)-2,3-dihydrobenzofuran-2- yl)methanol (8e) (100 mg, 0.36 mmol), N-(2-(isopropylsulfonyl)phenyl)-3-methyl-6- (methylsulfonyl)-lH-pyrazolo[3,4-d]pyrimidin-4-amine (Intermediate A) (163 mg, 0.400 mmol) and p-TsOH (69 mg, 0.36 mmol) in -PrOH (0.5 mL) was stirred in a sealed tube at 160 C for 5 h. The mixture was diluted with DCM (20 mL), ammonium hydroxide was added until pH =10, it was extracted with DCM (60 mL), washed with water, brine, dried and concentrated. The residue was purified by column chromatography on silica gel eluting with DCM/MeOH (10: 1) to give the title compound (8) as a yellow solid. MS-ESI (m z): 606 (M + 1)+.
Example 9
[0220] (R)-5-chloro-N-2-(2,5-dimethyl-4-(piperidin-4-yl)-2,3-dihydrobenzofuran-7-yl)- N-4-( 2-( isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (9)
Figure imgf000076_0001
3i 9
[0221] A mixture of 3i (0.8 g, 3.5 mmol), Intermediate B (1.32 g, 3.8 mmol) and TFA
(1.0 g, 8.8 mmol) was stirred in a sealed tube at 130 C for 5 h . The mixture was diluted with
EtOAc (20 mL), washed with water, brine, dried and concentrated. The residue was purified by column chromatography on silica gel eluting with DCM/MeOH (10: 1) to give the title compound (9) as a brown solid. MS-ESI (m z): 556 (M + 1)+.
Example 10
[0222] (R)-5-chloro-N-2-(2,5-dimethyl-4-(l-methylpiperidin-4-yl)-2,3- dihydrobenzofuran-7-yl)-N-4-(2-( isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (10)
Figure imgf000076_0002
1 0
[0223] A mixture of Compound 9 (210 mg, 0.38 mmol), formaldehyde (1 1.4 mg, 0.38 mmol) and NaBH3CN (57.3 mg, 0.91 mmol) was stirred at ambient temperature for 0.5 h. The mixture was diluted with NaHC03 (10 mL) and EtOAc (20 mL), extracted with EtOAc (60 mL), washed with water, brine, dried and concentrated. The residue was purified by column chromatography on silica gel eluting with DCM/MeOH (10: 1) to give the title compound (10) as a yellow solid. MS-ESI (m z): 570 (M + 1)+.
Example 1 1
[0224] (S)-5-chloro-N-2-(2,5-dimethyl-4-(piperidin-4-yl)-2,3-dihydrobenzofuran-7-yl)-N- 4-( 2-( isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (11 )
Figure imgf000077_0001
1 1
[0225] Prepared according to the method of Example 9 by replacing 3i with 5h. The title compound (11) was obtained. MS-ESI (m z): 556 (M + 1)+.
Example 12
[0226] (S)-5-chloro-N-2-(2,5-dimethyl-4-(l-methylviyeridin-4-yl)-2,3- dihydrobenzofuran-7-yl)-N-4-(2-( isoyrovylsulfonyl)vhenyl)yyrimidine-2,4-diamine (12)
Figure imgf000077_0002
[0227] Prepared according to the method of Example 10 by replacing Compound 9 with Compound 11. The title compound (12) was obtained. MS-ESI (m/z): 570 (M + 1)+.
Example 13
[0228] 5-chloro-N-4-(2-(isopropylsulfonyl)phenyl)-N-2-(5-methyl-4-(piperidin-4-yl)-2,3- dihydrobenzofuran-7-yl)pyrimidine-2,4-diamine (13)
Figure imgf000078_0001
13
[0229] Prepared according to the method of Example 9 by replacing 3i with 5-methyl-4- (piperidin-4-yl)-2,3-dihydrobenzofuran-7-amine (lg). The title compound (13) was obtained. MS-ESI (m/z): 542 (M + 1)+.
Example 14
[0230] 5-chloro-N-4-(2-( isopropylsulfonyl)phenyl)-N-2-( 5-methyl-4-( 1 -methylpiperidin- 4-yl)-2,3-dihydrobenzofuran-7-yl )pyrimidine-2,4-diamine (14)
Figure imgf000078_0002
14 [0231] Prepared according to the method of Example 10 by replacing Compound 9 with Compound 13. The title compound (14) was obtained. MS-ESI (m/z): 556 (M + 1)+.
Examples 15-58
[0232] Examples 15-58 (Table 1) were derivatized from Compound 9 or Compound 11 via N-alkylation, acylation, or sulfonylation as shown the following scheme using conditions known in the art. The carbon marked with "*" has chirality as set forth in the chemical structures in Table 1.
Figure imgf000079_0001
Table 1
Figure imgf000079_0002
O. .0
(R)-l -(4-(7-((5-chloro-4-((2- 598
(isopropylsulfonyl)phenyl)amino)pyrimidin- 2-yl)amino)-2,5-dimethyl-2,3-
HN
dihydrobenzofuran-4-yl)piperidin- 1 - xV N yl)ethanone
(S)-5-chloro-N-2-(2,5-dimethyl-4-(l - 634 (methylsulfonyl)piperidin-4-yl)-2,3- dihydrobenzofuran-7-yl)-N-4-(2- (isopropylsulfonyl)phenyl)pyrimidine-2,4- diamine
Figure imgf000080_0001
(R)-5-chloro-.V-2-(2,5-dimethyl-4-(l- 634 (methylsulfonyl)piperidin-4-yl)-2,3- HN
dihydrobenzofuran-7-yl)-N-4-(2-
HN
(isopropylsulfonyl)phenyl)pyrimidine-2,4- xV N diamine
Figure imgf000081_0001
Figure imgf000082_0001
Figure imgf000083_0001
Figure imgf000084_0001
Figure imgf000085_0001
Figure imgf000086_0001
Figure imgf000087_0001
Figure imgf000088_0001
Figure imgf000089_0001
Figure imgf000090_0001
(R)-l -(4-(7-((5-chloro-4-((2- 626
(isopropylsulfonyl)phenyl)amino)pyrimidin- 2-yl)amino)-2,5-dimethyl-2,3- dihydrobenzofuran-4-yl)piperidin- 1 -yl)-2- HN xV N
methylpropan- 1 -one
(R)-(4-(7-((5-chloro-4-((2- 624
(isopropylsulfonyl)phenyl)amino)pyrimidin- HN"^
2-yl)amino)-2,5-dimethyl-2,3-
HN
dihydrobenzofuran-4-yl)piperidin- 1 - xV N y 1) (cy clopropyl)methanone
(R)-5-chloro-.V-2-(4-(l- 648 (ethylsulfonyl)piperidin-4-yl)-2,5-dimethyl-
2,3-dihydrobenzofuran-7-yl)-N-4-(2-
(isopropylsulfonyl)phenyl)pyrimidine-2,4- diamine
Figure imgf000091_0001
Figure imgf000092_0001
(R).1 -(4-((R)-7-((5-chloro-4-((2- 642
(isopropylsulfonyl)phenyl)amino)pyrimidin- XX)
2-yl)amino)-2,5-dimethyl-2,3-
HN N
dihydrobenzofuran-4-yl)piperidin- 1 -yl)-2- xV
methoxypropan- 1 -one
(5)- 1 -(4-((R)-7-((5-chloro-4-((2- 642
(isopropylsulfonyl)phenyl)amino)pyrimidin- ΧΌ
2-yl)amino)-2,5-dimethyl-2,3-
HN
dihydrobenzofuran-4-yl)piperidin- 1 -yl)-2- xV N methoxypropan- 1 -one
(5)-l -(4-((5)-7-((5-chloro-4-((2- 642 (isopropylsulfonyl)phenyl)amino)pyrimidin- XX)
2-yl)amino)-2,5-dimethyl-2,3-
HN
dihydrobenzofuran-4-yl)piperidin- 1 -yl)-2- xV N methoxypropan- 1 -one
Biological Activity Inhibition Activity of Cell Proliferation
[0233] SU-DHL- 1 cells were seeded in 96-well tissue culture plates. On the next day, cells were exposed to various concentrations of compounds and further cultured for 72 h. Cell proliferation was then determined using Cell Counting Kit-8 [(CCK-8), Dojindo] assay. Briefly, add 10 of the CCK-8 solution to each well of the plate. Incubate the plate for 1 -4 hours in the incubator. Measure the absorbance at 450 nm using a multi-well spectrophotometer
(SpectraMAX 190, Molecular Devices). The inhibition rate (%) was calculated using the following equation: [1 -(A450 Compound/ A450 Control)] x l 00%. IC50 values were calculated according to inhibition curve by four-parameter fit.
Biological Data for Select Compounds
[0234] Select compounds prepared as described above were assayed according to the biological procedures described herein. The results are given in the table 2.
Table 2
Figure imgf000094_0001
14 6.6
15 38.2
16 11.6
17 68.5
18 15.9
19 4.9
20 61.9
21 68.6
22 86.0
23 12.3
24 8.3
25 36.3
26 13.7
27 37.2
28 46.6
29 64.7
30 17.4
31 74.5
32 19.3
33 11.8
34 12.3
35 36.9
36 26.2
37 12.5
38 13.6
39 10.3
40 119.6
41 43.2
42 54.6
Figure imgf000096_0001
* : LDK378 was prepared as example 7 of WO2008073687. in vivo antitumor activity
[0235] Male nude mice (6-week old) were housed in a specific pathogen-free room with a 12 h light/dark schedule at 20-25 °C and were fed an autoclaved chow diet and water ad libitum.
[0236] NCI-H2228 cells at a density of 5.1 x 106 in 200 uL were first implanted sc into the right flank of each nude mice and then allowed to grow to above 230 mm , the mice were randomly assigned into control and treatment groups (n = 6 per group for compound treated group, n = 12 per group for vehicle group). Vehicle control group were given vehicle alone, and treatment groups were received Compound 4, LDK378 or Crizotinib as indicated doses via oral administration once daily for 21 days. The mice tumor volumes in each group were measured twice per week.
[0237] The results are given in the Table 3 and Figure 1.
Table 3. Effect on relative tumor volume
Figure imgf000097_0001

Claims

WHAT IS CLAIMED IS:
1. At least one compound of formula (I):
Figure imgf000098_0001
and/or at least one pharmaceutically acceptable salt thereof,
wherein:
each R1 is independently selected from:
halogen,
hydroxyl,
Ci_io alkyl,
C3-10 cycloalkyl,
C3-10 cycloalkyl-alkyl,
heterocyclyl,
heterocyclylalkyl
aryl,
arylalkyl,
heteroaryl, and
heteroarylalkyl,
wherein alkyl, cycloalkyl, and heterocyclyl are each unsubstituted or substituted with at least one substituent independently selected from R6a, and wherein aryl and heteroaryl are each unsubstituted or substituted with at least one substituent independently selected from R6b; each R is indepedently selected from:
hydrogen, halogen,
hydroxyl,
Ci_io alkyl,
C2-10 alkenyl,
C2-10 alkynyl,
C3-io cycloalkyl,
C3_io cycloalkylalkyl,
heterocyclyl,
heterocyclylalkyl
heterocyclylcarbonyl,
aryl,
heteroaryl,
arylalkyl, and
heteroarylalkyl,
wherein alkyl, alkenyl, alkynyl, cycloalkyl, and heterocyclyl are each unsubstituted or substituted with at least one substituent independently selected from R6a, and each aryl and heteroaryl is unsubstituted or substituted with at least one substituent independently selected from R6b;
each R3 is independently selected from:
hydrogen,
halogen,
-CN,
-NR7R8, and
Ci_io alkyl;
wherein alkyl is unsubstituted or substituted with at least one substituent independently selected from R6a;
each R4 is independently selected from:
hydrogen,
halogen,
-CN, C1-10 alkyl,
C2-10 alkenyl,
C2_io alkynyl, and
C3-io cycloalkyl;
wherein C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, and C3-10 cycloalkyl are each
unsubstituted or substituted with at least one substituent independently selected from R6a;
or R3 and R4 together with the carbon atoms to which they are attached form a 5-6 membered ring containing 0, 1 , 2 or 3 heteroatoms independently selected from oxygen, sulfur and nitrogen, and optionally substituted with 1-2 R6b groups;
each R5 is indepedently selected from:
Ci_io alkyl,
C2_io alkenyl,
C2_io alkynyl,
C3_io cycloalkyl,
-OR8,
-NR7S(0)rR8,
-N02,
halogen,
-S(0)rR7,
-SR8,
-S(0)2OR7,
-OS(0)2R8,
-S(0)rNR7R8,
-NR7R8,
-O(CR9R10)tNR7R8,
-C(0)R7,
-C02R8,
-CO2(CR9R10)tCONR7R8,
-OC(0)R7,
-CN, -C(0)NR7R8,
-NR7C(0)R8,
-OC(0)NR7R8,
-NR7C(0)OR8,
-NR7C(0)NR7R8,
-CR7(N-OR8),
-CHF2,
-CF3,
-OCHF2, and wherein C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, and C3-10 cycloalkyl are each unsubstituted or substituted with at least one substituent independently selected from R6a; each R6a is independently selected from:
Ci_io alkyl,
C2_io alkenyl,
C2_io alkynyl,
C3-10 cycloalkyl,
-OR8,
-NR7S(0)rR8, halogen,
-S(0)rR7,
-SR8,
-S(0)2OR7,
-OS(0)2R8,
-S(0)rNR7R8,
-NR7R8,
-(CR9R10)tOR8,
-(CR9R10)tNR7R8,
-(CR9R10)tSR8, -(CR9R10)tS(O)rR8,
-(CR9R10)tCO2R8,
-(CR9R10)tCONR7R8,
-(CR9R10)tNR7CO2R8,
-(CR9R10)tOCONR7R8,
-(CR9R10)tNR7CONR7R8,
-(CR9R10)tNR7SO2NR7R8,
-O(CR9R10)tNR7R8,
-C(0)R7,
-C(O)(CR9R10)tOR8,
-C(O)(CR9R10)tNR7R8,
-C(O)(CR9R10)tSR8,
-C(O)(CR9R10)tS(O)rR8,
-C02R8,
-CO2(CR9R10)tCONR7R8,
-OC(0)R7,
-CN,
-C(0)NR7R8,
-NR7C(0)R8,
-OC(0)NR7R8,
-NR7C(0)OR8,
-NR7C(0)NR7R8,
-CR7(N-OR8),
-CHF2,
-CF3,
-OCHF2, and each R6b is independently selected from:
R6a,
aryl, aryl-Ci-4 alkyl,
heteroaryl, and
heteroaryl-Ci-4 alkyl;
each R 7 and each R 8 are independently selected from:
hydrogen,
Ci_io alkyl,
C2-10 alkenyl,
C2-10 alkynyl,
C3-10 cycloalkyl,
cycloalkyl-Ci-10 alkyl;
heterocyclyl,
heterocyclyl-Ci-10 alkyl,
aryl,
heteroaryl,
aryl-Ci-10 alkyl, and
heteroaryl-Ci-10 alkyl;
wherein alkyl, alkenyl, alkynyl, cycloalkyl, and heterocyclyl are each unsubstituted or substituted with at least one substituentindependently selected from R6a, and aryl and heteroaryl are each unsubstituted or substituted with at least one substituent independently selected from R6b; or
R7 and R8 together with the atom(s) to which they are attached form a heterocyclic ring of 4 to 7 members containing 0, 1, or 2 additional heteroatoms independently selected from oxygen, sulfur and NR11, each R7 and R8 may be unsubstituted or substituted on a carbon or nitrogen atom with at least one substituent independently selected from R 12 ;
each R9 and each R10 are independently selected from:
hydrogen,
Ci_io alkyl,
C2-10 alkenyl,
C2-10 alkynyl,
C3-10 cycloalkyl, cycloalkyl-Ci-io alkyl,
heterocyclyl,
heterocyclyl-Ci-io alkyl,
aryl,
heteroaryl,
aryl-Ci-io alkyl, and
heteroaryl-C i-io alkyl; or
R9 and R10 together with the carbon to which they are attached form a ring of 3 to 7 members containing 0, 1, or 2 heteroatoms independently selected from oxygen, sulfur and nitrogen; each R11 is independently selected from:
hydrogen,
Ci-io alkyl,
C3-io cycloalkyl,
C3-10 cycloalkyl-Ci-4 alkyl,
heterocyclyl,
heterocyclyl-Ci-4 alkyl,
aryl,
aryl-Ci-4 alkyl,
heteroaryl,
heteroaryl-C 1-4 alkyl,
-S(0)rR7,
-C(0)R7,
-C02R7,
-CO2(CR9R10)tCONR7R8, and
-C(0)NR7R8;
each R12 is independently selected from:
halogen,
Ci_io alkyl,
C3-i0 cycloalkyl,
C3-10 cycloalkylalkyl, heterocyclyl,
heterocyclylalkyl,
aryl,
aryl-Ci-4 alkyl,
heteroaryl,
heteroaryl-Ci-4 alkyl,
-OR7,
-NR7S(0)rR8,
-S(0)rR7,
-SR7,
-S(0)2OR7,
-OS(0)2R7,
-S(0)rNR7R8,
-NR7R8,
-O(CR9R10)tNR7R8,
-C(0)R7,
-C02R8,
-CO2(CR9R10)tCONR7R8,
-OC(0)R7,
-CN,
-C(0)NR7R8,
-NR7C(0)R8,
-OC(0)NR7R8,
-NR7C(0)OR8,
-NR7C(0)NR7R8,
-CHF2,
-CF3,
-OCHF2, and each m is independently selected from 0, 1 and 2; each n is independently selected from 1, 2, and 3;
each p is independently selected from 0, 1, 2, and 3;
each q is independently selected from 0, 1, 2, and 3;
each r is independently selected from 1 and 2;
each t is independently selected from 1 , 2, and 3.
2. At least one compound of claim 1 and/or at least one pharmaceutically acceptable salt thereof, wherein R1 is hydrogen or Ci_io alkyl, wherein alkyl is unsubstituted or substituted with at least one substituent independently selected from hydroxyl and Ci_io alkoxy.
3. At least one compound of claim 1 and/or at least one pharmaceutically acceptable salt thereof, wherein m is 0.
4. At least one compound of claim 1 and/or at least one pharmaceutically acceptable salt thereof, wherein R1 is Ci_io alkyl, wherein alkyl is unsubstituted or substituted with at least one substituent independently selected from hydroxyl and Ci_io alkoxy.
5. At least one compound of claim 1 and/or at least one pharmaceutically acceptable salt thereof, wherein m is 1.
6. At least one compound of claim 5 and/or at least one pharmaceutically acceptable salt thereof, wherein R1 is methyl, hydroxymethyl, or methoxymethyl.
7. At least one compound of claim 1 and/or at least one pharmaceutically acceptable salt thereof, wherein each R is independently selected from Ci_io alkyl, heterocyclylcarbonyl, and heterocyclyl, wherein alkyl and heterocyclyl are independently unsubstituted or substituted with at least one substituent independently selected from R6a, and p is selected from 0, 1 , 2, and 3.
8. At least one compound of claim 7 and/or at least one pharmaceutically acceptable salt thereof, wherein each R is independently selected from Ci_io alkyl and piperidinyl, and p is 2.
9. At least one compound of claim 8 and/or at least one pharmaceutically acceptable salt thereof, wherein each R2 is independently selected from methyl and 4-piperidinyl.
10. At least one compound of claim 9 and/or at least one pharmaceutically acceptable salt thereof, wherein each R is independently selected from methyl and 4-piperidinyl, wherein 4- piperidinyl is unsubstituted or substituted with at least one substituent independently selected from R6a, wherein R6a is independently selected from C1-10 alkyl, -C(0)R7, -S(0)rR7, - (CR9R10)tCO2R8, -C(O)(CR9R10)tOR8, -C(O)(CR9R10)tNR7R8, -(CR9R10)tOR8,
-(CR9R10)tCONR7R8, -(CR9R10)tS(O)rR8, -C02R8, -C(0)NR7R8, -(CR9R10)tOR8; wherein R7, R8, R9 , R10 , t and r are as described in claim 1.
11. At least one compound of claim 1 and/or at least one pharmaceutically acceptable salt thereof, wherein R3 is hydrogen.
12. At least one compound of claim 1 and/or at least one pharmaceutically acceptable salt thereof, wherein R4 is independently selected from hydrogen, C1-10 alkyl, and halogen.
13. At least one compound of claim 12 and/or at least one pharmaceutically acceptable salt thereof, wherein R4 is independently selected from halogen.
14. At least one compound of claim 13 and/or at least one pharmaceutically acceptable salt thereof, wherein R4 is chlorine.
15. At least one compound of claim 1 and/or at least one pharmaceutically acceptable salt thereof, wherein R3 and R4 together with the carbon atoms to which they are attached form a 5 membered ring containing 2 nitrogen atoms, wherein the 5-membered ring is optionally substituted with 1-2 C1-10 alkyl.
16. At least one compound of claim 1 and/or at least one pharmaceutically acceptable salt thereof, wherein R3 and R4 together with the carbon atoms to which they are attached form pyrazolo.
17. At least one compound of claim 1 and/or at least one pharmaceutically acceptable salt thereof, wherein R 5 is -S(0)rR 7.
18. At least one compound of claim 17 and/or at least one pharmaceutically acceptable salt thereof, wherein R5 is -S(0)2R7,wherein R7 is C1-10 alkyl, and q is 1.
19. At least one compound of claim 18 and/or at least one pharmaceutically acceptable salt
5 7 7
thereof, wherein R is -S(0)2R ,wherein R is isopropyl.
20. At least one compound of claim 1 and/or at least one pharmaceutically acceptable salt thereof, wherein n is i .
21. At least one compound selected from:
N-4-(2-(isopropylsulfonyl)phenyl)-3-methyl-N-6-(5-methyl-4-(piperidin-4-yl)-2,3- dihydrobenzofuran-7-yl)-iH-pyrazolo[3,4-d]pyrimidine-4,6-diamine;
N-4-(2-(isopropylsulfonyl)phenyl)-3-methyl-N-6-(5-methyl-4-(l-methylpiperidin-4-yl)- 2,3-dihydrobenzofuran-7-yl)-iH-pyrazolo[3,4-d]pyrimidine-4,6-diamine;
(ii)-N-6-(2,5-dimethyl-4-(piperidin-4-yl)-2,3-dihydrobenzofuran-7-yl)-N-4-(2- (isopropylsulfonyl)phenyl)-3-methyl-iH-pyrazolo[3,4-d]pyrimidine-4,6-diamine;
(ii)-N-6-(2,5-dimethyl-4-(l-methylpiperidin-4-yl)-2,3-dihydrobenzofuran-7-yl)-N-4-(2- (isopropylsulfonyl)phenyl)-3-methyl-lH-pyrazolo[3,4-d]pyrimidine-4,6-diamine;
(lS')-N-6-(2,5-dimethyl-4-(piperidin-4-yl)-2,3-dihydrobenzofuran-7-yl)-N-4-(2- (isopropylsulfonyl)phenyl)-3-methyl-iH-pyrazolo[3,4-d]pyrimidine-4,6-diamine;
(lS')-N-6-(2,5-dimethyl-4-(l-methylpiperidin-4-yl)-2,3-dihydrobenzofuran-7-yl)-N-4-(2- (isopropylsulfonyl)phenyl)-3-methyl-iH-pyrazolo[3,4-d]pyrimidine-4,6-diamine;
(7-(4-(2-(isopropylsulfonyl)phenylamino)-3-methyl-iH-pyrazolo[3,4-d]pyrimidin-6- ylamino)-5-methyl-4-(piperidin-4-yl)-2,3-dihydrobenzofuran-2-yl)methanol;
N-4-(2-(isopropylsulfonyl)phenyl)-N-6-(2-(methoxymethyl)-5-methyl-4-(piperidin-4-yl)- 2,3-dihydrobenzofuran-7-yl)-3-methyl-iH-pyrazolo[3,4-d]pyrimidine-4,6-diamine;
(ii)-5-chloro-N-2-(2,5-dimethyl-4-(piperidin-4-yl)-2,3-dihydrobenzofuran-7-yl)-N-4-(2- (isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine;
(ii)-5-chloro-N-2-(2,5-dimethyl-4-(l-methylpiperidin-4-yl)-2,3-dihydrobenzofuran-7-yl)- N-4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine;
(.S')-5-chloro-N-2-(2,5-dimethyl-4-(piperidin-4-yl)-2,3-dihydrobenzofuran-7-yl)-N-4-(2- (isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine;
(.S')-5-chloro-N-2-(2,5-dimethyl-4-(l-methylpiperidin-4-yl)-2,3-dihydrobenzofuran-7-yl)-
N-4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; 5-chloro-N-4-(2-(isopropylsulfonyl)phenyl)-N-2-(5-methyl-4-(piperidin-4-yl)-2,3- dihydrobenzofuran-7-yl)pyrimidine-2,4-diamine;
5-chloro-N-4-(2-(isopropylsulfonyl)phenyl)-N-2-(5-methyl-4-(l-methylpiperidin-4-yl)- 2,3-dihydrobenzofuran-7-yl)pyrimidine-2,4-diamine;
(^)-l-(4-(7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-2,5- dimethyl-2,3-dihydrobenzofuran-4-yl)piperidin- 1 -yl)ethanone;
(ii)-l-(4-(7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)- 2,5-dimethyl-2,3-dihydrobenzofuran-4-yl)piperidin-l-yl)ethanone;
(lS')-5-chloro-N-2-(2,5-dimethyl-4-(l-(methylsulfonyl)piperidin-4-yl)-2,3- dihydrobenzofuran-7-yl)-N-4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine;
(ii)-5-chloro-N-2-(2,5-dimethyl-4-(l-(methylsulfonyl)piperidin-4-yl)-2,3- dihydrobenzofuran-7-yl)-N-4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine;
(^)-2-(4-(7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-2,5- dimethyl-2,3-dihydrobenzofuran-4-yl)piperidin- 1 -yl)acetic acid;
(ii)-2-(4-(7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)- 2,5-dimethyl-2,3-dihydrobenzofuran-4-yl)piperidin-l-yl)acetic acid;
(^)-2-amino-l-(4-((^)-7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2- yl)amino)-2,5-dimethyl-2,3-dihydrobenzofuran-4-yl)piperidin-l-yl)propan-l-one;
(^)-2-amino-l-(4-((ii)-7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2- yl)amino)-2,5-dimethyl-2,3-dihydrobenzofuran-4-yl)piperidin-l-yl)propan-l-one;
(ii)-l-(4-((ii)-7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2- yl)amino)-2,5-dimethyl-2,3-dihydrobenzofuran-4-yl)piperidin-l-yl)propan-2-ol;
(^)-l-(4-((ii)-7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)- 2,5 -dimethyl-2,3 -dihydrobenzofuran-4-yl)piperidin- 1 -yl)propan-2-ol ;
(^)-2-(4-(7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-2,5- dimethyl-2,3-dihydrobenzofuran-4-yl)piperidin- 1 -yl)acetamide;
(ii)-2-(4-(7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)- 2,5-dimethyl-2,3-dihydrobenzofuran-4-yl)piperidin-l-yl)acetamide;
(^)-2-(4-(7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-2,5- dimethyl-2,3-dihydrobenzofuran-4-yl)piperidin-l-yl)-N,N-dimethylacetamide; (Zi)-2-(4-(7-((5-chloro-4-((2-(isopropylsulfony
2,5-dimethyl-2,3-dihydrobenzofuran-4-yl)piper^
(^)-5-chloro-N-2-(2,5-dimethyl-4-(l -(2-(methylsulfonyl)ethyl)piperidin-4-yl)-2,3- dihydrobenzofuran-7-yl)-N-4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine;
(ii)-5-chloro-N-2-(2,5-dimethyl-4-(l-(2-(methylsulfonyl)ethyl)piperidin-4-yl)-2,3- dihydrobenzofuran-7-yl)-N-4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine;
(.S')-5-chloro-N-4-(2-(isopropylsulfonyl)phenyl)-N-2-(4-(l-(2-methoxyethyl)piperidin-4- yl)-2,5-dimethyl-2,3-dihydrobenzofuran-7-yl)pyrimidine-2,4-diamine;
(ii)-5-chloro-N-4-(2-(isopropylsulfonyl)phenyl)-N-2-(4-(l-(2-methoxyethyl)piperidin-4- yl)-2,5-dimethyl-2,3-dihydrobenzofuran-7-yl)pyrimidine-2,4-diamine;
(ii)-2-(4-(7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)- 2,5-dimethyl-2,3-dihydrobenzofuran-4-yl)piperidin-l -yl)ethanol;
(^)-2-(4-(7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-2,5- dimethyl-2,3-dihydrobenzofuran-4-yl)piperidin-l -yl)ethanol;
(ii)-l-(4-((^)-7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)- 2,5-dimethyl-2,3-dihydrobenzofuran-4-yl)piperidin-l -yl)propan-2-ol;
(^)-l-(4-((^)-7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)- 2,5-dimethyl-2,3-dihydrobenzofuran-4-yl)piperidin-l -yl)propan-2-ol;
(ii)-l -(4-(7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)- 2,5-dimethyl-2,3-dihydrobenzofuran-4-yl)piperidin-l-yl)-2-hydroxyethanone;
(^)-l-(4-((ii)-7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)- 2,5-dimethyl-2,3-dihydrobenzofuran-4-yl)piperidin-l -yl)-2-hydroxypropan- l-one;
(ii)-l-(4-((ii)-7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2- yl)amino)-2,5-dimethyl-2,3-dihydrobenzofuran-4-yl)piperidin-l-yl)-2-hydroxypropan-l-one;
(^-methyl 4-(7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2- yl)amino)-2,5-dimethyl-2,3-dihydrobenzofuran-4-yl)piperidine-l-carboxylate;
Ci -ethyl 2-(4-(7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2- yl)amino)-2,5-dimethyl-2,3-dihydrobenzofuran-4-yl)piperidin-l-yl)acetate;
(^)-2-amino-l -(4-(7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2- yl)amino)-2,5-dimethyl-2,3-dihydrobenzofuran-4-yl)piperidin-l-yl)ethanone; (^)-4-(7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-2,5- dimethyl-2,3-dihydrobenzofuran-4-yl)piperidine- 1 -carboxamide;
(^)-l -(4-(7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-2,5- dimethyl-2,3-dihydrobenzofuran-4-yl)piperidin-l -yl)-2-(methylamino)ethanone;
(^)-l -(4-(7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-2,5- dimethyl-2,3-dihydrobenzofuran-4-yl)piperidin-l-yl)-2-(dimethylamino)ethanone;
(^)-(7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-2,5- dimethyl-2,3-dihydrobenzofuran-4-yl)(piperazin-l-yl)methanone;
(^)-(7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-2,5- dimethyl-2,3-dihydrobenzofuran-4-yl)(4-methylpiperazin-l -yl)methanone;
(^)-(7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-2,5- dimethyl-2,3-dihydrobenzofuran-4-yl)(morpholino)methanone;
(ii)-l -(4-(7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)- 2,5 -dimethyl-2,3 -dihydrobenzofuran-4-yl)piperidin- 1 -yl)propan- 1 -one;
(ii)-l -(4-(7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyriniidin-2-yl)amino)- 2,5-dimethyl-2,3-dihydrobenzofuran-4-yl)piperidin-l -yl)-2-methylpropan-l -one;
(ii)-(4-(7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-2,5- dimethyl-2,3-dihydrobenzofuran-4-yl)piperidin-l -yl)(cyclopropyl)methanone;
(ii)-5-chloro-N-2-(4-(l-(ethylsulfonyl)piperidin-4-yl)-2,5-dimethyl-2,3- dihydrobenzofuran-7-yl)-N-4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine;
(ii)-5-chloro-N-4-(2-(isopropylsulfonyl)phenyl)-N-2-(4-(l-(isopropylsulfonyl)piperidin- 4-yl)-2,5-dimethyl-2,3-dihydrobenzofuran-7-yl)pyrimidine-2,4-diamine;
(ii)-5-chloro-N-2-(4-(l-(cyclopropylsulfonyl)piperidin-4-yl)-2,5-dimethyl-2,3- dihydrobenzofuran-7-yl)-N-4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine;
(ii)-l-(4-((^)-7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyriniidin-2-yl)amino)- 2,5-dimethyl-2,3-dihydrobenzofuran-4-yl)piperidin-l -yl)-2-methoxypropan-l-one;
(ii)-l-(4-((ii)-7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2- yl)amino)-2,5-dimethyl-2,3-dihydrobenzofuran-4-yl)piperidin-l-yl)-2-methoxypropan-l-one;
(^)-l-(4-((ii)-7-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyriniidin-2-yl)amino)- 2,5-dimethyl-2,3-dihydrobenzofuran-4-yl)piperidin-l -yl)-2-methoxypropan-l-one; (S)-l-(4-((S)-7-((5-chloro-4-((2-(isopropyfc
dimethyl-2,3-dihydrobenzofuran-4-yl)piperidin- 1 -yl)-2-methoxypropan- 1 -one, and
pharmaceutically acceptable salts thereof.
22. A pharmaceutical composition, comprising at least one compound of claim 1, and/or at least one pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
23. A method for modulating anaplastic lymphoma kinase, comprising administering to a subject in need thereof a therapeutically effective amount of at least one compound of claim 1, and/or at least one pharmaceutically acceptable salt thereof , or at least one pharmaceutical composition thereof.
24. A method to treat, ameliorate or prevent a condition, which responds to inhibition of anaplastic lymphoma kinase, comprising administering to a subject in need of such treatment an effective amount of at least one compound of claim 1 , and/or at least one pharmaceutically acceptable salt thereof, or of at least one pharmaceutical composition thereof, and optionally in combination with a second therapeutic agent.
25. A method for making a medicament for treating a condition, which responds to inhibition of anaplastic lymphoma kinase, comprising including to the medicament at least one compound of claim 1 , and/or at least one pharmaceutically acceptable salt thereof .
26. A method for treating a cell proliferative disorder, comprising administering to a subject in need of such treatment an effective amount of at least one compound of claim 1, and/or at least one pharmaceutically acceptable salt thereof or of at least one pharmaceutical composition thereof, and optionally in combination with a second therapeutic agent.
27. A method for making a medicament for treating a cell -proliferative disorder, comprising including in the medicament at least one compound of claim 1 , and/or at least one
pharmaceutically acceptable salt thereof.
PCT/CN2013/086571 2012-11-06 2013-11-05 Alk kinase inhibitors WO2014071832A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
JP2015540039A JP6359020B6 (en) 2012-11-06 2013-11-05 ALK kinase inhibitor
DK13853072.0T DK2917210T3 (en) 2012-11-06 2013-11-05 ALK KINASE INHIBITORS
CN201380058088.6A CN104854101B (en) 2012-11-06 2013-11-05 Alk kinase inhibitors
RU2015121374A RU2675850C2 (en) 2012-11-06 2013-11-05 Alk kinase inhibitors
KR1020157014984A KR102156398B1 (en) 2012-11-06 2013-11-05 Alk kinase inhibitors
EP13853072.0A EP2917210B1 (en) 2012-11-06 2013-11-05 Alk kinase inhibitors
AU2013344049A AU2013344049B2 (en) 2012-11-06 2013-11-05 ALK kinase inhibitors
BR112015010221-2A BR112015010221B1 (en) 2012-11-06 2013-11-05 ALK KINASE INHIBITORS, THEIR USES, PHARMACEUTICAL COMPOSITION, AND DRUG MANUFACTURING METHOD
CA2890006A CA2890006C (en) 2012-11-06 2013-11-05 Alk kinase inhibitors
ES13853072T ES2728008T3 (en) 2012-11-06 2013-11-05 ALK kinase inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261723099P 2012-11-06 2012-11-06
US61/723,099 2012-11-06

Publications (1)

Publication Number Publication Date
WO2014071832A1 true WO2014071832A1 (en) 2014-05-15

Family

ID=50622903

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2013/086571 WO2014071832A1 (en) 2012-11-06 2013-11-05 Alk kinase inhibitors

Country Status (12)

Country Link
US (2) US9206166B2 (en)
EP (1) EP2917210B1 (en)
JP (2) JP6359020B6 (en)
KR (1) KR102156398B1 (en)
CN (1) CN104854101B (en)
AU (1) AU2013344049B2 (en)
BR (1) BR112015010221B1 (en)
CA (1) CA2890006C (en)
DK (1) DK2917210T3 (en)
ES (1) ES2728008T3 (en)
RU (1) RU2675850C2 (en)
WO (1) WO2014071832A1 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104892526A (en) * 2015-06-17 2015-09-09 药源药物化学（上海）有限公司 Preparation method of 2,5-dichloro-N-(2-isopropylsulfonyl) phenyl) pyrimidine-4-amine
CN105085550A (en) * 2014-05-21 2015-11-25 海门慧聚药业有限公司 High-activity ALK kinases inhibitor with novel structure and preparation method thereof
CN105272921A (en) * 2014-06-09 2016-01-27 江苏奥赛康药业股份有限公司 Method for preparing Ceritinib and intermediate compound of Ceritinib
WO2016050171A1 (en) * 2014-09-29 2016-04-07 山东轩竹医药科技有限公司 Polycyclic anaplastic lymphoma kinase inhibitor
CN105622520A (en) * 2014-08-25 2016-06-01 上海博悦生物科技有限公司 New intermediate of non-small-cell lung carcinoma treating drug Ceritinib, and preparation method thereof
CN106146525A (en) * 2015-04-10 2016-11-23 山东轩竹医药科技有限公司 Three and ring class anaplastic lymphoma kinase inhibitor
CN106699810A (en) * 2015-11-17 2017-05-24 清华大学 Nitrogen-containing heterogeneous ring compound, preparation method thereof and application of nitrogen-containing heterogeneous ring compound in inhibition of kinase activity
WO2018127184A1 (en) * 2017-01-06 2018-07-12 北京赛林泰医药技术有限公司 Anaplastic lymphoma kinase inhibitor and preparation method and use thereof
EP3476848A4 (en) * 2016-06-27 2020-01-15 Hangzhou Rex Pharmaceutical Co., Ltd Benzofuran pyrazole amine protein kinase inhibitor
EP3822270A4 (en) * 2018-05-02 2022-03-02 JW Pharmaceutical Corporation Novel heterocycle derivative
US11504375B2 (en) 2018-01-31 2022-11-22 Dizal (Jiangsu) Pharmaceutical Co., Ltd. ErbB/BTK inhibitors

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013344049B2 (en) * 2012-11-06 2017-12-21 Fochon Pharmaceuticals, Ltd. ALK kinase inhibitors
WO2016040882A1 (en) * 2014-09-13 2016-03-17 Novartis Ag Combination therapies of egfr inhibitors
CN106146478B (en) * 2015-04-10 2019-07-16 海南轩竹医药科技有限公司 Triazine derivatives species anaplastic lymphoma kinase inhibitor
CN109071512A (en) * 2016-02-03 2018-12-21 重庆复创医药研究有限公司 Phosphorus-containing compound as kinase inhibitor
KR20210024048A (en) 2018-06-22 2021-03-04 가부시키가이샤 준텐 바이오 Antibodies and induced lymphocytes that induce immune tolerance, using a mixture of cells having a complex state, and cell therapy and therapy using induced lymphocytes
AU2019288684A1 (en) 2018-06-22 2021-01-21 Junten Bio Co., Ltd. Composition for eliciting infectious immunological tolerance
CN110305140B (en) * 2019-07-30 2020-08-04 上海勋和医药科技有限公司 Dihydropyrrolopyrimidines selective JAK2 inhibitors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007066187A2 (en) * 2005-12-05 2007-06-14 Pfizer Products Inc. Method of treating abnormal cell growth
WO2008073687A2 (en) * 2006-12-08 2008-06-19 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2009008371A1 (en) * 2007-07-06 2009-01-15 Astellas Pharma Inc. Di(arylamino)aryl compound
WO2010128659A1 (en) * 2009-05-08 2010-11-11 アステラス製薬株式会社 Diamino heterocyclic carboxamide compound

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0305929D0 (en) * 2003-03-14 2003-04-23 Novartis Ag Organic compounds
GB0319227D0 (en) * 2003-08-15 2003-09-17 Novartis Ag Organic compounds
RU2400477C2 (en) * 2003-03-14 2010-09-27 Новартис Аг 2,4-di(phenylamino)pyrimidines, applied in treatment of neoplastic diseases, inflammatory disorders and immune system disorders
DK1660458T3 (en) * 2003-08-15 2012-05-07 Irm Llc 2,4-Pyrimidine diamines useful in the treatment of neoplastic diseases, inflammatory disorders and disorders of the immune system.
PT1713806E (en) * 2004-02-14 2013-08-27 Irm Llc Compounds and compositions as protein kinase inhibitors
GB0419161D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
TW200736232A (en) * 2006-01-26 2007-10-01 Astrazeneca Ab Pyrimidine derivatives
US20080033412A1 (en) * 2006-08-01 2008-02-07 Harry Thomas Whelan System and method for convergent light therapy having controllable dosimetry
ES2633318T3 (en) * 2006-10-23 2017-09-20 Cephalon, Inc. Bicyclic derivatives fused 2,4-diaminopyrimidine as inhibitors of ALK and c-Met
MY148427A (en) * 2006-12-08 2013-04-30 Irm Llc Compounds and compositions as protein kinase inhibitors
CN101827848B (en) * 2007-08-08 2012-11-07 葛兰素史密丝克莱恩有限责任公司 2- [ (2-{phenylamino}-1H-pyrrolo [2, 3-d] pyrimidin-4-yl) amino] benzamide derivatives as iIGF-1R inhibitors for the treatment of cancer
JP2010538004A (en) * 2007-08-28 2010-12-09 アイアールエム・リミテッド・ライアビリティ・カンパニー 2-Biphenylamino-4-aminopyrimidine derivatives as kinase inhibitors
WO2009032694A1 (en) 2007-08-28 2009-03-12 Dana Farber Cancer Institute Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis
TW200942537A (en) 2008-02-01 2009-10-16 Irm Llc Compounds and compositions as kinase inhibitors
AU2009233963B2 (en) * 2008-04-07 2011-10-06 Irm Llc Compounds and compositions as kinase inhibitors
CA2720946C (en) 2008-04-07 2013-05-28 Irm Llc Compounds and compositions as protein kinase inhibitors
MX2010012457A (en) 2008-05-13 2010-12-07 Irm Llc Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors.
SI2300013T1 (en) * 2008-05-21 2018-03-30 Adriad Pharmacaceuticals, Inc. Phosphorous derivatives as kinase inhibitors
UY31929A (en) 2008-06-25 2010-01-05 Irm Llc COMPOUNDS AND COMPOSITIONS AS CINASE INHIBITORS
AU2009262198B2 (en) 2008-06-25 2012-09-27 Irm Llc Pyrimidine derivatives as kinase inhibitors
US8722692B2 (en) 2009-07-30 2014-05-13 Jianwei Che Compounds and compositions as Syk kinase inhibitors
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
CA2770873A1 (en) 2009-08-12 2011-02-17 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
EP2467383A1 (en) 2009-08-20 2012-06-27 Novartis AG Heterocyclic oxime compounds
EP2475668A1 (en) 2009-09-10 2012-07-18 Novartis AG Ether derivatives of bicyclic heteroaryls
KR102325775B1 (en) 2010-12-17 2021-11-12 노파르티스 아게 Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine
ME02200B (en) 2011-02-02 2016-02-20 Novartis Ag Methods of using alk inhibitors
AU2013344049B2 (en) * 2012-11-06 2017-12-21 Fochon Pharmaceuticals, Ltd. ALK kinase inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007066187A2 (en) * 2005-12-05 2007-06-14 Pfizer Products Inc. Method of treating abnormal cell growth
WO2008073687A2 (en) * 2006-12-08 2008-06-19 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2009008371A1 (en) * 2007-07-06 2009-01-15 Astellas Pharma Inc. Di(arylamino)aryl compound
WO2010128659A1 (en) * 2009-05-08 2010-11-11 アステラス製薬株式会社 Diamino heterocyclic carboxamide compound

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2917210A4 *

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105085550A (en) * 2014-05-21 2015-11-25 海门慧聚药业有限公司 High-activity ALK kinases inhibitor with novel structure and preparation method thereof
CN105085550B (en) * 2014-05-21 2017-05-24 海门慧聚药业有限公司 ALK kinases inhibitor and preparation method thereof
CN105272921A (en) * 2014-06-09 2016-01-27 江苏奥赛康药业股份有限公司 Method for preparing Ceritinib and intermediate compound of Ceritinib
CN105622520A (en) * 2014-08-25 2016-06-01 上海博悦生物科技有限公司 New intermediate of non-small-cell lung carcinoma treating drug Ceritinib, and preparation method thereof
CN107108586A (en) * 2014-09-29 2017-08-29 山东轩竹医药科技有限公司 Polycyclic class anaplastic lymphoma kinase inhibitor
KR101909404B1 (en) * 2014-09-29 2018-10-17 수안주 파마 코포레이션 리미티드 Polycyclic inhibitor of anaplastic lymphoma kinase
WO2016050171A1 (en) * 2014-09-29 2016-04-07 山东轩竹医药科技有限公司 Polycyclic anaplastic lymphoma kinase inhibitor
JP2017530139A (en) * 2014-09-29 2017-10-12 シュエンジュウ・ファーマ・カンパニー・リミテッド Polycyclic inhibitors of anaplastic lymphoma kinase
US10011592B2 (en) 2014-09-29 2018-07-03 Xuanzhu Pharma Co., Ltd. Polycyclic inhibitor of anaplastic lymphoma kinase
EP3202765A4 (en) * 2014-09-29 2018-08-22 Xuanzhu Pharma Co., Ltd. Polycyclic anaplastic lymphoma kinase inhibitor
CN106146525A (en) * 2015-04-10 2016-11-23 山东轩竹医药科技有限公司 Three and ring class anaplastic lymphoma kinase inhibitor
CN104892526A (en) * 2015-06-17 2015-09-09 药源药物化学（上海）有限公司 Preparation method of 2,5-dichloro-N-(2-isopropylsulfonyl) phenyl) pyrimidine-4-amine
CN106699810A (en) * 2015-11-17 2017-05-24 清华大学 Nitrogen-containing heterogeneous ring compound, preparation method thereof and application of nitrogen-containing heterogeneous ring compound in inhibition of kinase activity
EP3476848A4 (en) * 2016-06-27 2020-01-15 Hangzhou Rex Pharmaceutical Co., Ltd Benzofuran pyrazole amine protein kinase inhibitor
US10710993B2 (en) * 2016-06-27 2020-07-14 Hangzhou REX Pharmaceutical Co., LTD. Benzofuran pyrazole amine kinase inhibitor
WO2018127184A1 (en) * 2017-01-06 2018-07-12 北京赛林泰医药技术有限公司 Anaplastic lymphoma kinase inhibitor and preparation method and use thereof
US11504375B2 (en) 2018-01-31 2022-11-22 Dizal (Jiangsu) Pharmaceutical Co., Ltd. ErbB/BTK inhibitors
EP3822270A4 (en) * 2018-05-02 2022-03-02 JW Pharmaceutical Corporation Novel heterocycle derivative

Also Published As

Publication number Publication date
EP2917210B1 (en) 2019-02-27
BR112015010221B1 (en) 2022-09-13
AU2013344049A1 (en) 2015-07-02
DK2917210T3 (en) 2019-05-27
US9206166B2 (en) 2015-12-08
RU2015121374A (en) 2016-12-27
JP2015535266A (en) 2015-12-10
CA2890006A1 (en) 2014-05-15
EP2917210A1 (en) 2015-09-16
JP2018119003A (en) 2018-08-02
US9567342B2 (en) 2017-02-14
CN104854101B (en) 2018-05-01
KR102156398B1 (en) 2020-09-15
ES2728008T3 (en) 2019-10-21
US20140128387A1 (en) 2014-05-08
BR112015010221A2 (en) 2017-07-11
EP2917210A4 (en) 2016-05-25
AU2013344049B2 (en) 2017-12-21
JP6570001B2 (en) 2019-09-04
US20160046638A1 (en) 2016-02-18
RU2675850C2 (en) 2018-12-25
CA2890006C (en) 2021-11-23
JP6359020B2 (en) 2018-07-18
CN104854101A (en) 2015-08-19
JP6359020B6 (en) 2018-08-15
KR20150093687A (en) 2015-08-18

Similar Documents

Publication Publication Date Title
JP6570001B2 (en) ALK kinase inhibitor
AU2014244555B2 (en) DNA-PK inhibitors
US10087195B2 (en) Certain protein kinase inhibitors
US10022374B2 (en) Certain protein kinase inhibitors
WO2015188777A1 (en) Certain protein kinase inhibitors
AU2014259477B2 (en) 3-(2-aminopyrimidin-4-yl)-5-(3-hydroxypropynyl)-1H-pyrrolo[2,3-c]pyridine derivatives as NIK inhibitors for the treatment of cancer
CA2735779A1 (en) Bicyclic kinase inhibitors
USRE48974E1 (en) (5,6-dihydro)pyrimido[4,5-E]indolizines
US10053449B2 (en) Quinazoline derivatives, compositions thereof, and use as pharmaceuticals
AU2014247215A1 (en) Novel N-(2,3-dihydro-1H-pyrrolo[2,3-b]jpyridin-5-yl)-4- quinazolinamine and N-(2,3-dihydro-1H-indol-5-yl)-4- quinazolinamine derivatives as perk inhibitors
CN113677680A (en) EGFR inhibitor and composition and application thereof
US10328060B2 (en) Certain protein kinase inhibitors
US20160145244A1 (en) Certain protein kinase inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13853072

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2890006

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2015540039

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2013853072

Country of ref document: EP

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112015010221

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20157014984

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2015121374

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2013344049

Country of ref document: AU

Date of ref document: 20131105

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112015010221

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20150505